<html><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31644200>Protease Inhibitors (HIV).</a></h2><p>The human immunodeficiency virus (HIV) protease inhibitors are a broad class of agents that are widely used in the therapy and prevention of HIV infection and the acquired immunodeficiency syndrome (AIDS). All of the currently available protease inhibitors have been associated with transient and usually asymptomatic elevations in serum aminotransferase levels, and several (atazanavir, indinavir) with mild-to-moderate elevations in indirect and total bilirubin concentration. The protease inhibitors are rare causes of clinically apparent, acute liver injury. In HBV or HCV coinfected patients, antiretroviral therapy with highly active antiretroviral therapy (HAART) including protease inhibitors may result in an exacerbation of the underlying chronic hepatitis  or C. The antiretroviral protease inhibitors act by binding to the catalytic site of the HIV protease, thereby preventing the cleavage of viral polyprotein precursors into mature, functional proteins that are necessary for viral replication. Most of these agents were developed by rational drug design based upon chemical structures that would interact with the catalytic site of the HIV protease, based upon x-ray crystallographic studies defining the three-dimensional molecular structure of the protease. For these reasons, the protease inhibitors are heterogeneous molecules with little structural similarity, most of which are peptide-like and resemble the short peptide that is cleaved by the viral protease (usually the N terminal side of the middle proline residue is phenylalanine-proline-proline). The initial HIV protease approved for use in the United States was ritonavir (1996), followed in short order by indinavir (1996), nelfinavir (1997), saquinavir (1997), amprenavir (1999), lopinavir/ritonavir (2000), atazanavir (2003), fosamprenavir (2003), tipranavir (2005), and darunivir (2006). The potencies of these agents are similar and the major reason for using one or the other relates to pharmacokinetics (whether they are taken once vs multiple times daily), tolerance and presence of antiviral resistance.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31642329>Optimism and depressive symptoms following a  diagnosis: Results from the Health and Retirement Study.</a></h2><p>Depression is common among individuals with  and contributes to poorer prognoses. Optimism is associated with enhanced mental health. Therefore, this study tested whether optimism buffered against increases in depressive symptoms following a  diagnosis. Participants were drawn from the Health and Retirement Study ( = 328, M = 65.8). Optimism, assessed before diagnosis, was inversely associated with depressive symptoms within 2 ( = -.30,  = .004, Δ = .02) and 6 ( = -.29,  = .008, Δ = .02) years of a  diagnosis. Results suggest that optimism is a protective factor for comorbid depressive symptoms.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643779>Venetoclax.</a></h2><p>Venetoclax is an oral selective BCL-2 inhibitor and antineoplastic agent used in the therapy of refractory chronic lymphocytic leukemia (CLL). Venetoclax is associated with a low rate of transient serum enzyme elevations during therapy, but has not been implicated in cases of clinically apparent acute liver injury with jaundice. Venetoclax has potent immunosuppressive activity and may be capable of causing reactivation of hepatitis .</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31630146>Single-Cell Sequencing Reveals the Relationship between Phenotypes and Genotypes of Klinefelter Syndrome.</a></h2><p>Klinefelter syndrome (KS) is one of the most common congenital disorders of male infertility. Given its high heterogeneity in clinical and genetic presentation, the relationship between transcriptome, clinical phenotype, and associated co-morbidities seen in KS has not been fully clarified. Here, we report a 47,XXY Chinese male with infertility and analyzed the differences in gene expression patterns of peripheral blood mononuclear cells (PBMCs) with regard to a Chinese male and a female control with normal karyotype by single-cell sequencing. A total of 24,439 cells were analyzed and divided into 5 immune cell types (including  cells, T cells, macrophage cells, dendritic cells, and natural killer cells) according to marker genes. Using unsupervised dimensionality reduction and clustering algorithms, we identified molecularly distinct subpopulations of cells between the KS patient and both controls. Gene ontology enrichment analyses yielded terms associated with well-known comorbidities seen in KS as well as an affected immune system and type I . Based on our data, we identified several candidate genes which may be implicated in regulating the phenotype of KS. Overall, this analysis provides a comprehensive map of the cell types of PBMCs in a KS patient at the single-cell level, which will contribute to the prevention of comorbidity and improvement of the life quality of KS patients.© 2019 S. Karger AG, Basel.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31644162>Parkinson Disease Agents.</a></h2><p>Parkinson disease is a progressive neurological condition characterized by slowness and paucity of movement (bradykinesia), muscle rigidity, resting tremors, and disordered posture. The onset is typically in the 6th or 7th decade of life with slow progression to akinesia, severe tremors, physical disability and death within 10 to 25 years of initial symptoms. Parkinson disease is common and affects approximately 1% of Americans above the age of 60 years. The cause of Parkinson disease is unknown, but is marked by loss of dopamine-containing neurons in the substantia nigra pars compacta of the brainstem and loss of normal dopaminergic neurotransmission. Therapy of Parkinson disease continues to evolve and has resulted in improved quality of life and survival. The initial agents used for Parkinson disease were anticholinergic agents including trihexyphenidyl (Artane, Trihexy: 1949), benztropine (Cogentin: 1954), and biperiden (Akineton: 1959); their mechanism of action in Parkinsonism is not completely clear. With the increased understanding of the role of dopamine in the pathophysiology of Parkinsonism, agents that directly or indirectly affect dopaminergic transmission have been developed that have resulted in marked improvements in the management of symptoms of Parkinson disease. Levodopa (L-DOPA: 1970) is a metabolic precursor of dopamine and is the single most effective agent for Parkinson disease. It is usually combined with carbidopa (Sinemet: 1975), which increases the drug levels and half life of levodopa by inhibiting the amino acid decarboxylase that metabolizes levodopa peripherally. Dopaminergic receptor agonists are also beneficial in Parkinson disease and are often combined with levodopa/carbidopa. Dopamine receptor agonists currently available include bromocriptine (1978: Parlodel), pergolide (Permax: 1988), apomorphine (Apokyn: 2004) and more selective agonists for the D2 class of dopamine receptors – ropinirole (Requip: 1997), pramipexole (Mirapex: 1997) and rotigotine (Neupro which is formulated in a transdermal patch: 2007). More recently, inhibitors of catechol-O-methyltransferase (COMT) have been developed that block the major enzyme responsible for the metabolism of dopamine; these agents include tolcapone (Tasmar: 1998) and entacapone (Comtan: 2003). Dopamine is also metabolized by the monamine oxidases and selegiline (Atapryl: 2006) and rasagiline (Azilect: 2007) which are specific inhibitors of monamine oxidase (MAO) type , and are used as an adjunctive therapy with levodopa in therapy of Parkinson disease. Amantadine (Symmetrel: 1987) also has activity in Parkinson disease, perhaps through stimulation of release of dopamine in the substantial nigra. It is discussed separately as an anti-influenza agent. Other agents used in the management of Parkinson disease are used to treat specific complications such as psychosis (pimavanserin: Nuplazid, 2016) and postural hypotension (droxidopa: Vectibix, 2014). Most of the drugs used to treat Parkinson disease have little potential for hepatotoxicity and are rare causes of clinically apparent acute liver injury, the exception being tolcapone. The full references on hepatotoxicity and safety of the drugs for Parkinson disease are given in the discussion of the individual agents listed below.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31663720>Rational design of a rigid fluorophore-molecular rotor-based probe for high signal-to-background ratio detection of sulfur dioxide in viscous system.</a></h2><p>Many viscous microenvironments exist in living systems. For instance, at the cellular level, the viscosity of subcellular organelles (mitochondria, lysosomes, endoplasmic reticulum, nucleus, etc.) is much greater than that of cytoplasm; at the organismal level, compared with normal states of health, blood or lymphatic fluid viscosity will increase to some extent in , hypertension, inflammation, tumors and so on. However, due to the design shortcoming, there is a lack of efficient tool for detecting biomolecules in viscous living systems. Herein, we propose a rational design strategy for constructing ratiometric fluorescent probes with superior response signal-to-background (S/) ratio in viscous systems based on rigid-fluorophore-molecular rotor platform, and a practical sulfur dioxide (SO2) probe (RFC-MRC) based on conmarin-cyanine dyad was prepared as a proof-of-concept. The probe performs a significant enhancement (71.5-fold) of ratiometric response signal stimulated by SO2 in viscous aqueous media. The cationic probe can selectively in mitochondria and was successfully utilized to sense SO2 in living HeLa cells through ratiometric fluorescence imaging. What's more, in the fluorescence imaging experiments of monitoring SO2 in apoptotic cells using probe RFC-MRC, a more obvious superior of S/ ratio was observed in the early apoptotic cells than in the lately apoptotic cells.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643624>Ritonavir.</a></h2><p>Ritonavir is an antiretroviral protease inhibitor that is widely used in combination with other protease inhibitors in the therapy and prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). Ritonavir can cause transient and usually asymptomatic elevations in serum aminotransferase levels and, rarely, can lead to clinically apparent acute liver injury. In HBV or HCV coinfected patients, highly active antiretroviral therapy with ritonavir may result of an exacerbation of the underlying chronic hepatitis  or C.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31641635>Comparison of the Different PCOS Phenotypes Based on Clinical Metabolic, and Hormonal Profile, and their Response to Clomiphene.</a></h2><p>To compare the different polycystic ovarian syndrome (PCOS) phenotypes based on their clinical, metabolic, hormonal profile, and their differential response to clomiphene.Prospective observational study.Infertility clinic, a government hospital.164 women with PCOS-related infertility.Sample population was divided into four phenotypes based on the NIH (National Institute of Health) consensus panel criteria. The incremental dose of clomiphene from 50 to 150 mg/day over three cycles was given.Clinical history, metabolic, hormonal profile, and ultrasound features of each phenotype. Also, the response to clomiphene citrate was studied as presence or absence of ovulation.The prevalence of phenotypes A, , C, and D were 67.7%, 11%, 17.7%, and 3.6%, respectively. Phenotype A had significantly higher weight, body mass index, clinical, and biochemical hyperandrogenism, menstrual irregularities, ovarian reserve parameters, fasting insulin, HOMA-IR, and more deranged lipid profile ( < 0.05). Clomiphene resistance was significantly more common in phenotype A ( < 0.05). No significant differences were noted in the waist circumference, waist-hip ratio, blood pressure and blood sugar values (fasting, 1-hour postprandial, 2-hour postprandial). Also, the Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH), LH-FSH ratio, 17-hydroxyprogesterone, and vitamin D levels were not significantly different among various PCOS phenotypes.Full-blown PCOS (phenotype A) is at a higher risk of adverse metabolic and cardiovascular outcomes as compared with the others, and phenotype D is the least severe phenotype. Thus, the phenotypic division of patients with PCOS-related infertility can help in prognosticating the patients about the severity of the disease and the fertility outcome.Copyright: © 2019 Indian Journal of Endocrinology and Metabolism.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31667355>Risk Factors and Drug Resistance of the MDR Acinetobacter Baumannii in Pneumonia Patients in ICU.</a></h2><p>To investigate the risk factors and drug resistance of MDR Acinetobacter baumannii in pneumonia patients.From January 2013 to February 2016, 98 pneumonia patients with MDR Acinetobacter baumannii in our hospital ICU were selected as the observation group, and 49 pneumonia patients with not-MDR Acinetobacter baumannii in our hospital ICU were selected as the control group in accordance with the proportion of 2:1. Sputum samples were collected from the two groups for drug resistance, and the risk factors and prognosis of MDR Acinetobacter baumannii in pneumonia patients were given survey analysis.The observation group was highly resistant to cefotaxime, piperacillin, imipenem, levofloxacin, gentamicin, tetracycline and ceftazidime, and was only sensitive to polymyxin. In addition to piperacillin, polymyxin , the other antimicrobial drug resistance rates in the control group was significantly lower than in the observation group (P<0.05). Univariate analysis showed that , infection before hospitalization, admission 24h score of APACHE II and GCS scores, deep venous catheterization, and mechanical ventilation were related to the MDR Acinetobacter baumannii in pneumonia patients(P<0.05). Non conditional logistic regression analysis showed that , infection before hospitalization, admission 24h score of APACHE II and GCS scores were the independent risk factors for the MDR Acinetobacter baumannii in pneumonia patients(P<0.05).MDR Acinetobacter baumannii in pneumonia patients in ICU is common, where  infection before hospitalization, admission 24h score of APACHE II and GCS scores are the main risk factors, and the vast majority of the antibiotics are resistant to the MDR Acinetobacter baumannii that can lead to poorer prognosis and followed-up of patients with increased mortality.© 2019 Jichen Ren et al., published by De Gruyter.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643585>Emtricitabine.</a></h2><p>Emtricitabine is a nucleoside analogue and reverse transcriptase inhibitor used in combination with other agents for treatment and prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). Emtricitabine does not appear to be a significant cause of drug induced liver injury, but may cause flares of disease in patients with underlying chronic hepatitis  virus (HBV) infection.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31618597>Prep1 regulates angiogenesis through a PGC-1α-mediated mechanism.</a></h2><p>Angiogenesis depends on a delicate balance between the different transcription factors, and their control should be considered necessary for preventing or treating diseases. Pre--cell leukemia transcription factor regulating protein 1 (Prep1) is a homeodomain transcription factor that plays a primary role in organogenesis and metabolism. Observations performed in a  hypomorphic mouse model, expressing 3-5% of the protein, show an increase of embryonic lethality due, in part, to defects in angiogenesis. In this study, we provide evidence that overexpression of  in mouse aortic endothelial cells (MAECs) stimulates migration, proliferation, and tube formation. These effects are paralleled by an increase of several proangiogenic factors and by a decrease of the antiangiogenic gene neurogenic locus notch homolog protein 1 (Notch1). Prep1-mediated angiogenesis involves the activation of the p160 Myb-binding protein (p160)/peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) pathway. Indeed,  overexpression increases its binding with p160 and induces a 4-fold increase of p160 and 70% reduction of PGC-1α compared with control cells. Incubation of MAECs with a synthetic Prep1(54-72) peptide, mimicking the Prep1 region involved in the interaction with p160, reverts the proangiogenic effects mediated by Prep1. In addition, Prep1 levels increase by 3.2-fold during the fibroblast growth factor β (bFGF)-mediated endothelial colony-forming cells' activation, whereas Prep1(54-72) peptide reduces the capability of these cells to generate tubular-like structures in response to bFGF, suggesting a possible role of Prep1 both in angiogenesis from preexisting vessels and in postnatal vasculogenesis. Finally,  hypomorphic heterozygous mice, expressing low levels of Prep1, show attenuated placental angiogenesis and vessel formation within Matrigel plugs. All of these observations indicate that Prep1, complexing with p160, decreases PGC-1α and stimulates angiogenesis.-Cimmino, I., Margheri, F., Prisco, F., Perruolo, G., D'Esposito, V., Laurenzana, A., Fibbi, G., Paciello, O., Doti, N., Ruvo, M., Miele, C., Beguinot, F., Formisano, P., Oriente, F. Prep1 regulates angiogenesis through a PGC-1α-mediated mechanism.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643785>Certolizumab.</a></h2><p>Certolizumab is a Fab fragment of a monoclonal antibody to human tumor necrosis factor alpha (TNFα) which has potent antiinflammatory activity and is used in the therapy of severe rheumatoid arthritis and inflammatory bowel disease. Certolizumab has had limited use and has yet to be specifically linked to instances of idiosyncratic acute liver injury or reactivation of hepatitis , but is likely to cause similar hepatic injury to what has been described for other TNFα antagonists such as infliximab and adalimumab.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31662777>GC-MS Analysis and Inhibitory Evaluation of  Leaf Extracts on Major Enzymes Linked to .</a></h2><p> leaves are used in managing both  and its complications in Southwest Nigeria. However, its inhibitory activity on enzymes implicated in  is not very clear. This study investigated the  inhibitory properties and mode of inhibition of  leaf extracts on enzymes associated with . The study also identified some bioactive compounds as well as their molecular interaction in the binding pocket of these enzymes. Standard enzyme inhibition and kinetics assays were performed to determine the inhibitory effects of aqueous extract (TCA) and ethanol extract (TCE) of  leaves on -glucosidase and -amylase activities. The phytoconstituents of TCA and TCE were determined using GC-MS. Molecular docking of the phytocompounds was performed using Autodock Vina. TCA and TCE were the most potent inhibitors of -glucosidase (IC = 3.28 ± 0.47 mg/mL) and -amylase (IC = 0.24 ± 0.08 mg/mL), respectively. Both extracts displayed a mixed mode of inhibition on -amylase activity, while mixed and noncompetitive modes of inhibition were demonstrated by TCA and TCE, respectively, on -glucosidase activity. The GC-MS analytic chromatogram revealed the presence of 24 and 22 compounds in TCE and TCA, respectively, which were identified mainly as phenolic compounds, terpenes/terpenoids, fatty acids, and other phytochemicals. The selected compounds exhibited favourable interactions with the enzymes compared with acarbose. Overall, the inhibitory effect of  on -amylase and -glucosidase may be ascribed to the synergistic action of its rich phenolic and terpene composition giving credence to the hypoglycaemic nature of  leaves.Copyright © 2019 Franklyn Nonso Iheagwam et al.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643183>Peramivir.</a></h2><p>Peramivir is an inhibitor of the influenza neuraminidase enzyme and is used as therapy of acute symptomatic influenza A and . Peramivir has not been associated with serum enzyme elevations during therapy or with clinically apparent liver injury.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31668448>Estimated Glomerular Filtration Rate, Activation of Cardiac Biomarkers and Long-Term Cardiovascular Outcomes: A Population-Based Cohort.</a></h2><p>To classify subjects in a general population per their renal function and characterize the cardiac biomarker levels, left ventricular function and cardiovascular outcomes over a 10.2 year follow-up period (interquartile range, 5.1-11.4 years).This was a retrospective review of a population-based random sample of residents aged ≥45 years. Data were collected between January 1, 1997, and December 31, 2000. One thousand nine hundred eighty-one individuals were classified based on estimated glomerular filtration rate (eGFR) into group I (>90 mL/min/1.73 m), group II (60 to 89 mL/min/1.73 m) and group III (<60 mL/min/1.73 m; chronic kidney disease [CKD]). Age/sex-adjusted baseline characteristics, tertiles of N-terminal pro -type natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hs-TnT) and their interactions with eGFR were examined. Outcomes measured included incident myocardial infarction (MI), congestive heart failure, stroke, and all-cause mortality.Eight hundred nineteen patients were classified as group I, 1036 as group II, and 126 of 1981 (6.4%) as group III or CKD. Subjects in group III were older and had a higher incidence of hypertension, , and MI at baseline. Over a 10.2-year follow-up period, CKD was associated with an increased risk of MI (hazard ratio, 1.95; 95% CI, 1.2-3.14; P=.006) and composite cardiovascular outcomes including MI, congestive heart failure, stroke, and all-cause mortality (hazard ratio, 1.38; 95% CI, 1.05-1.83 ;P=.02). Subjects with NT-proBNP or hs-TnT in the third tertile were at greater risk of cardiovascular events without significant interactions between eGFR and levels of NT-proBNP and hs-TnT.Subjects with CKD had significantly elevated cardiac biomarkers and were at an increased risk of MI and adverse cardiovascular events. This warrants future studies to investigate whether these cardiac biomarkers could identify high-risk CKD patients for aggressive management of cardiovascular risk factors.Copyright © 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31657647>Inositol polyphosphate multikinase is a metformin target that regulates cell migration.</a></h2><p>Metformin has been shown to alter cell adhesion protein expression, which is thought to play a role in its observed antitumor properties. We found that metformin treatment down-regulated integrin β1 concomitant with the loss of inositol polyphosphate multikinase (IPMK) in murine myocytes, adipocytes, and hepatocytes. To determine if IPMK was upstream of integrin β1 expression, we examined IPMK mouse embryonic fibroblast cells and found that integrins β1 and β3 gene expression was reduced by half, relative to wild-type cells, whereas focal adhesion kinase (FAK) activity and Rho/Rac/Cdc42 protein levels were increased, resulting in migration defects. Using nanonet force microscopy, we determined that cell:extracellular matrix adhesion and cell contractility forces were decreased, confirming the functional relevance of integrin and Rho protein dysregulation. Pharmacological studies showed that inhibition of both FAK1 and proline-rich tyrosine kinase 2 partially restored integrin β1 expression, suggesting negative regulation of integrin β1 by FAK. Together our data indicate that IPMK participates in the regulation of cell migration and provides a potential link between metformin and wound healing impairment.-Tu-Sekine, ., Padhi, A., Jin, S., Kalyan, S., Singh, K., Apperson, M., Kapania, R., Hur, S. C., Nain, A., Kim, S. F. Inositol polyphosphate multikinase is a metformin target that regulates cell migration.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643343>Fosamprenavir.</a></h2><p>Amprenavir is an antiretroviral protease inhibitor used in the therapy and prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). Fosamprenavir is a prodrug of amprenavir that has better oral bioavailability and that has largely replaced amprenavir in clinical use. Both amprenavir and fosamprenavir can cause transient and usually asymptomatic elevations in serum aminotransferase levels and are rare causes of clinically apparent, acute liver injury. In coinfected patients, hepatic injury during highly active antiretroviral therapy may be a result of exacerbation of the underlying chronic hepatitis  or C rather than a direct toxic effect of the medication.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31673082>Associations of autozygosity with a broad range of human phenotypes.</a></h2><p>In many species, the offspring of related parents suffer reduced reproductive success, a phenomenon known as inbreeding depression. In humans, the importance of this effect has remained unclear, partly because reproduction between close relatives is both rare and frequently associated with confounding social factors. Here, using genomic inbreeding coefficients (F) for >1.4 million individuals, we show that F is significantly associated (p < 0.0005) with apparently deleterious changes in 32 out of 100 traits analysed. These changes are associated with runs of homozygosity (ROH), but not with common variant homozygosity, suggesting that genetic variants associated with inbreeding depression are predominantly rare. The effect on fertility is striking: F equivalent to the offspring of first cousins is associated with a 55% decrease [95% CI 44-66%] in the odds of having children. Finally, the effects of F are confirmed within full-sibling pairs, where the variation in F is independent of all environmental confounding.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31644000>Heroin.</a></h2><p>Heroin and opium are potent opiates that are currently banned in the United States and considered drugs of abuse. Persons who actively use heroin or opium often have liver disease due to substance abuse (alcoholic liver injury) or injection drug use (chronic hepatitis , D or C), but neither heroin nor opium have been convincingly linked to clinically apparent liver injury or worsening of a concurrent liver disease.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643960>Ofatumumab.</a></h2><p>Ofatumumab is a recombinant human monoclonal antibody to CD20 a cell surface antigen found on pre- and mature  lymphocytes and which is approved for use in resistant chronic lymphocytic leukemia. Ofatumumab therapy has not been associated with serum enzyme elevations during therapy or to cases of idiosyncratic, clinically apparent liver injury. However, ofatumumab has potent immunosuppressive activity and its use has been associated with cases of reactivation of inactive or previously resolved hepatitis  which can be severe and can result in fatality.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31649929>Selective Phosphorylation of Akt/Protein-Kinase  Isoforms in Response to Dietary Cues.</a></h2><p>A calorie-rich diet is one reason for the continuous spread of metabolic syndromes in western societies. Smart food design is one powerful tool to prevent metabolic stress, and the search for suitable bioactive additives is a continuous task. The nutrient-sensing insulin pathway is an evolutionary conserved mechanism that plays an important role in metabolism, growth and development. Recently, lipid cues capable to stimulate insulin signaling were identified. However, the mechanistic base of their activity remains obscure to date. We show that specific Akt/Protein-kinase  isoforms are responsive to different calorie-rich diets, and potentiate the activity of the cellular insulin cascade. Our data add a new dimension to existing models and position  as a powerful tool to study the relation between dietary lipid cues and the insulin-induced cellular signal pathway.Copyright © 2019 Trautenberg, Prince, Maas, Beier, Honold, Grzybek and Brankatschk.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643592>Oseltamivir.</a></h2><p>Oseltamivir is an inhibitor of the influenza neuramidase enzyme and is used as therapy and prophylaxis against influenza A and . Oseltamivir has not been associated with clinically apparent liver injury.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31670404>Experience of family function, family involvement, and self-management in adult patients with type 2 : A thematic analysis.</a></h2><p>To describe the patient's experience of family function and its importance in -related self-management.Many patients fail to reach the targeted glycemic level due to low self-management adherence. Knowledge is needed regarding the impact of family function on  self-management.A qualitative descriptive design.A purposive sample of 20 patients with type 2 . Data were collected in March-June 2017 via audio recorded semi-structured interviews, field notes and Eco-maps. Analyzed using thematic framework matrix and thematic analysis.Four themes were identified: (1) Downplaying disease. The disease was trivialized creating a barrier to family involvement; (2) Second guessing. When  was not discussed, patient and family made their own assumptions; (3) Going it alone. The participants preferred sole disease responsibility to maintain usual family life; (4) No regrets. The participants managed their disease with medications only to maintain family cohesion and "the good life".The participants in our study downplayed the consequences of type 2  and chose to control their disease medically rather than by lifestyle changes. They renounced family involvement to maintain their lifestyle and promote family cohesion.© 2019 John Wiley & Sons Ltd.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31650071>A study protocol on nerve mobilization induced diffusion tensor imaging values in posterior tibial nerve in healthy controls and in patients with diabetic neuropathy-multigroup pretest posttest design.</a></h2><p>Diabetic neuropathy is the commonest chronic disabling complication of  which may lead to amputation and compromising patient's quality of life. It is characterized by pain, sensation loss associated with neural edema. Diffusion tensor imaging parameter i.e. fraction anisotropy determines the free water proton diffusion in the healthy nerve. Since the  leads to altered mechanosensitivity of the posterior tibial nerve thereby, might interferes with the water molecules movement. Therefore the present clinical trial will provide the evidence of improving the diffusion tensor imaging in the diabetic neuropathy directly by targeting the nerve through nerve mobilization treatment.Participants with Type II  induced peripheral neuropathy will be selected randomly on the basis of eligibility criteria and informed consent will be taken. Participants will be recruited into three groups. Group A (experimental group A) will receive neural mobilization technique, Group  (experimental group ) will receive conventional therapy and Group C (control group) will receive sham treatment for 3 weeks. MRI technique, Visual analogue scale and neuropathy specific quality of life questionnaire will be used as assessment tools. Assessment will be taken at baseline and post intervention.this clinical trial will provide the evidence of efficacy of nerve mobilization in determining the diffusion tensor imaging (DTI) changes in the posterior tibial nerve in patients with diabetic neuropathy. This trial will also be the first one in itself to look at the treatment induced DTI changes in the peripheral nerve.Clinical Trial Registry of India (CTRI/2019/06/019552).© 2019 Published by Elsevier Inc.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31644170>Bezlotoxumab.</a></h2><p>Bezlotoxumab is a human monoclonal antibody to the Clostridium difficile toxin  that is used to reduce the risk of recurrence in high risk patients being treated for C. difficile infection. Bezlotoxumab has not been associated with serum enzyme elevations during therapy or with instances of clinically apparent liver injury.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31664920>Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.</a></h2><p>We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared findings with recent trials of pharmacological inhibitors of PCSK9.Published and individual participant level data (300,000+ participants) were combined to construct a weighted PCSK9 gene-centric score (GS). Seventeen randomized placebo controlled PCSK9 inhibitor trials were included, providing data on 79,578 participants. Results were scaled to a one mmol/L lower LDL-C concentration.The PCSK9 GS (comprising 4 SNPs) associations with plasma lipid and apolipoprotein levels were consistent in direction with treatment effects. The GS odds ratio (OR) for myocardial infarction (MI) was 0.53 (95% CI 0.42; 0.68), compared to a PCSK9 inhibitor effect of 0.90 (95% CI 0.86; 0.93). For ischemic stroke ORs were 0.84 (95% CI 0.57; 1.22) for the GS, compared to 0.85 (95% CI 0.78; 0.93) in the drug trials. ORs with type 2  (T2DM) were 1.29 (95% CI 1.11; 1.50) for the GS, as compared to 1.00 (95% CI 0.96; 1.04) for incident T2DM in PCSK9 inhibitor trials. No genetic associations were observed for cancer, heart failure, atrial fibrillation, chronic obstructive pulmonary disease, or Alzheimer's disease - outcomes for which large-scale trial data were unavailable.Genetic variation at the PCSK9 locus recapitulates the effects of therapeutic inhibition of PCSK9 on major blood lipid fractions and MI. While indicating an increased risk of T2DM, no other possible safety concerns were shown; although precision was moderate.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643346>Ustekinumab.</a></h2><p>Ustekinumab is human monoclonal antibody to a polypeptide found on interleukin-12 and -23 that is used to treat autoimmune conditions and is approved for use in severe psoriasis. Ustekinumab is associated with a low rate of serum enzyme elevations during therapy, but has not been linked to cases of idiosyncratic, clinically apparent liver injury. Ustekinumab has immunomodulatory activity and may cause reactivation of hepatitis  in susceptible patients.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31672602>The Promotion of Bone Regeneration through CS/GP-CTH/antagomir-133a/ Sustained Release System.</a></h2><p>Few studies reported the application of miRNA in bone regeneration. In this study, the expression of miR133a and miR133b in murine BMSCs was inhibited via antagomiR-133a/ and the osteogenic differentiation in murine BMSCs was evaluated. The RT-PCR, flow cytometry, cell counting kit-8, and annexin V-FITC/PI double staining assays were performed. Double knockdown miR133a and miR133b can promote BMSC osteogenic differentiation. At optimum N/P ration (15:1), the loading efficiency can reach over 90%. CTH-antagomiR-133a/ showed no cytotoxicity to BMSCs and diminished miR133a and miR133b expression in BMSCs. Furthermore, chitosan-based sustained delivery system can continuous dose CTH-antagomiR-133a/ and calcium deposition and osteogenic specific gene expression were enhanced in vitro. The new bone formation was enhanced after the sustained delivery system containing CTH-antagomiR-133a/ nanoparticles was used in mouse calvarial bone defect model. Our results demonstrate that CTH nanoparticles could facilitate continuous dosing of antagomiR133a/, which can promote osteogenic differentiation.Copyright © 2019 Elsevier Inc. All rights reserved.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31644159>Tumor Necrosis Factor Antagonists.</a></h2><p>Tumor necrosis factor (TNF) alpha is a bioactive cytokine that is an important component of the inflammatory and pain pathways. Inhibition of TNF can decrease the inflammatory response, and this approach has been used in therapy of autoimmune conditions, most effectively in inflammatory bowel disease (IBD), rheumatoid arthritis, juvenile idiopathic arthritis (also known as juvenile rheumatoid arthritis), psoriasis, psoriatic arthritis and ankylosing spondylitis. Five anti-TNF antagonists have been developed and introduced into clinical medicine: a mouse-human chimeric monoclonal antibody to TNF (infliximab), two human monoclonal antibodies to TNF (adalimumab and golimumab), a humanized Fab fragment of anti-TNF linked to polyethylene glycol (certolizumab), and a soluble recombinant form of the TNF cellular receptor (etanercept) which, on binding, blocks the activity of TNF. These TNF antagonists have potent activity in several autoimmune diseases marked by excessive production of this proinflammatory cytokine. All five of these agents are approved for use in rheumatoid arthritis and are considered “disease modifying anti-rheumatic drugs” (DMARDs), having been shown to decrease pain, improve function, and ameliorate progressive joint damage in rheumatoid arthritis. The monoclonal antibodies to TNF have also been shown to be effective in psoriatic arthritis, ankylosing spondylitis and inflammatory bowel disease. The five agents rarely cause serum aminotransferase elevations, but have been linked to rare instances of clinically apparent, acute liver injury which often resembles autoimmune hepatitis and can be severe or require corticosteroid therapy. TNF antagonists are also immunosuppressive and can lead to reactivation of latent infections such as tuberculosis and hepatitis . Severe and even fatal instances of reactivation of hepatitis  have been linked to several anti-TNF agents, and routine screening for HBsAg before starting therapy with these agents is recommended. Patients with HBsAg should receive prophylaxis with an oral antiviral agent during therapy with one of the TNF antagonists. Among the TNF antagonists, infliximab has been most frequently and etanercept least frequently linked to liver injury, including asymptomatic serum aminotransferase elevations, induction of clinically apparent autoimmune hepatitis, and reactivation of hepatitis . However, infliximab has been most extensively used and studied than the other anti-TNF monoclonal antibodies, and liver injury due to these agents is probably class specific. For these reasons, all five of these agents should be considered potentially hepatotoxic, etanercept perhaps less so that the others. Drug Class: Antirheumatic Agents; Gastrointestinal Agents; Psoriasis Agents</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31635944>Chronic atrophic gastritis: Natural history, diagnosis and therapeutic management. A position paper by the Italian Society of Hospital Gastroenterologists and Digestive Endoscopists [AIGO], the Italian Society of Digestive Endoscopy [SIED], the Italian Society of Gastroenterology [SIGE], and the Italian Society of Internal Medicine [SIMI].</a></h2><p>Chronic atrophic gastritis (CAG) is an underdiagnosed condition characterised by translational features going beyond the strict field of gastroenterology as it may manifest itself by a variable spectrum of gastric and extra-gastric symptoms and signs. It is relatively common among older adults in different parts of the world, but large variations exist. Helicobacter pylori-related CAG [multifocal] and autoimmune CAG (corpus-restricted) are apparently two different diseases, but they display overlapping features. Patients with cobalamin and/or iron deficiency anaemia or autoimmune disorders, including autoimmune thyroiditis and type 1 , should be offered screening for CAG. Pepsinogens, gastrin-17, and anti-H. pylori antibodies serum assays seem to be reliable non-invasive screening tools for the presence of CAG, helpful to identify individuals to refer to gastroscopy with five standard gastric biopsies in order to obtain histological confirmation of diagnosis. Patients with CAG are at increased risk of developing gastric cancer, and they should be estimated with histological staging systems (OLGA or OLGIM). H. pylori eradication may be beneficial by modifying the natural history of atrophy, but not that of intestinal metaplasia. Patients with advanced stages of CAG (Stage III/IV OLGA or OLGIM) should undergo endoscopic surveillance every three years, those with autoimmune CAG every three-five years. In patients with CAG, a screening for autoimmune thyroid disease and micronutrient deficiencies, including iron and vitamin , should be performed. The optimal treatment for dyspeptic symptoms in patients with CAG remains to be defined. Proton pump inhibitors are not indicated in hypochlorhydric CAG patients.Copyright © 2019 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31613983>Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure.</a></h2><p>Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally. Early intervention for those with high cardiovascular risk is crucial in improving patient outcomes. Traditional prevention strategies for CVD have focused on conventional risk factors, such as overweight, dyslipidaemia, , and hypertension, which may reflect the potential for cardiovascular insult. Natriuretic peptides (NPs), including -type natriuretic peptide (BNP) and N-terminal pro -type natriuretic peptide (NT-proBNP), are well-established biomarkers for the detection and diagnostic evaluation of heart failure. They are of interest for CVD prevention because they are secreted by the heart as a protective response to cardiovascular stress, strain, and damage. Therefore, measuring NP levels in patients without heart failure may be valuable for risk stratification, to identify those at highest risk of CVD who would benefit most from intensive risk reduction measures.To assess the effects of natriuretic peptide (NP)-guided treatment for people with cardiovascular risk factors and without heart failure.Searches of the following bibliographic databases were conducted up to 9 July 2019: CENTRAL, MEDLINE, Embase, and Web of Science. Three clinical trial registries were also searched in July 2019.We included randomised controlled trials enrolling adults with one or more cardiovascular risk factors and without heart failure, which compared NP-based screening and subsequent NP-guided treatment versus standard care in all settings (i.e. community, hospital).Two review authors independently screened titles and abstracts and selected studies for inclusion, extracted data, and evaluated risk of bias. Risk ratios (RRs) were calculated for dichotomous data, and mean differences (MDs) with 95% confidence intervals (CIs) were calculated for continuous data. We contacted trial authors to obtain missing data and to verify crucial study characteristics. Using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, two review authors independently assessed the quality of the evidence and GRADE profiler (GRADEPRO) was used to import data from Review Manager to create a 'Summary of findings' table.We included two randomised controlled trials (three reports) with 1674 participants, with mean age between 64.1 and 67.8 years. Follow-up ranged from 2 years to mean 4.3 years.For primary outcome measures, effect estimates from a single study showed uncertainty for the effect of NP-guided treatment on cardiovascular mortality in patients with cardiovascular risk factors and without heart failure (RR 0.33, 95% CI 0.04 to 3.17; 1 study; 300 participants; low-quality evidence). Pooled analysis demonstrated that in comparison to standard care, NP-guided treatment probably reduces the risk of cardiovascular hospitalisation (RR 0.52, 95% CI 0.40 to 0.68; 2 studies; 1674 participants; moderate-quality evidence). This corresponds to a risk of 163 per 1000 in the control group and 85 (95% CI 65 to 111) per 1000 in the NP-guided treatment group.When secondary outcome measures were evaluated, evidence from a pooled analysis showed uncertainty for the effect of NP-guided treatment on all-cause mortality (RR 0.90, 95% CI 0.60 to 1.35; 2 studies; 1354 participants; low-quality evidence). Pooled analysis indicates that NP-guided treatment probably reduces the risk of all-cause hospitalisation (RR 0.83, 95% CI 0.75 to 0.92; 2 studies; 1354 participants; moderate-quality evidence). This corresponds to a risk of 601 per 1000 in the control group and 499 (95% CI 457 to 553) per 1000 in the NP-guided treatment group. The effect estimate from a single study indicates that NP-guided treatment reduced the risk of ventricular dysfunction (RR 0.61, 95% CI 0.41 to 0.91; 1374 participants; high-quality evidence). The risk in this study's control group was 87 per 1000, compared with 53 (95% CI 36 to 79) per 1000 with NP-guided treatment. Results from the same study show that NP-guided treatment does not affect change in NP level at the end of follow-up, relative to standard care (MD -4.06 pg/mL, 95% CI -15.07 to 6.95; 1 study; 1374 participants; moderate-quality evidence).This review shows that NP-guided treatment is likely to reduce ventricular dysfunction and cardiovascular and all-cause hospitalisation for patients who have cardiovascular risk factors and who do not have heart failure. Effects on mortality and natriuretic peptide levels are less certain. Neither of the included studies were powered to evaluate mortality. Available evidence shows uncertainty regarding the effects of NP-guided treatment on both cardiovascular mortality and all-cause mortality; very low event numbers resulted in a high degree of imprecision in these effect estimates. Evidence also shows that NP-guided treatment may not affect NP level at the end of follow-up.As both trials included in our review were pragmatic studies, non-blinding of patients and practices may have biased results towards a finding of equivalence. Further studies with more adequately powered sample sizes and longer duration of follow-up are required to evaluate the effect of NP-guided treatment on mortality. As two trials are ongoing, one of which is a large multi-centre trial, it is hoped that future iterations of this review will benefit from larger sample sizes across a wider geographical area.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643805>Acalabrutinib.</a></h2><p>Acalabrutinib is an oral inhibitor of Bruton’s tyrosine kinase that is used in the therapy of  cell malignancies including refractory mantle cell lymphoma. Acalabrutinib has not been associated with serum enzyme elevations during therapy or with cases of idiosyncratic acute liver injury, but has been linked to cases of reactivation of hepatitis .</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31659242>A randomized controlled trial to determining the effect of cinnamon on the plasma levels of soluble forms of vascular adhesion molecules in type 2 .</a></h2><p>Soluble forms of vascular adhesion molecules, ICAM-1 and VCAM-1, accelerate atherosclerosis pathogenesis. The present study was conducted to evaluate the effect of daily supplementation of 3 g cinnamon on the plasma levels of ICAM-1 and VCAM-1 among patients with type 2 . This randomized double-blind placebo-controlled trial was performed on 44 adult patients with type 2  aged 25-70 years. The patients were randomized to two groups of intervention (n = 22) and control (n = 22), differing by daily cinnamon supplementation or placebo (3 g) for 8 weeks. Plasma levels of ICAM-1 and VCAM-1 were measured at the beginning and end of the study. After 8 weeks, 39 subjects (n = 20 in the cinnamon and n = 19 in the placebo groups) completed the trial. There was a significant reduction in the mean levels of ICAM-1 and VCAM-1 within cinnamon and placebo groups (P < 0.001). But there was no significant difference in ICAM-1 (P = 0.75) and VCAM-1 (P = 0.72) between the groups at the end of the trial. According to the results, cinnamon supplementation has no beneficial effect on the reduction of ICAM-1 and VCAM-1 levels in patients with type 2 , which have a role in the development of atherogenesis.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31611548>Gpr17 deficiency in POMC neurons ameliorates the metabolic derangements caused by long-term high-fat diet feeding.</a></h2><p>Proopiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus (ARH) control energy homeostasis by sensing hormonal and nutrient cues and activating secondary melanocortin sensing neurons. We identified the expression of a G protein-coupled receptor, Gpr17, in the ARH and hypothesized that it contributes to the regulatory function of POMC neurons on metabolism.In order to test this hypothesis, we generated POMC neuron-specific Gpr17 knockout (PGKO) mice and determined their energy and glucose metabolic phenotypes on normal chow diet (NCD) and high-fat diet (HFD).Adult PGKO mice on NCD displayed comparable body composition and metabolic features measured by indirect calorimetry. By contrast, PGKO mice on HFD demonstrated a sexually dimorphic phenotype with female PGKO mice displaying better metabolic homeostasis. Notably, female PGKO mice gained significantly less body weight and adiposity (p < 0.01), which was associated with increased energy expenditure, locomotor activity, and respiratory quotient, while males did not have an overt change in energy homeostasis. Though PGKO mice of both sexes had comparable glucose and insulin tolerance, detailed analyses of liver gene expression and serum metabolites indicate that PGKO mice could have reduced gluconeogenesis and increased lipid utilization on HFD. To elucidate the central-based mechanism(s) underlying the better-preserved energy and glucose homeostasis in PGKO mice on HFD, we examined the electrophysiological properties of POMC neurons and found Gpr17 deficiency led to increased spontaneous action potentials. Moreover, PGKO mice, especially female knockouts, had increased POMC-derived alpha-melanocyte stimulating hormone and beta-endorphin despite a comparable level of prohormone POMC in their hypothalamic extracts.Gpr17 deficiency in POMC neurons protects metabolic homeostasis in a sex-dependent manner during dietary and aging challenges, suggesting that Gpr17 could be an effective anti-obesity target in specific populations with poor metabolic control.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643973>Antiviral Agents.</a></h2><p>The antivirals are a large and diverse group of agents that are typically classified by the virus infections for which they are used, their chemical structure and their mode of action. Most antiviral agents have been developed in the last 20 to 25 years, many as a result of the major research efforts to develop therapies and means of prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). Some of the agents developed to treat HIV infection, AIDS and its complications were found to also inhibit other viruses, and the novel approaches taken in development of antiretroviral therapy have been applied to develop therapies of other viral infections. . The antiretroviral agents include nucleoside analogues with reverse transcriptase activity (such as tenofovir, emtricitabine, lamivudine, abacavir, stavudine, didanosine, zidovudine), the nonnucleoside reverse transcriptase inhibitors (such as delavirdine, efavirenz, etravirine, nevirapine and rilpivirine), protease inhibitors (atazanavir, darunavir, indinavir, ritonavir, tipranavir and many others), and miscellaneous agents such as maraviroc that inhibits binding of the HIV virus its T cell receptor (CCR5 coreceptor antagonist), enfuvirtide that blocks the uptake of HIV into cells (fusion inhibitor), and integrase inhibitors (raltegravir, elvitegravir and dolutegravir) that block the integrase enzyme of HIV. . The agents active against hepatitis  virus (HBV) include several nucleoside analogues that are also active against and used to treat HIV infection (tenofovir, emtricitabine, lamivudine), as well as agents that are poorly if at all active against HIV (adefovir, entecavir and telbivudine). Alpha interferon and peginterferon (its long acting pegylated form) are also active against hepatitis , but are no longer commonly used for this indication.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643768>Ibrutinib.</a></h2><p>Ibrutinib is an oral inhibitor of Bruton’s tyrosine kinase that is used in the therapy of refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. Ibrutinib has not been associated with serum enzyme elevations during therapy, but has been linked to rare cases of clinically apparent acute liver injury and to reactivation of hepatitis .</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31620350>Metabolic profile and prolactin serum levels in men with type 2 : Old-new rubric.</a></h2><p>Prolactin (PRL) is involved in the regulation of glucose metabolism since high PRL serum levels are associated with low incidence of type 2  (T2DM). Therefore, the aim of the present study was to assess the metabolic effects of PRL on glucose homeostasis in men with T2DM.Eighty male patients with T2DM compared with 25 male healthy controls matched with patients for age and weight were divided into four groups: Group (A): patients with T2DM on metformin ( = 29), Group (): patients with T2DM on glyburide ( = 30), Group (C): patients with T2DM on glyburide plus metformin ( = 21), and Group (D): healthy male subjects as control ( = 25). Body mass index (BMI) and blood pressure measurements were determined. Fasting blood glucose (FBG), glycated hemoglobin, total cholesterol, triglyceride (TG), high-density lipoprotein, low-density lipoprotein, atherogenic index, fasting serum insulin, insulin resistance (IR), and β-cell function of the pancreas were determined by homeostatic model assessment-2 (HOMA-IR). Furthermore, C-reactive protein and PRL serum level were determined in patients with T2DM and healthy control men.BMI of T2DM patients was higher as compared with control ( = 0.003). Combination therapy (glyburide plus metformin) in patients with T2DM showed better effect on most of glycemic indices and lipid profile than glyburide or metformin monotherapy ( < 0.05). PRL serum level was higher in patients with T2DM as compared with control ( = 0.001). PRL serum level was high in glyburide-treated patients as compared with metformin-treated patients ( = 0.002).This study concludes that elevated PRL serum level in patients with T2DM is associated with diabetic complications. Diabetic pharmacotherapy mainly metformin reduced PRL serum level in patients with T2DM through amelioration of IR.Copyright: © 2019 International Journal of Critical Illness and Injury Science.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31621728>Effects of theabrownin on serum metabolites and gut microbiome in rats with a high-sugar diet.</a></h2><p>Evidence has proven that the gut microbiota is an important environmental factor contributing to obesity by altering host energy harvest and storage. We performed a high-throughput 16S rDNA sequencing association study and serum metabolomics profiling in rats with a high-sugar diet. Our studies revealed that the high sugar diet reduced the diversity of cecal microorganisms, while the combination of theabrownin and the high sugar diet increased the diversity of cecal microorganisms and promoted reproduction of Alloprevotella, Coprostanoligenes_group, Bacteroides, Prevotellaceae_NK3B31_group, Desulfovibrio, Intestinimonas, Alistipes, Bifidobacterium, Phascolarctobacterium, Ruminococcaceae_UCG-010 and Staphylococcus. The combination also inhibited the growth of Lactobacillus, Prevotellaceae_Ga6A1_group and Tyzzerella. The Firmicutes/Bacteroidetes (F/) ratio can be significantly reduced after the intervention of theabrownin in high sugar diet rats, and the reproduction of Bacteroides acidifaciens (BA) and Staphylococcus saprophyticus subsp. saprophyticus can be promoted. We found that the obesity-associated gut microbial species were linked to the changes in circulating metabolites. Serum levels of deoxycholic acid, cholic acid, 1H-indole-3-acetic acid, 3-indole acrylic acid and melatonin were negatively correlated with BA and Staphylococcus saprophyticus subsp. saprophyticus, but positively correlated with Lactobacillus murinus, Leptum and Gut_metagenome. 2-Hydroxy-6-methylpyridin-3-carboxylic acid, l-homoserine, and 1,7-dimethylxanthine were positively correlated with BA and Staphylococcus saprophyticus subsp. saprophyticus, but negatively correlated with Lactobacillus murinus, Leptum, and Gut_metagenome. In a high sugar diet mode, theabrownin reduced the body weight and triglycerides and improved insulin resistance mainly by targeting the reproduction of intestinal microorganisms such as BA, Staphylococcus saprophyticus subsp. saprophyticus, Lactobacillus murinus, Leptum, Gut_metagenome and so on. A strong correlation between cecal microorganisms and serum metabolites, obesity and insulin resistance was observed. Theabrownin has high potential in reducing the risk of cardiovascular diseases such as  and obesity.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31615314>Comparison of Urinary Sodium and Blood Pressure Relationship From the Spot Versus 24-Hour Urine Samples.</a></h2><p>Background We compared the relationship between sodium (Na) intake and blood pressure when Na intake was estimated from first- and second-morning spot urine samples using the INTERSALT (International Study on Salt and Blood Pressure) formula, versus directly measured 24-hour samples. Methods and Results We collected 24-hour urine and first- and second-morning voids of 383 participants in coastal Bangladesh for 2 visits. We measured participants' blood pressure using an Omron HEM-907 monitor. To assess the shape of the relationship between urinary Na and blood pressure, we created restricted cubic spline plots adjusted for age, sex, body mass index, smoking and alcohol consumption, physical activities, religion, sleep hours, and household wealth. To assess multicollinearity, we reported variance inflation factors, tolerances, and Leamer's and Klein's statistics following linear regression models. The mean daily urinary Na was 122 (SD 26) mmol/d for the first; 122 (SD 27) mmol/d for the second; and 134 (SD 70) mmol/d for the 24-hour samples. The restricted cubic spline plots illustrated no association between first-morning urinary Na and systolic blood pressure until the 90th percentile distribution followed by a downward relationship; a nonlinear inverse-V-shaped relationship between second-morning urinary Na and systolic blood pressure; and a monotonic upward relationship between 24-hour urinary Na and systolic blood pressure. We found no evidence of multicollinearity for the 24-hour urinary Na model. Conclusions The urinary Na and systolic blood pressure relationship varied for 3 urinary Na measurements. Twenty-four-hour urinary Na captured more variability of Na intake compared with spot urine samples, and its regression models were not affected by multicollinearity.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643634>Nelfinavir.</a></h2><p>Nelfinavir is an antiretroviral protease inhibitor used in the therapy and prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). Nelfinavir can cause transient and usually asymptomatic elevations in serum aminotransferase levels and is a rare cause of clinically apparent, acute liver injury. In HBV or HCV coinfected patients, hepatic injury during antiretroviral therapy that includes nelfinavir may be a result of exacerbation of the underlying chronic hepatitis  or C, rather than a direct effect of the medication.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31634866>DNA methylation analysis of negative pressure therapy effect in diabetic foot ulcers.</a></h2><p>Negative pressure wound therapy (NPWT) has been used to treat diabetic foot ulcerations (DFUs). Its action on the molecular level, however, is only partially understood. Some earlier data suggested NPWT may be mediated through modification of local gene expression. As methylation is a key epigenetic regulatory mechanism of gene expression, we assessed the effect of NPWT on its profile in patients with type 2  (T2DM) and neuropathic non-infected DFUs.Of 36 included patients, 23 were assigned to NPWT and 13 to standard therapy. Due to ethical concerns, the assignment was non-randomized and based on wound characteristics. Tissue samples were obtained before and 8±1 days after therapy initiation. DNA methylation patterns were checked by Illumina Methylation EPIC kit.In terms of clinical characteristics, the groups presented typical features of T2DM; however, the NPWT group had significantly greater wound area: 16.8 cm2 vs. 1.4 cm2 (p=0.0003). Initially only one region at chromosome 5 was differentially methylated. After treatment, 57 differentially methylated genes were found, mainly located on chromosomes 6 (chr6p21) and 20 (chr20p13); they were associated with DNA repair and autocrine signaling via retinoic acid receptor. We performed differential analyses pre-treatment and post-treatment. The analysis revealed 426 differentially methylated regions in the NPWT group, but none in the control group. The enrichment analysis showed 11 processes significantly associated with NPWT, of which 4 were linked with complement system activation. All but one were hypermethylated after NPWT.The NPWT effect on DFUs may be mediated through epigenetic changes resulting in inhibition of complement system activation.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31664089>A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice.</a></h2><p>Pathological tau correlates well with cognitive impairments in Alzheimer's disease (AD) patients and therefore represents a promising target for immunotherapy. Targeting an appropriate  cell epitope in pathological tau could in theory produce an effective reduction of pathology without disrupting the function of normal native tau. Recent data demonstrate that the N-terminal region of tau (aa 2-18), termed the "phosphatase activation domain (PAD)", is hidden within native Tau in a 'paperclip'-like conformation. Conversely, PAD is exposed in pathological tau and plays an essential role in the inhibition of fast axonal transport and tau polymerization. Thus, we hypothesized that anti-tau2-18 antibodies may safely and specifically reduce pathological tau and prevent further aggregation, which in turn would neutralize tau toxicity. Therefore, we evaluated the immunogenicity and therapeutic efficacy of our MultiTEP platform-based vaccine targeting tau2-18 formulated with Advax adjuvant (AV-1980R/A) in PS19 tau transgenic mice. The AV-1980R/A induced extremely high antibody responses and the resulting sera recognized neurofibrillary tangles and plaque-associated dystrophic neurites in AD brain sections. In addition, under non-denaturing conditions AV-1980R/A sera preferentially recognized AD-associated tau. Importantly, vaccination also prevented age-related motor and cognitive deficits in PS19 mice and significantly reduced insoluble total and phosphorylated tau species. Taken together, these findings suggest that predominantly targeting misfolded tau with AV-1980R/A could represent an effective strategy for AD immunotherapy.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643351>Saquinavir.</a></h2><p>Saquinavir is an antiretroviral protease inhibitor that is used in the therapy and prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). Saquinavir can cause transient and usually asymptomatic elevations in serum aminotransferase levels and, rarely, can lead to clinically apparent acute liver injury. In HBV or HCV coinfected patients, highly active antiretroviral therapy with saquinavir may result of an exacerbation of the underlying chronic hepatitis  or C.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31661872>Being Conscious of Water Intake Positively Associated with Sufficient Non-Alcohol Drink Intake Regardless of Seasons and Reasons in Healthy Japanese; the KOBE Study: A Cross Sectional Study.</a></h2><p>The present study sought to clarify if being conscious of water intake (CWI) is associated with sufficient non-alcohol drink (NAD) intake. We used data of healthy participants without , aged 40-74 years, in the Kobe Orthopedic and Biomedical Epidemiologic (KOBE) study. The association between being CWI and NAD intake was evaluated by multivariate linear regression analyses after adjusting for age, sex, surveyed months (seasons), alcohol drinking, health-awareness life habits, socioeconomic factors, serum osmolarity, estimated daily salt intake, and reasons for NAD intake. Among 988 (698 women and 290 men) participants eligible for the present analyses, 644 participants (65.2%) were CWI and 344 participants (34.8%) were not CWI (non-CWI). The most popular reason for being CWI was to avoid heat stroke in summer and to prevent ischemic cerebral stroke in winter. The CWI group took more NAD, especially decaffeinated beverages, than the non-CWI group (1846.7 ± 675.1 mL/day vs. 1478.0 ± 636.3 ml/day,  < 0.001). There was a significant association between being CWI and NAD intake in multivariate linear regression analyses ever after adjusting for the relevant variables (β = 318.1,  < 0.001). These findings demonstrated CWI, regardless of the reasons and the seasons, was associated with high NAD intake in Japanese healthy population.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31665341>Varicella Zoster Virus Infection of Primary Human Spinal Astrocytes Produces Intracellular Amylin, Amyloid-beta, and an Amyloidogenic Extracellular Environment.</a></h2><p>Herpes zoster is linked to amyloid-associated diseases, including dementia, macular degeneration, and , in epidemiological studies. Thus, we examined whether varicella zoster virus (VZV)-infected cells produce amyloid.Production of intracellular amyloidogenic proteins (amylin, amyloid precursor protein [APP], and amyloid-beta [Aβ]) and amyloid, as well as extracellular amylin, Aβ, and amyloid was compared between mock- and VZV-infected quiescent primary human spinal astrocytes (qHA-sps). The ability of supernatant from infected cells to induce amylin or Aβ42 aggregation was quantitated. Finally, the amyloidogenic activity of viral peptides was examined.VZV-infected qHA-sps, but not mock-infected qHA-sps, contained intracellular amylin, APP and/or Aβ, and amyloid. No differences in extracellular amylin, Aβ40, or Aβ42 were detected, yet only supernatant from VZV-infected cells induced amylin aggregation and, to a lesser extent, Aβ42 aggregation into amyloid fibrils. VZV glycoprotein  (gB) peptides assembled into fibrils and catalyzed amylin and Aβ42 aggregation.VZV-infected qHA-sps produced intracellular amyloid and their extracellular environment promoted aggregation of cellular peptides into amyloid fibrils that may be due, in part, to VZV gB peptides. These findings suggest that together with host and other environmental factors, VZV infection may increase the toxic amyloid burden and contribute to amyloid-associated disease progression.© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643755>Denileukin Diftitox.</a></h2><p>Denileukin diftitox is a recombinant fusion protein of human interleukin-2 (IL-2) attached to diphtheria toxin fragments A and  that is used as an antineoplastic agent to treat cutaneous T cell lymphomas that express IL-2 receptors. High doses of denileukin diftitox can cause mild-to-moderate elevations in serum enzymes and bilirubin, but rarely result in clinically significant acute liver injury.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31630778>Volume changes of the pancreatic head remnant after distal pancreatectomy.</a></h2><p>Little is known about pancreatic regeneration in humans after surgical resection. We examined pancreatic head volume changes after distal pancreatectomy.Using computed tomography or magnetic resonance imaging volumetry, we assessed volume changes of the pancreatic head remnant in 67 patients at defined time points (3, 6, 9, and 12 months) after distal pancreatectomy. A volume increase of >1 cm³ was defined as hypertrophy, a decrease of >1 cm³ as atrophy, and alterations of ±1 cm³ were considered as unchanged. Volumetry results were correlated with clinical patient data, histology, and immunohistochemistry for the pancreatic regeneration markers Pax4, Ghrelin, cholecystokinin receptor A, and cholecystokinin receptor  of the resection margin.Of 67 patients, 33 patients (49%) exhibited a hypertrophy of the pancreatic head remnant with a median increase of 5.08 cm³, 26 patients (39%) showed an atrophy, and in 8 patients (12%) pancreatic volume remained unchanged. No correlation of preoperative, postoperative, and new-onset  with hypertrophy or atrophy was found. In patients with ductal adenocarcinoma, hypertrophy occurred less frequently compared to patients with other pathologies (38% vs 63%; P = .04). In patients with ductal adenocarcinoma, hypertrophy was associated with significantly shorter survival. Patients with a postoperative hypertrophy that did not suffer from ductal adenocarcinoma displayed significantly less fibrosis at the resection margin compared to patients with a postoperative atrophy and pancreatic ductal adenocarcinoma patients. Immunohistochemical staining revealed no differential expression of the tested regeneration markers in hypertrophy versus atrophy.This study demonstrates volume changes of the pancreatic head remnant after distal pancreatectomy. Clinical and functional significance and underlying molecular mechanisms in humans remain unclear.Copyright © 2019 Elsevier Inc. All rights reserved.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31625413>Comparison of Interstitial Fluid Glucose Levels Obtained by Continuous Glucose Monitoring and Flash Glucose Monitoring in Patients With Type 2  Undergoing Hemodialysis.</a></h2><p>The accuracy of flash glucose monitoring (FGM, FreeStyle Libre Pro [FSL-Pro]) remains unclear in patients with type 2  (T2DM) undergoing hemodialysis.We assessed 13 patients with T2DM undergoing hemodialysis. They simultaneously underwent FGM, continuous glucose monitoring (CGM, iPro2), and self-monitoring blood glucose (SMBG).Parkes error grid analysis against SMBG showed that 49.0% and 51.0% of interstitial fluid glucose (ISFG) levels measured using FGM and 93.3% and 6.7% of those measured using CGM fell into zones A and , respectively. Mean absolute relative difference (MARD) against SMBG for FGM was significantly higher than that for CGM (19.5% ± 13.2% vs 8.1% ± 7.6%,  < .0001). Parkes error grid analysis of 2496 paired ISFG levels between FGM and CGM showed that 53.6%, 46.2%, and 0.2% of the plots fell into zones A, , and C, respectively. Mean ISFG levels were lower with FGM than with CGM (143.7 ± 67.2 mg/dL vs 164.6 ± 58.5 mg/dL;  < .0001). Mean absolute relative difference of ISFG levels between FGM and CGM was 19.2% ± 13.8%. Among three groups classified according to CGM ISFG levels (hypoglycemia, <70 mg/dL; euglycemia, 70-180 mg/dL; and hyperglycemia, >180 mg/dL), the MARDs for hypoglycemia (31.9% ± 25.0%) and euglycemia (22.8% ± 14.6%) were significantly higher than MARD for hyperglycemia (13.0% ± 8.5%) ( < .0001 in both).Flash glucose monitoring may be clinically acceptable. Average ISFG levels were lower with FGM than with CGM, and MARDs were higher for hypoglycemia and euglycemia in patients with T2DM undergoing hemodialysis.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31627238>[Multimorbidity in elder psychiatric patients].</a></h2><p>Multimorbidity in older psychiatric patients.Multimorbidity represents a great challenge in the medical care of older people.This exploratory study was part of the Gerontopsychiatry study Berlin (Gepsy-), an analysis of data on all 941 older inpatients (> 65 years) admitted to a psychiatric hospital within a period of 3 years.Nearly all patients (94,2 %) suffered from a chronic somatic disorder. The mean number of chronic somatic disorders was 2.70 + 1.39 and showed age dependency (r = 0.257, p < .001). The most prevalent disorders were cerebrovascular disorders (56.5 %), hypertension (54.8 %), chronic ischemic heart diseases or arrhythmias (52.2 %) and  type II (37.5 %). Furthermore, many of the patients suffered from disabilities such as movement disorders (26.2 %), severe hearing loss (16.5 %), incontinence (15.1 %) or severely reduced vision (7.4 %). Organic brain disorders were more often associated with chronic somatic disorders or disabilities.Older patients treated for psychiatric disorders very often show somatic multimorbidity that probably limit treatment outcome.© Georg Thieme Verlag KG Stuttgart · New York.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31614369>Negative Effects of Age at Menarche on Risk of Cardiometabolic diseases in Adulthood: A Mendelian Randomization Study.</a></h2><p>Observational studies showed that early menarche is associated with cardiometabolic diseases, but confounding factors make it difficult to infer causality.We herein used Mendelian randomization (MR) to examine whether age at menarche (AAM) is causally associated with Type 2  (T2D), Coronary Artery Diseases (CAD) and Cardiometabolic traits.A two-sample MR analysis was conducted using genome-wide association study (GWAS) summary statistics from the  Genetics Replication and Meta-analysis (DIAGRAM) consortium (n = 159,208) for T2D and the Coronary Artery Disease Genome-wide Replication and Meta-analysis plus the Coronary Artery Disease Genetics (CARDIoGRAMplusC4D) consortium (n = 184,305) for CAD. 122 instrumental variables (IVs) extracted from a published GWAS meta-analysis incorporating 182,416 women were used to determine the causal effect of AAM on cardiometabolic diseases, treating childhood and adult body mass index (BMI) as the confounders. Sensitivity analyses were also performed to detect the pleiotropy of the IVs.Through the MR approach we found that later AAM was associated with decreased risk of CAD (OR 0.92 [95% CI 0.88, 0.96], P = 2.06 × 10-4) in adults, as well as lower blood levels of log fasting insulin, log HOMA-, log HOMA-IR, triglyceride (TG) and diastolic blood pressure (DBP), but higher blood level of high density lipoprotein (HDL). However, the associations were substantially attenuated after excluding BMI-related variants. MR analyses provide little evidence on the causal effect between AAM and T2D.Our findings showed that AAM did not appear to have a causal effect on the risk of cardiometabolic diseases in adult life, as their associations observed in epidemiological studies might be largely mediated through excessive adiposity. We propose adiposity might be a primary target in future intervention strategy.© Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643524>Blinatumomab.</a></h2><p>Blinatumomab is a recombinant mouse derived bispecific monoclonal antibody to the CD3 cell surface antigen found on T lymphocytes and the CD19 site for the targeted (malignant)  lymphocytes. Blinatumomab is approved for use as a second line treatment of relapsed or refractory  cell precursor related acute lymphoblastic leukemia (ALL). Blinatumomabis commonly associated with mild-to-moderate serum enzyme and bilirubin elevations during the first cycle of therapy, but it has not been linked to cases of clinically apparent liver injury.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31659795>Clinical characteristics analysis of 1180 patients with hepatocellular carcinoma secondary to hepatitis , hepatitis C and alcoholic liver disease.</a></h2><p>To determine the clinical and liver stiffness characteristics of a cohort of Chinese patients with Hepatocellular carcinoma in different stages of Barcelona clinic liver cancer.Details of 1180 patients with Hepatocellular carcinoma referred from October 2014 to November 2017 were collected retrospectively. Demographic data, etiology, clinical, and biochemical details were retrospectively analyzed. The changes of liver stiffness in different etiologies and different stages of Barcelona clinic liver cancer were especially analyzed.The onset age was 60.33 ± 9.11 (range 24-84) years, 9 cases were ≤40 years, 572 cases were 41-60 years, males accounted for 83.92%, females accounted for 16.08%; 599 cases were ≥61 years, males accounted for 78.25%, females accounted for 21.75%. Compared with males, the proportion of females ≥61 is higher than that of men. Majority (n = 787; 66.69%) had HBV infection; second commonest cause was HCV infection (n = 217; 18.39%). More patients with HBV infection were 41-60 years (69.06%) and were younger than HCV patients. There was no statistical difference in etiology, age, gender, and distribution of  among different Barcelona clinic liver cancer stages (P > .05). The overall Hepatocellular carcinoma (HCC) was found to be positively correlated with alkaline phosphatase, γ-glutamyltransferase, and alpha-fetoprotein and liver stiffness measurement values from stage A to stage D (P < .05). ANOVA analysis showed that the overall liver stiffness measurement among the four BCLC stages was found to be statistically significant different in HBV-infected and HCV-infected HCC patients.Majority (99.24%) were patients aged >40 years old. Male is a high incidence population. In etiological analysis, HBV dominates HCC occurrence, HBV-, HCV-, and alcohol-associated HCC have distinct clinical and biochemical characteristics, necessitating different screening policies to optimize HCC surveillance and management.© 2019 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals, Inc.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31644075>Telbivudine.</a></h2><p>Telbivudine is a nucleoside analogue and antiviral inhibitor of hepatitis  virus (HBV) replication which is used alone and in combination with other agents in the therapy of the hepatitis . Telbivudine does not appear to be a significant cause of drug induced liver injury, but can be associated with flares of the underlying hepatitis  either during therapy or upon withdrawal.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31663569>Daily consumption of fruit-flavored yoghurt enriched with vitamins  contributes to lower energy intake and body weight reduction, in type 2 diabetic patients: a randomized clinical trial.</a></h2><p>Yoghurt naturally contains vitamins of -complex which play a central role in energy metabolism. This study investigates the effects of consumption of yoghurt enriched with vitamins , in comparison with conventional yoghurt, on body weight management and glycemic control of patients with Type 2  (T2DM). Thirty-three overweight/obese patients (BMI 27-36 kg m-2) were randomized into two groups receiving two servings of non-fat yoghurt per day, either strawberry-flavored enriched with vitamins B1, B5 and B6 (VY) or conventional (CY) for 12 weeks. At the beginning and the end of the dietary intervention, anthropometric characteristics, biochemical parameters, glycosylated haemoglobin (HbA1c), interleukin-6 (IL-6) and interleukin-1b (IL-1b), vitamins  and homocysteine concentrations were determined. Dietary assessments were also performed. At the end of the intervention, body weight and BMI were reduced in the VY group (86.5 ± 3.1 vs. 87.7 ± 3.0 kg, and 29.2 ± 1.0 vs. 29.6 ± 0.9 kg m-2, respectively, P < 0.05) and dietary intake was lower compared to the CY group (7277.6 ± 332.6 vs. 9918.2 ± 612.1 kJ day-1, P < 0.05). HbA1c was marginally reduced in the VY group (6.2 ± 0.2 vs. 6.4 ± 0.3%, P = 0.08), concentrations of B1, B2 and B6 were increased (63.8 ± 5.6 vs. 52.8 ± 1.7 μg L-1, P = 0.09, 9.2 ± 1.5 vs. 6.9 ± 1.4 μg L-1, P < 0.05 and 23.0 ± 2.8 vs. 14.9 ± 1.2 μg L-1, P < 0.05, respectively) and a trend towards reduced homocysteine concentrations was observed (16.9 ± 1.7 vs. 18.3 ± 2.0 μmol L-1, P = 0.06). IL-6 was decreased in both groups but significantly in the CY group (1.33 ± 0.13 vs. 1.67 ± 0.63 pg mL-1, P < 0.05). Daily consumption of fruit-flavored yoghurt enriched with vitamins  facilitates body weight management and improves vitamins  status and homocysteine levels in overweight/obese T2DM patients.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31622736>Regression of Fibrosis Stage With Treatment Reduces Long-Term Risk of Liver Cancer in Patients With Hemochromatosis Caused by Mutation in HFE.</a></h2><p>Fibrosis stage can decrease following treatment in patients with hemochromatosis caused by mutations in the homeostatic iron regulator gene (HFE), but the effects on cirrhosis are not clear. We assessed regression of severe fibrosis and the ensuing risk of liver cancer after treatment.We performed a retrospective analysis of data from 106 patients in France or Australia who were homozygous for the C282Y mutation in HFE with F3 fibrosis (n=40) or F4 fibrosis (n=66) at diagnosis and from whom at least 1 liver biopsy was collected during follow up. We collected data from the time of first biopsy and during follow-up period on patient demographics, treatment, smoking habits, alcohol consumption, infection with hepatitis  or C viruses, and other diseases. The median time between first and last liver biopsy was 9.5 years (range, 3.5-15.6 years). We collected results of tests for liver function, markers of iron stores, and platelet levels. patients were followed for a median 17.6 years (range, 9.8-24.1 years) for development of liver cancer occurrence.At last liver biopsy, 41 patients (38.6%) had fibrosis scores of F2 or less. Liver cancer occurred in 34 patients (52.3%) with F3 or F4 fibrosis at last liver biopsy vs 2 patients (4.8%) patients with fibrosis scores of F2 or less at last liver biopsy (P<.001). Liver cancer incidences were 32.8 per 1000 person-years (95% CI, 22.7-45.9 per 1000 person-years) in patients with F3 or F4 fibrosis and 2.3 per 1000 person-years (95% CI, 0.2-8.6 per 1000 person-years) in patients with fibrosis scores of F2 or less (P<.001). In multivariate analysis, male sex (hazard ratio [HR], 6.09; 95% CI, 1.21-30.4), age at diagnosis (HR, 1.16; 85% CI, 1.09-1.25), presence of  (HR, 3.07; 95% CI, 1.35-6.97), excess alcohol consumption (HR, 3.1; 95% CI, 1.47-6.35), serum level of ferritin at diagnosis (P<.01), and regression to fibrosis scores of F2 or less (HR, 0.08; 95% CI, 0.01-0.62) were significantly associated with risk of liver cancer.In a retrospective analysis of patients with hemochromatosis caused by the C282Y mutation in HFE, we found that severe liver fibrosis can regress with treatment. In patients with fibrosis regression to a stage F2 or less, the long-term risk for liver cancer is significantly reduced.Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643860>Adalimumab.</a></h2><p>Adalimumab is a monoclonal antibody to human tumor necrosis factor (TNF) alpha which has potent antiinflammatory activity and is used in the therapy of severe rheumatoid arthritis and inflammatory bowel disease. Adalimumab has been linked to rare instances of idiosyncratic acute liver injury and is a potential cause of reactivation of hepatitis .</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643294>Lopinavir.</a></h2><p>Lopinavir is an antiretroviral protease inhibitor used in combination with ritonavir in the therapy and prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). Lopinavir can cause transient and usually asymptomatic elevations in serum aminotransferase levels and, rarely, clinically apparent, acute liver injury. In HBV or HCV coinfected patients, highly active antiretroviral therapy with lopinavir may result of an exacerbation of the underlying chronic hepatitis  or C.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31661547>Effect of Ropivacaine on Peripheral Neuropathy in Streptozocin -induced Rats through TRPV1-CGRP pathway.</a></h2><p>Objective To determine the effect of ropivacaine on peripheral neuropathy in diabetic rats and its possible mechanism.Methods Forty-eight Sprague Dawley rats were randomly divided into six groups: nondiabetic control group, nondiabetic group A (0.25% ropivacaine), nondiabetic group  (0.75% ropivacaine), diabetic control group (Diabetic peripheral neuropathy (DPN) +artificial cerebrospinal fluid), diabetic group A (DPN+0.25% ropivacaine), and diabetic group  (DPN + 0.75% ropivacaine), with eight rats in each group. Within an hour of the last administration, the sciatic nerve motor conduction velocity (MNCV) of each group was measured, and the morphological changes of rat sciatic nerve were observed by HE, Weil's staining and electron microscopy. The expression of TRPV-1 in the spinal cord dorsal horn of rats was analyzed by immunohistochemistry, and the expression of CGRP protein in the spinal cord was analyzed by Western blot. Results Compared with the nondiabetic control group, elevated blood glucose, decreased weight and reduced average mechanical withdrawal threshold (MWT), additionally, the sciatic nerves showed significantly slowed conduction velocity (both p&lt;0.001) and damaged pathological structure, the expression of TRPV1 and CGRP were decreased (both p&lt;0.001) in the diabetic groups. Compared with the diabetic control group, down-regulation of TRPV1 and CGRP in spinal cord was significant for the diabetic group A and  treated with 0.25% and 0.75% ropivacaine, the higher concentration of ropivacaine correlated with a greater change. Conclusion Ropivacaine can significantly block sciatic nerve conduction velocity in DPN rats in a concentration-dependent manner, which may be related to the expression of the TRPV1-CGRP pathway.Copyright 2019 The Author(s).</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31639710>Diagnostic Accuracy of Neutrophil Gelatinase-Associated Lipocalin for Predicting Early Diabetic Nephropathy in Patients with Type 1 and Type 2 : A Systematic Review and Meta-analysis.</a></h2><p>Currently, there is a lack of prediction markers for diabetic nephropathy (DN) in patients with type 1 and type 2  (T1DM/T2DM). The aim of this systematic review and meta-analysis was to evaluate the value of a promising biomarker, neutrophil gelatinase-associated lipocalin (NGAL), in both serum and urine for the diagnosis of early DN in T1DM and T2DM patients with different stages of albuminuria.A comprehensive search was performed on PubMed by 2 reviewers until September 2018. Studies in which () the degree of DN was determined according to the urinary albumin/creatinine ratio and () NGAL was measured in healthy individuals and in  patients with DN were included in the meta-analysis. For each study, a 2 × 2 contingency table was formulated. Sensitivity, specificity, and other estimates of accuracy were calculated using a bivariate random effects model. The hierarchical summary ROC method was used to pool data and to evaluate the area under the curve (AUC). The sources of heterogeneity were explored by subgroup analysis. Publication bias was assessed using the Deeks test.The meta-analysis enrolled 22 studies involving 683 healthy individuals and 3249 patients with , of which 488 were T1DM and 2761 were T2DM patients. Overall, pooled sensitivity and specificity among the different settings analyzed ranged from 0.42 (95% CI, 0.22-0.66) to 1.00 (95% CI, 0.99-1.00) and 0.72 (95% CI, 0.62-0.80) to 0.98 (95% CI, 0.50-1.00) in T2DM patients, respectively. For T1DM patients, the corresponding estimates were 0.71 (95% CI, 0.59-0.81) to 0.89 (95% CI, 0.64-0.97) and 0.72 (95% CI, 0.62-0.80) to 0.79 (95% CI, 0.67-0.87). The AUC of NGAL for T2DM patients ranged from 0.69 (95% CI, 0.65-0.73) to 1.00 (95% CI, 0.99-1.00) in the different settings.The results of this meta-analysis suggest that NGAL in both serum and urine can be considered a valuable biomarker for early detection of DN in  patients.© 2019 American Association for Clinical Chemistry.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31619588>MicroRNA-7a overexpression in VMH restores the sympathoadrenal response to hypoglycemia.</a></h2><p>It is proposed that the impaired sympathoadrenal response to hypoglycemia induced by recurrent insulin-induced hypoglycemia (RH) is an adaptive phenomenon induced by specific changes in microRNA expression in the ventromedial hypothalamus (VMH). To test this hypothesis, genome-wide microRNAomic profiling of the VMH by RNA-sequencing was performed in control rats and rats treated for RH. Differential expression analysis identified microRNA-7a-5p and microRNA-665 as potential mediators of this phenomenon. To further test this hypothesis, experiments were conducted consisting of targeted lentiviral-mediated overexpression of microRNA-7a-5p and downregulation of microRNA-665 in the VMH. Hyperinsulinemic hypoglycemic clamp experiments demonstrated that targeted overexpression of microRNA-7a-5p (but not downregulation of microRNA-665) in the VMH of RH rats restored the epinephrine response to hypoglycemia. This restored response to hypoglycemia was associated with a restoration of GABAA receptor gene expression. Finally, a direct interaction of microRNA-7a-5p with the 3'-UTR of GABAA receptor α1-subunit (Gabra1) gene was demonstrated in a luciferase assay. These findings indicate that (a) the impaired sympathoadrenal response RH induces is associated with changes in VMH microRNA expression and () microRNA-7a-5p, possibly via direct downregulation of GABA receptor gene expression, may serve as a mediator of the altered sympathoadrenal response to hypoglycemia.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31648710>Resting Heart Rate and Type 2 : A Complex Relationship in Need of Greater Understanding.</a></h2><p></p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31652576> Plants-Drifting from Farm to Food Applications, Phytotherapy, and Phytopharmacology.</a></h2><p>The genus  includes about 500 different species and commonly grown in Europe, the United States, South Asia, and some northern areas of Iran and Pakistan. Leaves and fruits can be prepared as food flavorings, juices, and teas. Phytochemical analysis of these species has reported alkaloids, tannins, phenolic compounds and oleanolic acid, among others. Moreover, -cymene, limonene and ocimene as major compounds in essential oils were found by gas chromatography.  is an important group of the plants having enormous potential in the food and pharmaceutical industry, since they possess several properties, including antioxidant, antimicrobial, anticancer activities. Here we would like to review the biological properties of the phytoconstituents of this genus. We emphasize the cultivation control in order to obtain the main bioactive compounds, the antioxidant and antimicrobial properties in order to apply them for food preservation and for treating several diseases, such as cancer,  or Alzheimer. However, further study is needed to confirm the biological efficacy as well as, the toxicity.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643309>Antithymocyte Globulin.</a></h2><p>Antithymocyte globulin (ATG) is an antibody preparation derived from rabbits or horses hyperimmunized with human thymocytes, which is used to prevent or treat acute cellular rejection after solid organ transplantation and as a therapy of acute aplastic anemia. ATG has been linked to acute elevations in serum enzyme elevations shortly following infusions, but has not been linked to cases of clinically apparent liver injury. ATG is a potent immunosuppressive agent and may result in reactivation of hepatitis  in susceptible patients.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31654660>Vascular endothelial growth factor (VEGF)-releasing microspheres based on poly(ε-caprolactone-PEG-ε-caprolactone)--poly(L-lactide) multi-block copolymers incorporated in a 3D-printed poly(dimethylsiloxane) (PDMS) cell macroencapsulation device.</a></h2><p>Pancreatic islet transplantation is a promising advanced therapy that has been used to treat patients suffering from  type 1. Traditionally, pancreatic islets are infused via the portal vein which are subsequently intended to engraft in the liver. Severe immunosuppressive treatments are necessary, however, to prevent rejection of the transplanted islets. Novel approaches therefore have focused on encapsulation of the islets in biomaterial implants which can protect the islets and offer an organ-like environment. Vascularization of the device's surface is a prerequisite for the survival and proper functioning of transplanted pancreatic islets. We are pursuing a prevascularization strategy by incorporation of vascular endothelial growth factor (VEGF) loaded microspheres in 3D-printed poly(dimethylsiloxane) (PDMS)-based devices prior to their prospective loading with transplanted cells. Microspheres (∼ 50 μm) were based on poly(ε-caprolactone-PEG-ε-caprolactone)--poly(L-lactide) multi-block copolymers and were loaded with 10 μg VEGF/mg microspheres, and subsequently dispersed in a hyaluronic acid carrier liquid. In vitro release studies at 37°C demonstrated continuous release of fully bioactive VEGF for four weeks. In conclusion, our results demonstrate that incorporation of VEGF-releasing microspheres ensures adequate release of VEGF for a time window of four weeks, which is attractive in view of the vascularization of artificial pancreas implants.Copyright © 2019. Published by Elsevier Inc.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31647813>Thymically-derived Foxp3+ regulatory T cells are the primary regulators of type 1  in the non-obese diabetic mouse model.</a></h2><p>Regulatory T cells (Tregs) are an immunosuppressive population that are identified based on the stable expression of the fate-determining transcription factor forkhead box P3 (Foxp3). Tregs can be divided into distinct subsets based on whether they developed in the thymus (tTregs) or in the periphery (pTregs). Whether there are unique functional roles that distinguish pTregs and tTregs remains largely unclear. To elucidate these functions, efforts have been made to specifically identify and modify individual Treg subsets. Deletion of the conserved non-coding sequence (CNS)1 in the Foxp3 locus leads to selective impairment of pTreg generation without disrupting tTreg generation in the C57BL/6J background. Using CRISPR-Cas9 genome editing technology, we removed the Foxp3 CNS1 region in the non-obese diabetic (NOD) mouse model of spontaneous type 1  (T1D) to determine if pTregs contribute to autoimmune regulation. Deletion of CNS1 impaired in vitro induction of Foxp3 in naïve NOD CD4+ T cells, but it did not alter Tregs in most lymphoid and non-lymphoid tissues analyzed except for the large intestine lamina propria, where a small but significant decrease in RORγt+ Tregs and corresponding increase in Helios+ Tregs was observed in NOD CNS1-/- mice. CNS1 deletion also did not alter the development of T1D or glucose tolerance despite increased pancreatic insulitis in pre-diabetic female NOD CNS1-/- mice. Furthermore, the proportions of autoreactive Tregs and conventional T cells (Tconvs) within pancreatic islets were unchanged. These results suggest that pTregs dependent on the Foxp3 CNS1 region are not the dominant regulatory population controlling T1D in the NOD mouse model.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31636768>Association of vascular calcification of breast with carotid intima media thickness.</a></h2><p>To assess the relationship between breast arterial calcification (BAC) on mammography and carotid intima medial thickness (C-IMT) by comparing these patients with healthy control subjects.The study included 100 women divided into two groups based on presence of BAC on mammography using the WIPRO GE - DMR PLUS mammography unit. The groups included 50 BAC(+) (case group) and 50 BAC(-) (control group). BAC is defined as two linear calcific deposits forming the rail-road track pattern, with ring-like appearance in cross section. Relevant previous clinical and surgical history was taken and C-IMT was measured using -mode ultrasonography Aplio XG (Toshiba medical systems corp., Japan) using an 8-13 MHz linear transducer within 1 cm from the proximal and distal portion of the common carotid artery and the mean value was taken.All the participants included in this study were within the age group of 40-70 years. Mean age with BAC(+) was 59.18 ± 8.59 years and BAC(-) was 50.70 ± 7.93 years. Mean C-IMT in the BAC(+) group was 0.86 ± 0.21 mm vs. 0.71 ± 0.12 mm in the BAC(-) group. Chi-square test, independent  test and Spearman's rho correlation to assess the association of the breast arterial calcification were performed. The study showed significant difference in mean C-IMT between two groups ( value < 0.001) when correlated with age, , hypertension, presence of BAC and history of surgery and drug intake.BAC in mammography is independently associated with C-IMT. Furthermore, apart from age and menopausal status a statistically significant positive correlation with C-IMT was observed.Copyright © Polish Medical Society of Radiology 2019.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31672472>Isoflurane aggravates peripheral and central insulin resistance in high-fat diet/streptozocin-induced type 2 diabetic mice.</a></h2><p>Isoflurane anesthesia is reported to induce insulin resistance (IR) in the peripheral tissues. However, researches on the impact of isoflurane on insulin-related metabolism in the central nervous system, especially in type 2  (T2DM), are scarce. This study sought to explore whether isoflurane anesthesia had a negative effect on insulin sensitivity both in peripheral and central tissues. Moreover, the possible role of isoflurane anesthesia in T2DM mice with pre-existing IR was analyzed. T2DM model in C57BL/6J mice was established by high fat diet (HFD) and single intraperitoneal injection of streptozotocin (STZ, 60 mg/kg). Both HFD/STZ-induced T2DM mice and normal mice received 6 h isoflurane exposure. Blood glucose level and serum insulin concentration were detected and the homeostasis model assessment of IR (HOMA-IR) index was calculated to estimate peripheral IR. Relative levels of genes and proteins in the insulin-dependent signaling pathway in mouse prefrontal cortex and hippocampus were determined to measure central IR. Results indicated that 6 h isoflurane exposure induced hyperglycemia, hyperinsulinemia and raised HOMA-IR index. Meanwhile, phosphorylated insulin receptor substrate-1 (pIRS1) (Ser639) and phosphorylated insulin receptor substrate-2 (pIRS2) (Ser731) were upregulated, while phosphorylated protein kinase  (pAKT) (Ser473) and phosphorylated glycogen synthase kinase-3 beta (pGSK3β) (Ser9) were downregulated in the prefrontal cortex and hippocampus of anesthetized mice. Notably, isoflurane anesthesia significantly aggravated the degree of central IR in the aspects of gene transcriptions and protein expressions in HFD/STZ-induced T2DM mice with pre-existing IR. This study suggested that isoflurane anesthesia induced peripheral and central IR and aggravated pre-existing insulin resistance in T2DM mice.Copyright © 2019. Published by Elsevier .V.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643268>Mogamulizumab.</a></h2><p>Mogamulizumab is a humanized monoclonal antibody to the T cell CC chemokine receptor 4 which is used to treat peripheral and cutaneous T-cell lymphomas. Mogamulizumab is associated with a low rate of serum enzyme elevations during treatment and has been linked to several instances of reactivation of hepatitis .</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31656107>Optimisation of novel 4, 8-disubstituted dihydropyrimido[5,4-][1,4]oxazine derivatives as potent GPR 119 agonists.</a></h2><p>GPR119 is a promising target for discovery of anti-type 2  agents. We described the optimisation of a novel series of pyrimido[5,4-][1,4]oxazine derivatives as GPR119 agonists. Most designed compounds exhibited good agonistic activities. Among them, compound  and  demonstrated the potent EC values (13 and 12 nM, respectively) and strong inherent activities. Moreover, significant hypoglycaemic effect of compound  was observed by reducing the blood glucose AUC at the dose of 30 mg/kg, which is stronger than Vildagliptin (23.4% reduction vs. 17.9% reduction).</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31611502>Functional heterogeneity of resident fibroblasts in the kidney.</a></h2><p>Chronic kidney disease (CKD) is a global public health problem, affecting over 10% of the world's population and more than half of the population aged over 70 years, imposing major costs on healthcare systems. Although the primary causes of CKD include various diseases such as , glomerulonephritis, and acute kidney injury (AKI), the progression of CKD is mediated by a common pathological pathway, which is mainly characterized by fibrosis and chronic inflammation. In this process, resident fibroblasts in the kidney play crucial roles. Accumulating evidence highlights the existence of functional heterogeneity and plasticity of fibroblasts and their diverse roles in kidney disease progression and resolution. In addition to renal fibrosis, renal anemia and peritubular capillary loss, two major complications of progressive CKD, are also caused by dysfunction of resident fibroblasts. Furthermore, age-dependent alterations in fibroblast behavior also contribute to age-dependent unique pathological conditions. In this article, we describe the current understanding regarding the behaviors of fibroblasts in the kidney in health, disease, and aging.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31644098>Efalizumab.</a></h2><p>Efalizumab is a humanized monoclonal antibody to human CD11a subunit of the lymphocyte function-associated antigen 1, which acts as an immunosuppressant agent blocking lymphocyte activation and was formerly used to treat severe plaque psoriasis. Efalizumab has been linked to rare instances of idiosyncratic acute liver injury and may be a rare cause of reactivation of hepatitis .</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643708>Tipranavir.</a></h2><p>Tipranavir is an antiretroviral protease inhibitor used in the therapy and prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). Tipranavir can cause transient and usually asymptomatic elevations in serum aminotransferase levels and is a rare cause of clinically apparent, acute liver injury. In coinfected patients, hepatic injury during highly active antiretroviral therapy including tipranavir may be a result of exacerbation of the underlying chronic hepatitis  or C, rather than a direct effect of the medication.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31667053>Case report of penile  infection in an unexpected patient.</a></h2><p>There are few reports of penile mucormycosis and even fewer in the absence of overt immune suppression. An eighty year old male with  presents with penile mass. The pathology and culture demonstrated . He was treated with surgery and liposomal amphotericin . His therapy was stopped after pathology demonstrated clear surgical margins. His good outcome provides evidence that stopping antifungal therapy after achieving clear surgical margins is acceptable in patients without ongoing immunosuppression.© 2019 The Authors.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31630321>Body muscle-to-fat ratio gender-specific cut-off values for impaired insulin sensitivity in patients with treatment-naïve type 2 .</a></h2><p>We previously reported that the body muscle-to-fat ratio (BMFR), measured using bioelectrical impedance, significantly correlated with whole-body insulin sensitivity. We examined BMFR gender-specific cut-off values for impaired insulin sensitivity in treatment-naïve type 2  (T2DM) patients.Subjects included 101 untreated T2DM patients (male, 66; female, 35). We performed a hyperinsulinemic-euglycemic clamp examination to measure the steady-state glucose infusion rate (M value) as an indicator of whole-body insulin resistance. We defined the M value divided by the steady-state serum insulin value as the M/I value. We defined the existence of insulin resistance using an M/I ratio <9.0. The optimal cut-off value for BMFR was calculated by receiver operating characteristics (ROC) analysis.The cut-off value of the BMFR for insulin resistance was 2.75 (area under the curve [AUC] = 0.83, sensitivity 75%, and specificity 76%, P < 0.001) for males and 1.65 (AUC = 0.87, sensitivity 84%, and specificity 81%, P < 0.001) for females. Simple linear regression analysis showed that BMFR was significantly correlated with the M/I value in both genders (males,  = 0.77, P< 0.01; females,  = 0.83, P< 0.01).BMFR cut-off values for impaired insulin sensitivity in treatment-naïve T2DM patients were 2.75 for males and 1.65 for females.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643324>Ramucirumab.</a></h2><p>Ramucirumab is a human monoclonal antibody to the vascular endothelial growth factor (VEGF) receptor 2 and is an antiangiogenesis agent used in the therapy of advanced colorectal, gastric and lung cancers. Ramucirumab has not been linked to serum enzyme elevations during therapy or to instances of idiosyncratic acute liver injury, but has been reported to worsen liver failure in patients with decompensated cirrhosis (Child Class  or C).</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643442>Golimumab.</a></h2><p>Golimumab is a human monoclonal antibody to tumor necrosis factor (TNF) alpha that is used in the treatment of rheumatoid arthritis and ulcerative colitis. Golimumab has been linked to a low rate of serum enzyme elevations during therapy, but has not been linked to cases of idiosyncratic, clinically apparent liver injury with jaundice. Because golimumab is a potent inhibitor of TNF alpha, it is likely to cause reactivation of chronic hepatitis  in susceptible patients.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31653645>Oxidatively Damaged DNA/RNA and 8-Isoprostane Levels Are Associated With the Development of Type 2  at Older Age: Results From a Large Cohort Study.</a></h2><p>Oxidative stress is believed to play an important role in the pathophysiology of type 2 , but the few cohort studies that have assessed the association of oxidative stress biomarkers with type 2  incidence were small and reported inconclusive results.We examined the associations of urinary oxidized guanine/guanosine (OxGua) levels (a biomarker of DNA/RNA oxidation) and urinary 8-isoprostane levels (a biomarker of lipid peroxidation) with type 2  incidence in 7,828 individuals initially without  from a population-based German cohort study with 14 years of follow-up. Hazard ratios (HRs) and 95% CIs per 1 SD were obtained using multivariable-adjusted Cox proportional hazards regression models.In the total population, weak but statistically significant associations with type 2  incidence were observed for OxGua (HR [95% CI] per 1 SD 1.05 [1.01; 1.09]) and 8-isoprostane (1.04 [1.00; 1.09]) levels. Stratified analyses showed that associations of both biomarkers with type 2  incidence were absent in the youngest age-group (50-59 years) and strongest in the oldest age-group (65-75 years) of the cohort, with HRs of OxGua levels of 1.14 (1.05; 1.23) per 1 SD and of 8-isoprostane levels of 1.22 (1.02; 1.45) per 1 SD.These results from a large cohort study support suggestions that an imbalanced redox system contributes to the development of type 2  but suggest that this association becomes clinically apparent at older ages only, possibly as a result of reduced cellular repair capacity.© 2019 by the American  Association.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31666589>Natural phenolic compounds potentiate hypoglycemia via inhibition of Dipeptidyl peptidase IV.</a></h2><p>Dipeptidyl peptidase IV (DPP IV) is a surface glycoprotein that can degrade glucagon like pepetide-1 (GLP-1) by decreasing blood sugar. Herbal medicines for diabetic therapy are widely used with acceptable efficacy but unsatisfied in advances. DPP IV was chosen as a template to employ molecular docking via Discovery Studio to search for natural phenolic compounds whether they have the inhibitory function of DPP IV. Then, docking candidates were validated and further performed signal pathway via Caco-2, C2C12, and AR42J cells. Lastly, a diet-induced  in mice were applied to examine the efficacy and toxicity of hit natural phenolic products in long-term use (in vivo). After screening, curcumin, syringic acid, and resveratrol were found in high affinity with DPP IV enzymes. In enzymatic tests, curcumin and resveratrol showed potential inhibition of DPP IV. In vitro assays, curcumin inhibited of DPP IV activity in Caco-2 cells and ERK phosphorylation in C2C12 cells. Additionally, curcumin attenuated blood sugar in S961-treated C57BL/6 mice and in diet-induced diabetic ICR mice and long-term regulate HbA1c in diabetic mice. Curcumin targeted to DPP IV for reducing blood glucose, it possesses potential and alternative substitution of synthetic clinical drugs for the medication of .</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31652638>Antioxidant and Anti-Inflammatory Effects of Curcumin Nanoparticles on Drug-Induced Acute Myocardial Infarction in Diabetic Rats.</a></h2><p>We have investigated the cardio-protective effects of pretreatment with curcumin nanoparticles (CUN) compared to conventional curcumin (CUS) on the changes in oxidative stress parameters and inflammatory cytokine levels during induced acute myocardial infarction (AMI) in rats with  (DM). DM was induced with streptozotocin, and AMI with isoproterenol. Eight groups of seven Wister Bratislava rats were included in the study. The N-C was the normal control group, AMI-C was the group with AMI, DM-C was the group with DM, and DM-AMI-C was the group with DM and AMI. All four groups received saline solution orally during the whole experiment. S-DM-CUS-AMI and S-DM-CUN-AMI groups received saline for seven days prior to DM induction and continued with CUS (200 mg/kg bw, bw = body weight) for S-DM-CUS-AMI and CUN for S-DM-CUN-AMI (200 mg/kg bw) for 15 days before AMI induction. The CUS-DM-CUS-AMI group received CUS (200 mg/kg bw), while the CUN-DM-CUN-AMI received CUN (200 mg/kg bw) for seven days prior to DM induction, and both groups continued with administration in the same doses for 15 days before AMI induction. CUS and CUN prevented elevation of creatine kinase, creatine kinase-MB, lactate dehydrogenase in all groups, with better results in the CUN (S-DM-CUN-AMI and CUN-DM-CUN-AMI groups). CUS and CUN significantly reduced serum levels of oxidative stress markers (malondialdehyde, the indirect assessment of nitric oxide synthesis, and total oxidative status) and enhanced antioxidative markers (total antioxidative capacity and thiols, up to 2.5 times). All groups that received CUS or CUN showed significantly lower serum levels of tumor necrosis factor-alpha, interleukin-6, and interleukin-1β. The best antioxidative and anti-inflammatory effects were obtained for the group that received CUN before DM induction (CUN-DM-CUN-AMI group). Pretreatment with CUN proved higher cardio-protective effects exerting an important antioxidative and anti-inflammatory impact in the case of AMI in DM.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31652837>Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer.</a></h2><p>Liver cancer is one of the leading causes of death worldwide due to late diagnosis and scarcity of treatment options. The major risk factor for liver cancer is cirrhosis with the underlying causes of cirrhosis being viral infection (hepatitis  or C), metabolic deregulation (Non-alcoholic fatty liver disease (NAFLD) in the presence of obesity and ), alcohol or cholestatic disorders. Lysophosphatidic acid (LPA) is a bioactive phospholipid with numerous effects, most of them compatible with the hallmarks of cancer (proliferation, migration, invasion, survival, evasion of apoptosis, deregulated metabolism, neoangiogenesis, etc.). Autotaxin (ATX) is the enzyme responsible for the bulk of extracellular LPA production, and together with LPA signaling is involved in chronic inflammatory diseases, fibrosis and cancer. This review discusses the most important findings and the mechanisms related to ATX/LPA/LPAR involvement on metabolic, viral and cholestatic liver disorders and their progression to liver cancer in the context of human patients and mouse models. It focuses on the role of ATX/LPA in NAFLD development and its progression to liver cancer as NAFLD has an increasing incidence which is associated with the increasing incidence of liver cancer. Bearing in mind that adipose tissue accounts for the largest amount of LPA production, many studies have implicated LPA in adipose tissue metabolism and inflammation, liver steatosis, insulin resistance, glucose intolerance and lipogenesis. At the same time, LPA and ATX play crucial roles in fibrotic diseases. Given that hepatocellular carcinoma (HCC) is usually developed on the background of liver fibrosis, therapies that both delay the progression of fibrosis and prevent its development to malignancy would be very promising. Therefore, ATX/LPA signaling appears as an attractive therapeutic target as evidenced by the fact that it is involved in both liver fibrosis progression and liver cancer development.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31633211>Chronic administration of Cl-amidine, a pan-peptidylarginine deiminase inhibitor, does not reverse bone loss in two different murine models of osteoporosis.</a></h2><p>Recent in vitro studies have shown a role for the peptidyl-arginine deiminases (PADs) in bone resorption. However, it is unknown whether these enzymes are involved in bone loss in vivo. Thus, we evaluated the antiresorptive effect of a pan-PAD inhibitor in two murine models of osteoporosis: (a) primary osteoporosis induced by ovariectomy (OVX); and () secondary osteoporosis associated to Type-1  induced by streptozotocin (STZ, 50 mg/kg, i.p., five daily administrations). Five weeks after OVX and 15 weeks after injections of STZ, mice received daily administrations of Cl-amidine (3 or 10 mg/kg, i.p.) or vehicle for 30 consecutive days. At the end of the treatment, femur and vertebra were harvested for microCT analysis. Blood samples were collected for determination of antibodies against cyclic citrullinated peptides (anti-CCP) by enzyme-linked immunosorbent assay. Serum levels of anti-CCP antibodies from diabetic mice were not significantly different compared to control mice. However, a significant loss of both trabecular bone at the femoral neck and cortical bone at the femoral diaphysis was found in diabetic mice, and Cl-amidine did not reverse the -induced bone loss. Mice with OVX had significantly lower serum levels of anti-CCP compared to mice with sham surgery. OVX resulted in significant loss of both trabecular bone at the L5 vertebra and distal femoral metaphysis. Cl-amidine did not block the OVX-induced bone loss. Our results suggest that chronic treatment with Cl-amidine at the doses and period of time administered is not long enough to inhibit bone loss in two different murine models of osteoporosis.© 2019 Wiley Periodicals, Inc.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643537>Alemtuzumab.</a></h2><p>Alemtuzumab is a recombinant humanized monoclonal antibody to human CD52 which is used in the therapy of chronic lymphocytic leukemia, and off-label for induction regimens for solid organ transplantation and for resistant or relapsing multiple sclerosis. Alemtuzumab has been linked to occasional serum enzyme elevations during therapy and, while alemtuzumab has not been linked to cases of idiosyncratic, clinically apparent liver injury, it is a potent immunosuppressive agent and can lead to reactivation of chronic hepatitis  and exacerbations of chronic hepatitis C that can be severe and even fatal.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31620092>Molecular Mechanisms of Glucose Fluctuations on Diabetic Complications.</a></h2><p>Accumulating evidence indicates the occurrence and development of diabetic complications relates to not only constant high plasma glucose, but also glucose fluctuations which affect various kinds of molecular mechanisms in various target cells and tissues. In this review, we detail reactive oxygen species and their potentially damaging effects upon glucose fluctuations and resultant downstream regulation of protein signaling pathways, including protein kinase C, protein kinase , nuclear factor-κ, and the mitogen-activated protein kinase signaling pathway. A deeper understanding of glucose-fluctuation-related molecular mechanisms in the development of diabetic complications may enable more potential target therapies in future.Copyright © 2019 Zhang, Miao, Qian, Wang, Qi, Zhang, Dang, Wu and Wang.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643253>Atazanavir.</a></h2><p>Atazanavir is an antiretroviral protease inhibitor that is used in the therapy and prevention of human immunodeficiency virus (HIV-1) infection and the acquired immunodeficiency syndrome (AIDS). Atazanavir can cause transient and usually asymptomatic elevations in serum aminotransferase levels, mild elevations in indirect bilirubin concentration and, rarely, clinically apparent, acute liver injury. In HBV or HCV coinfected patients, highly active antiretroviral therapy with atazanavir may result of an exacerbation of the underlying chronic hepatitis  or C.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31644070>Belimumab.</a></h2><p>Belimumab is a human monoclonal antibody to the soluble -lymphocyte stimulator (BLsY) which is used in the therapy of systemic lupus erythematous. Belimumab has been linked to an uncommon incidence of transient serum enzyme elevations during therapy, but has yet to be linked to instances of clinically apparent liver injury.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643870>Lamivudine.</a></h2><p>Lamivudine is a nucleoside analogue and reverse transcriptase inhibitor used in the therapy of human immunodeficiency virus (HIV) and hepatitis  virus (HBV) infection. Lamivudine is a very rare cause of clinically apparent drug induced liver injury, but is associated with flares of underlying hepatitis  during therapy or with abrupt withdrawal.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31659627>Impact of Carbohydrate on Glucose Variability in Patients with Type 1  Assessed Through Professional Continuous Glucose Monitoring: A Retrospective Study.</a></h2><p>The aim of this study was to objectively analyze the correlation between dietary components and blood glucose variation by means of continuous glucose monitoring (CGM).Patients with type 1  (T1DM) who received CGM to manage their blood glucose levels were enrolled into the study, and the components of their total caloric intake were analyzed. Glycemic variation parameters were calculated, and dietary components, including percentages of carbohydrate, protein and fat in the total dietary intake, were analyzed by a dietitian. The interaction between parameters of glycemic variability and dietary components was analyzed.Sixty-one patients with T1DM (33 females, 28 males) were enrolled. The mean age of the participants was 34.7 years, and the average duration of  was 14 years. Glycated hemoglobin before CGM was 8.54%. Participants with a carbohydrate intake that accounted for < 50% of their total caloric intake had a longer DM duration and a higher protein and fat intake than did those with a carbohydrate intake that accounted for ≥ 50% of total caloric intake, but there was no between-group difference in total caloric intake per day. The group with a carbohydrate intake that accounted for < 50% of their total caloric intake also had lower nocturnal continuous overlapping net glycemic action (CONGA) 1, - 2 and - 4 values. The percentage of protein intake had a slightly negative correlation with mean amplitude of glycemic excursions (MAGE) (r = - 0.286, p < 0.05) and a moderately negative correlation with coefficient of variation (CV) (r = 0.289, p < 0.05). One additional percentage of protein calories of total calories per day decreased the MAGE to 4.25 mg/dL and CV to 0.012 (p < 0.05). The optimal dietary protein percentage for MAGE < 140 mg/dL was 15.13%. The performance of predictive models revealed the beneficial effect of adequate carbohydrate intake on glucose variation when combined with protein consumption.Adequate carbohydrate consumption-but not more than half the daily total calories-combined with protein calories that amount to approximately 15% of the daily caloric intake is important for glucose stability and beneficial for patients with T1DM.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31644110>Mavyret.</a></h2><p>Mavyret is an oral, fixed combination of antiviral agents used to treat chronic hepatitis C virus (HCV) infection due to any genotype (1 through 6). This combination has not been linked to instances or worsening of serum enzymes during therapy or with de novo appearance of clinically apparent liver injury. However, all effective direct acting antiviral agents for hepatitis C are considered capable of causing reactivation of hepatitis  in susceptible patients.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31670921>Stroke Care and Application of Thrombolysis in Ibero-America: Report From the SITS-SIECV Ibero-American Stroke Register</a></h2><p>Standardized registries may provide valuable data to further improve stroke care. Our aim was to
obtain updated information about characteristics of stroke patients and management of stroke across the Ibero-American countries, using a common in-hospital registry (Safe Implementation of Treatments in Stroke–Sociedad Iberoamericana de Enfermedades Cerebrovasculares) as a basis for further quality improvement.Data for this study were entered into the Safe Implementation of Treatments in Stroke registry from September
2009 to December 2013 by 58 centers in 14 countries. Data included demographics, risk factors, onset-to-door time, National Institutes of Health Stroke Scale score, stroke subtype, ischemic stroke etiology, treatments, 3-month mortality, and modified Rankin Scale score. Time to treatment was also recorded for patients treated with thrombolysis.Five thousand four hundred one patients were registered; median age, 65 years; 46% women; 3915 (72.5%)
ischemic strokes; 686 (13.7%) hemorrhagic strokes; 213 (4.3%) subarachnoid hemorrhages; 414 (8.3%) transient ischemic attacks; and 31 (0.6%) cerebral vein thrombosis. The most prevalent risk factors were hypertension (71.3%), dyslipidemia (35.2%), and  (23.6%). Atrial fibrillation was present in 15.1%. Three hundred one ischemic strokes were treated with intravenous thrombolysis (IVT; 7.7%). Patients undergoing IVT were more severely affected (median baseline National Institutes of Health Stroke Scale score, 11 versus 6). The rate of symptomatic intracerebral hemorrhages after IVT was 5.7%. At 3 months, 60.3% of IVT-treated patients and 59.1% of untreated patients were independent (modified Rankin Scale score, 0–2). Mortality was 11.4% in treated and 12.8% in untreated patients.Safe Implementation of Treatments in Stroke–Sociedad Iberoamericana de Enfermedades Cerebrovasculares
is the largest registry of a general stroke population and the first study to evaluate the level of IVT use in Ibero-America. It provides valuable information that may help to improve the quality of stroke care in the Ibero-American region.© 2019 American Heart Association, Inc.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31647140>The route from the folded to the amyloid state: exploring the potential energy surface of a drug-like miniprotein.</a></h2><p>The amyloid formation of the folded segment of a variant of Exenatide (a marketed drug for Type-2  ) was studied by ECD and NMR. We found that the optimum temperature for E5 protein amyloidosis coincides with body temperature and requires well below physiological salt concentration. Decomposition of the ECD spectra and its barycentric representation on the folded-unfolded-amyloid potential energy surface allowed us to monitor the full range of molecular transformation of amyloidogenesis. We identified points of no return ( e.g. T =37°C, pH =4.1, c E5 =250µM, c NaCl =50mM, t >4-6 h) which will inevitably gravitate into the amyloid-state. The strong -type FUV-ECD spectra and an unexpectedly strong NUV-ECD signal (Θ ~275-285nm ) indicate that the amyloid phase of E5 is built from monomers of quasi -elongated backbone structure ( φ ~-145°, ψ ~+145°) with strong interstrand Tyr↔Trp interaction. Misfolded intermediers and the buildup of "toxic" early-stage oligomers leading to self-association were identified and monitored as function of time. Results indicate that the amyloid transition is triggered by subtle misfolding of the α-helix exposing aromatic and hydrophobic side chains that may provide the first centers for an intermolecular reorganization. These initial clusters provide the spatial closeness and sufficient time for a transition to the β-structured amyloid nucleus thus the process follows a nucleated growth mechanism.© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643326>Darunavir.</a></h2><p>Darunavir is an antiretroviral protease inhibitor that is used in the therapy and prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). Darunavir can cause transient and usually asymptomatic elevations in serum aminotransferase levels and has been linked to rare instances of clinically apparent, acute liver injury. In HBV or HCV coinfected patients, highly active antiretroviral therapy with darunavir may result of an exacerbation of the underlying chronic hepatitis  or C.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31666818>Telemonitoring in : evolution of concepts and technologies, with a focus on results of the more recent studies.</a></h2><p>This is a narrative review of telemonitoring (remote monitoring) projects and studies within the field of , with a focus on results of the more recent studies. Since the beginning of the 1990s, several telemedicine projects and studies focused on type 1 and type 2 . Over the last 5 years, numerous telemedicine projects based on connected objects and new information and communication technologies (ICT) (elements defining telemedicine 2.0) have emerged or are still under development. Two examples are the DIABETe and Telesage telemonitoring project which perfectly fits within the telemedicine 2.0 framework - the first to include artificial intelligence (AI) with MyPredi and Diabeo. Mainly, these projects and studies show that telemonitoring diabetic result in: improvements in control of blood glucose (BG) level and significant reduction in HbA1c (e.g., for Telescot et TELESAGE studies); positive impact on co-morbidities (arterial hypertension, weight, dyslipidemia) (e.g., for Telescot and DIABETe studies); better patient's quality of life (e.g., for DIABETe study); positive impact on appropriation of the disease by patients and/or greater adherence to therapeutic and hygiene-dietary measures (e.g., The Utah Remote Monitoring Project); and at least, good receptiveness by patients and their empowerment. To date, the magnitude of its effects remains debatable, especially with the variation in patients' characteristics (e.g., background, ability for self-management, medical condition), samples selection and approach for the treatment of control groups. All of the recent studies have been classified as "Moderate" to "High".©Carol Davila University Press.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31625262>Three-year clinical outcome in all-comers with "silent" , prediabetes, or normoglycemia, treated with contemporary coronary drug-eluting stents: From the BIO-RESORT Silent  study.</a></h2><p>Patients with coronary disease may have unknown  or prediabetes. We evaluated 3-year outcomes after percutaneous coronary intervention (PCI) with contemporary drug-eluting stents (DES) in patients with silent , prediabetes, and normoglycemia.All BIO-RESORT trial () participants without known , enrolled at our center, were invited for oral glucose tolerance testing (OGTT) and measurements of fasting plasma glucose and glycated hemoglobin (HbA1c).OGTT detected silent  in 68 (6.9%), prediabetes in 132 (13.4%), and normoglycemia in 788 (79.8%) of all 988 study participants. Follow-up was available in 986 (99.8%) patients. The main endpoint target vessel failure (TVF: cardiac death, target vessel-related myocardial infarction [MI], or target vessel revascularization) differed between groups (14.8, 9.9, and 5.6%; p = .002), driven by MI during the first 48 hr and by cardiac death (p < .001; p = .026). Between 48 hr and 3-years, there was no significant between-group difference in TVF, target vessel MI, and target vessel revascularization. Multivariable analysis demonstrated that silent  was independently associated with TVF (adjusted HR: 2.52, 95%-CI: 1.26-5.03). An alternative diagnostic approach-HbA1c and fasting plasma glucose-detected silent  and prediabetes in 33 (3.3%) and 217 (22.0%) patients, and normoglycemia in 738 (74.7%); TVF rates were 12.1, 7.9, and 6.0% (p = .23).In patients without known , abnormal glucose metabolism by OGTT was independently associated with higher 3-year TVF rates after PCI with contemporary DES. This difference was driven by periprocedural MI and cardiac death. After the first 48 hr, the rates of TVF, target vessel MI, and target vessel revascularization were low and did not differ significantly between metabolic groups.© 2019 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals, Inc.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31626838>A sea cucumber (Holothuria leucospilota) polysaccharide improves the gut microbiome to alleviate the symptoms of type 2  in Goto-Kakizaki rats.</a></h2><p> has become a worldwide concern in recent years. In this study, the effect of Holothuria leucospilota polysaccharide (HLP) on type 2  (T2DM) was investigated in Goto-Kakizaki (GK) rats. The results showed that HLP significantly improved glucose intolerance and regulated blood lipid and hormone levels (p < 0.05). Pathological analysis showed that HLP repaired the impairments of the pancreas and colon in diabetic rats. In addition, a high dose of HLP (200 mg/kg) significantly upregulated the gene expression of peroxisome proliferator-activated receptor-α (PPAR-α), peroxisome proliferator-activated receptor-γ (PPAR-γ), phosphoinositide 3-kinase (PI3K), protein kinase  (PKB/AKT), glucose transporter-4 (GLUT4) and anti-apoptotic (Bcl-2), and downregulated the mRNA levels of pro-apoptotic (Bax) and cluster of differentiation 36 (CD36) in diabetic rats (p < 0.05). Furthermore, HLP treatment increased the short-chain fatty acid-producing bacteria and decreased the opportunistic bacterial pathogen in the feces of diabetic rats. These results demonstrated that HLP has the potential to ameliorate T2DM in GK rats.Copyright © 2019. Published by Elsevier Ltd.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643905>Muromonab-CD3.</a></h2><p>Muromonab-CD3 is a mouse monoclonal antibody to CD3, often referred to as OKT3, which is used to treat acute cellular rejection after solid organ transplantation. Muromonab has been linked to mild and transient serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent liver injury. Muromonab is a potent immunosuppressive agent and may result in reactivation of hepatitis  in susceptible patients.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31648850>Dietary instructions focusing on meal-sequence and nutritional balance for prediabetes subjects: An exploratory, cluster-randomized, prospective, open-label, clinical trial.</a></h2><p>Although lifestyle modifications are known to be effective in type 2  (T2D) as well as in prediabetes, adherence to a healthy diet is difficult for some, and interventions of lifestyle modifications need to be revised occasionally. Meal sequence has been gaining attention as a part of a healthy diet among T2D individuals to improve glycemia and body weight. In addition, a dietary instruction program, SMART Washoku®, which can help individuals to consume a more nutritionally balanced diet, has been developed.The current exploratory trial was designed to examine the effects of dietary instructions focusing on meal sequence and nutritional balance in individuals with prediabetes in the Japanese national health check-up and guidance program. Participants were cluster-randomized into three groups: Group A, receiving a conventional health guidance program (n = 11); Group , receiving health guidance with dietary instructions focusing on meal sequence (n = 18); and Group C, receiving health guidance with dietary instructions focusing on nutritional balance (n = 13). Participants received health guidance education and various measurements before and 6 months after the instructions.Body weight in Group  was significantly reduced compared to that in Group A, with similar adherence, while the effects on glycemia were similar between the two Groups. Body weight reduction was greater in Group C compared to that in Group A, although adherence in Group C was significantly lower than that in Group A.The group receiving health guidance with dietary instructions focusing on meal sequence exhibited similar adherence and greater reduction in body weight than the group receiving conventional health guidance.Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31623226>Effects of Resveratrol in Goto-Kakizaki Rat, a Model of Type 2 .</a></h2><p>Resveratrol exhibits a pleiotropic, favorable action under various pathological conditions, including type 2 . However, its anti-diabetic effects in animal models and human trials have not been fully elucidated. The aim of the present study was to determine whether resveratrol is capable of inducing beneficial changes in the Goto-Kakizaki rat, a spontaneous model of , which in several aspects is similar to type 2  in humans. Goto-Kakizaki (GK) rats and control Sprague-Dawley (SD) rats were treated intragastrically with resveratrol (20 mg/kg .w./day) for 10 weeks. Then, a glucose tolerance test was performed and levels of some adipokines in blood were measured. Moreover, lipid contents in skeletal muscle and liver tissues, along with the expression and phosphorylation of pivotal enzymes (AMP-activated protein kinase-AMPK, acetyl-CoA carboxylase-ACC, protein kinase -Akt) in these tissues were determined. Histology of pancreatic islets was also compared. GK rats non-treated with resveratrol displayed a marked glucose intolerance and had increased lipid accumulation in the skeletal muscle. Moreover, upregulation of the expression and phosphorylation of AMPK, ACC and Akt was shown in the muscle tissue of GK rats. Those rats also had an abnormal structure of pancreatic islets compared with control animals. However, treatment with resveratrol improved glucose tolerance and prevented lipid accumulation in the skeletal muscle of GK rats. This effect was associated with a substantial normalization of expression and phosphorylation of ACC and Akt. In GK rats subjected to resveratrol therapy, the structure of pancreatic islets was also clearly improved. Moreover, blood adiponectin and leptin levels were partially normalized by resveratrol in GK rats. It was revealed that resveratrol ameliorates key symptoms of  in GK rats. This compound improved glucose tolerance, which was largely linked to beneficial changes in skeletal muscle. Resveratrol also positively affected pancreatic islets. Our new findings show that resveratrol has therapeutic potential in GK rats.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31644524>Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers.</a></h2><p>BACKGROUND  causes damage to the soft tissue and bone structure of the foot, referred to as "diabetic foot". Ibrutinib is a Bruton tyrosine kinase (Btk) inhibitor, and the role and mechanism of ibrutinib on the diabetic foot have not been elucidated. MATERIAL AND METHODS Male Wister rats were randomly divided into 3 groups: control group, model group, and ibrutinib group. After 14 days, the ulcer wound size of each group was measured, and the ulcer healing rate was calculated. The level of inflammatory factors interleukin (IL)-1ß, tumor necrosis factor (TNF)-alpha, and IL-6 was detected by enzyme-linked immunosorbent assay (ELISA). Real-time polymerase chain reaction (PCR) was used to analyze the changes of Toll-like receptor 2 (TLR2) and TLR4. The expression of vascular endothelial growth factor (VEGF) and the RAGE (receptor for advanced glycation end product/NF-kappaB (nuclear factor-kappa ) pathway was detected by western blot. RESULTS Blood glucose, blood lipids, serum creatinine, and urea nitrogen (BUN) levels were increased in the model group, together with increased levels of IL-1ß, TNF-alpha, IL-6, as well as TLR2 and TLR4 expression, and there were significant differences compared with the control group (P<0.05). Meanwhile, the model group showed decreased VEGF expression and increased expression of RAGE and NF-kappaB. However, ibrutinib reduced blood sugar, blood lipids, creatinine, and urea nitrogen levels, inhibited the secretion of inflammatory factors, promoted ulcer healing, improved ulcer healing rate, decreased the expression of TLR2, TLR4, RAGE, and NF-kappaB, and increased VEGF expression; there were significant differences in the ibrutinib group compared with the model group (P<0.05). CONCLUSIONS The Btk inhibitor ibrutinib can upregulate VEGF expression, inhibit the expression of TLRs, inhibit the secretion of inflammatory factors, and promote the healing of diabetic foot ulcer possibly by regulating the RAGE/NF-kappaB pathway.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31632934>Hepatitis  And Hepatitis C Viral Infections And Associated Factors Among Patients With  Visiting Gondar Referral Teaching Hospital, Northwest Ethiopia: A Comparative Cross-Sectional Study.</a></h2><p>The liver is the major site of Hepatitis  virus and Hepatitis C virus replications. Patients with  tend to be at an increased risk for developing various forms of liver diseases. The infection of the liver can cause or exacerbate . On the other hand,  can cause or intensify the severity of liver infection. This comparative cross-sectional study was conducted with the aim to determine the prevalence of Hepatitis  and Hepatitis C virus infections and associated factors among patients with  visiting the University of Gondar referral teaching hospital, northwest Ethiopia.Out of the 610 participants (305 patients with , 305 people with no ) of the study, 65 (10.7%) were positive for Hepatitis infections, of whom 44 (14.4%) and 21 (6.9%) were positive for at least one of the viruses in patients with  and people with no , respectively. Out of the diabetic and non-diabetic groups of the study, 26 (8.5%) and 14 (4.6%) (95% CI, 0.96-4.02) were positive for Hepatitis  virus, respectively, while 23 (7.5%) and 7 (2.3%) (95% CI, 1.46-8.68) of the  and non-diabetic groups were positive for Hepatitis C virus, respectively. History of blood transfusion (95% CI, 1.36-12.71) and unprotected sex (95% CI, 1.25-10.15) were significantly associated with Hepatitis  virus infection, while the type of  (95% CI, 1.25-10.89) was associated with anti-Hepatitis C virus positivity.Positivity for Hepatitis C virus was significantly associated with Type II . Blood transfusion and unprotected sex were risk factors for Hepatitis  virus infections. Further studies that elaborate temporal associations and find out explanations for the relationship between  and Hepatitis C viral infections are of paramount importance.© 2019 Million et al.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643471>Amphotericin .</a></h2><p>Amphotericin  is an antifungal agent with a broad spectrum of activity against many fungal species. Amphotericin  commonly causes mild to moderate serum aminotransferase elevations and can cause hyperbilirubinemia, but acute, clinically apparent drug induced liver injury from amphotericin  therapy is exceedingly rare.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31661834>Estimation of Biological Parameters of Cutaneous Ulcers Caused by Leishmaniasis in an Animal Model Using Diffuse Reflectance Spectroscopy.</a></h2><p>Cutaneous leishmaniasis (CL) is a neglected tropical disease that requires novel tools for its understanding, diagnosis, and treatment follow-up. In the cases of other cutaneous pathologies, such as cancer or cutaneous ulcers due to , optical diffuse reflectance-based tools and methods are widely used for the investigation of those illnesses. These types of tools and methods offer the possibility to develop portable diagnosis and treatment follow-up systems. In this article, we propose the use of a three-layer diffuse reflectance model for the study of the formation of cutaneous ulcers caused by CL. The proposed model together with an inverse-modeling procedure were used in the evaluation of diffuse-reflectance spectral signatures acquired from cutaneous ulcers formed in the dorsal area of 21 golden hamsters inoculated with Leishmanisis braziliensis. As result, the quantification of the model's variables related to the main biological parameters of skin were obtained, such as: diameter and volumetric fraction of keratinocytes, collagen; volumetric fraction of hemoglobin, and oxygen saturation. Those parameters show statistically significant differences among the different stages of the CL ulcer formation. We found that these differences are coherent with histopathological manifestations reported in the literature for the main phases of CL formation.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643935>Natalizumab.</a></h2><p>Natalizumab is a monoclonal antibody to human alpha-4 integrin which has potent immune suppressive activity and is used in the therapy of severe inflammatory bowel disease and relapsing multiple sclerosis. Natalizumab has been linked to rare instances of idiosyncratic acute liver injury and may be a rare cause of reactivation of hepatitis .</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643909>Purine Analogues.</a></h2><p>The purine analogues used as antineoplastic agents are a group of agents with similar structures, but somewhat different mechanisms of action, pharmacokinetics, indications and adverse effects. These agents are nucleoside analogues and are considered antimetabolites, interfering or competing with nucleoside triphosphates in the synthesis of DNA or RNA or both. The agents are analogues of adenine or guanine and generally have excellent activity against leukemias and lymphomas, perhaps because of their preferential uptake, activation and effects in lymphoid tissue. The thiopurines include mercaptopurine, azathiopurine and thioguanine, which are active against several forms of leukemia and are also used as immunosuppressive and immunomodulatory agents in the treatment of autoimmune conditions (Crohn disease, autoimmune hepatitis, lupus nephritis) and in regimens to prevent transplant rejection. All three agents are generally well tolerated and commonly used in cancer chemotherapy as well as autoimmune conditions. The other antineoplastic purine analogues are used almost exclusively for malignant conditions, typically leukemia or lymphomas. Fludarabine is the most commonly used of these purine analogues and is a first line agent in the treatment of chronic lymphocytic leukemia. Fludarabine also has profound immunosuppressive activity and is used in nonmyeloablative regimens in preparation for hematopoietic cell transplantation. Because of its immunosuppressive activity, fludarabine is associated with reactivation of viral infections, including hepatitis . Cladribine and pentostatin are adenosine derivatives and are used predominantly for hairy cell leukemia. They have minimal hepatotoxic potential, at least at the doses that are used to treat hairy cell leukemia. Clofarabine is also an adenosine derivative and is used as therapy of acute lymphoblastic leukemia, mostly in children who have failed previous therapies. Nelarabine is a guanine derivative and is used in T cell malignancies, usually after failure of prior therapies. Both of these agents are associated with high rates of serum aminotransferase elevations during therapy, but are very rare causes of clinically apparent liver injury. Thus, all of the purine analogues have some degree of direct hepatotoxic potential. In the doses and regimens in current use, this hepatotoxicity is generally mild and manifested only by transient, mild-to-moderate serum aminotransferase elevations. For many of these agents, however, more clinically apparent liver injury has been described, particularly with mercaptopurine and azathioprine. Each of the antineoplastic purine analogues are discussed separately and with their specific references. Links to the individual drug records are given below. Azathioprine. Cladribine. Clofarabine. Fludarabine. Mercaptopurine. Nelarabine. Pentostatin. Thioguanine. Drug Class: Antineoplastic Agents, Antimetabolites</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31644243>Nucleoside Analogues.</a></h2><p>The nucleoside analogues are an important class of antiviral agents now commonly used in the therapy of human immunodeficiency virus (HIV) infection, hepatitis  virus (HBV), cytomegalovirus (CMV) and herpes simplex virus (HSV) infection. The nucleoside analogues resemble naturally occurring nucleosides and act by causing termination of the nascent DNA chain. These agents are generally safe and well tolerated as they are used by the viral, but not human polymerases in DNA replication. Actually, nucleoside analogues are a large class of agents that include drugs for cancer (cytarabine, gemcitabine, mercaptopurine), rheumatologic diseases (azathioprine, allpurinol) and even bacterial infections (trimethoprim). The nucleoside analogues used to treat HIV infection are often referred to as reverse transcriptase inhibitors (NRTIs). However, they have activity against both DNA dependent and RNA dependent DNA polymerases. They are believed to inhibit viral replication by several mechanisms, either by competitive inhibition of the viral polymerase or by DNA chain termination. Many of the antiviral nucleoside analogues are blocked at the 3’ hydroxyl group of the deoxyribonucleic acid, which results in failure of elongation of the nascent DNA molecule. Other antiviral nucleoside analogues are negative enantiomers (L-forms: lamivudine, emtricitabine, telbivudine) of the natural (D-form) nucleosides and interfere with replication, partially because of steric hindrance when they are taken up by the viral polymerase or added to the DNA molecule. Nucleoside analogues that are phosphorylated at the 5’ site are often referred to as nucleotide analogues, but this distinction is artificial as these agents (tenofovir, adefovir) are also nucleoside analogues. These features of the structure of nucleoside analogues are important because of the danger that they might be used by human polymerases and incorporated into RNA or DNA, which is the basis of the serious toxicities of the nucleoside analogues. Nucleoside analogues can cause liver injury by several mechanisms. Most characteristic is a mitochondrial type of hepatic injury that is probably caused by the nucleoside analogue becoming incorporated into or blocking mitochondrial DNA synthesis by the mitochondrial gamma polymerase, leading to a depletion of mitochondria or decrease in their function. Mitochondrial injury can affect multiple tissues thereby causing myopathy, neuropathy, pancreatitis, bone marrow suppression and/or hepatic injury. The hepatic injury is characterized by accumulation of lactic acidosis, microvesicular steatosis and hepatic synthetic failure (LASH). Serum aminotransferase levels may be minimally elevated and jaundice arises late. The most dramatic example of hepatic mitochondrial injury occurred with the drug fialuridine (FIAU), a nucleoside analogue that was withdrawn after several fatalities due to hepatic failure, lactic acidosis and pancreatitis arising 2 to 3 months after initiation of therapy during phase 2 trials in humans. A similar, but rare and less dramatic and partially reversible hepatic mitochondrial injury has been linked to use of didanosine (dideoxyinosine: ddI), zalcitabine (dideoxycytine: ddC), stavudine (d4T) and less commonly to zidovudine (AZT).</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643504>Niacin.</a></h2><p>Niacin, also known as nicotinic acid and vitamin B3, is a water soluble, essential  vitamin which, when given in high doses, is effective in lowering low density lipoprotein (LDL) cholesterol and raising high density lipoprotein (HDL) cholesterol, which makes this agent of unique value in the therapy of dyslipidemia. Niacin can cause mild-to-moderate serum aminotransferase elevations and high doses and certain formulations of niacin have been linked to clinically apparent, acute liver injury which can be severe as well as fatal.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31672446>Predictive value of gastrointestinal hormones on weight loss.</a></h2><p>Bariatric surgery leads to profound and sustainable weight loss. Gastrointestinal hormones are involved in energy and glucose homeostasis, thus postoperative changes of their circulating levels may be mediating future weight loss. To investigate how the circulating concentrations of gastrointestinal hormones change in response to the most common types of bariatric operation and whether these changes can predict future weight loss.We measured circulating GLP-1, GLP-2, oxyntomodulin, glicentin, glucagon, major proglucagon fragment (MPGF), ghrelin, GIP, PYY after overnight fasting and/or after a mixed meal test (MMT) in: a) 14 subjects that have undergone either an adjustable gastric banding [AGB] (n = 9) or a Roux-en-Y bypass (RYGB) (n = 5) (Pilot study 1), ) 28 subjects that have undergone either a vertical sleeve gastrectomy (n = 17) or a RYGB (n = 11) before and three, six and twelve months after surgery.In addition to the expected associations with GLP-1, the most robust increases were observed in postprandial levels of oxyntomodulin and glicentin three months after VSG or RYGB (but not after AGB) and are associated with degree of weight loss. Oxyntomodulin and glicentin levels at the third and sixth month postoperative visit are positively associated with feeling of satiety which may be underlying the observed associations with future weight loss.Beyond GLP-1, early postprandial changes in circulating oxyntomodulin and glicentin are predictors of weight loss after bariatric surgery, possibly through regulation of satiety. Further studies should focus on underlying mechanisms, and their potential as attractive therapeutic tools against obesity and related comorbidities.Copyright © 2019. Published by Elsevier Inc.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31654495>Ganglion cell layer thickening in well-controlled patients with type 1 : an early sign for diabetic retinopathy?</a></h2><p>To evaluate early changes in retinal layers using optical coherence tomography (OCT) in patients with long-standing type 1  (DM1) receiving intensified insulin therapy.In a cross-sectional case-control study 150 patients with DM1 and 150 age- and sex-matched healthy control participants underwent OCT imaging. Scans of both eyes were analysed for different layers (NFL, GCL (+IPL), INL, outer layer complex (OLC, including OPL, ONL and ELM) and photoreceptors (PR)) in all subfields of an ETDRS grid. All analyses were performed semi-automatically using custom software by certified graders of the Vienna Reading Center. ANOVA models were used to compare the mean thickness of the layers between patients and controls.Six hundred eyes with 512 datapoints in 49 -scans in each OCT were analysed. Mean thickness in patients/controls was 31.35 μm/30.65 μm (NFL, p = 0.0347), 76.7 μm/73.15 μm (GCL, p ≤ 0.0001), 36.29 μm/37.13 μm (INL, p = 0.0116), 114.34 μm/112.02 μm (OLC, p < 0.0001) and 44.71 μm/44.69 μm (PR, p = 0.9401). When evaluating the ETDRS subfields separately for clinically meaningful hypotheses, a significant swelling of the GCL in patients could be found uniformly and a central swelling for the OLC, whereas the distribution of NFL and INL thickening suggests that their statistical significance was not clinically relevant.These preliminary results demonstrate that preclinical retinal changes in patients with long-standing DM1 can be found by retinal layer evaluation. However, the changes are layer-specific, with significant thickening of the GCL and less so of the OLC suggesting a role as an early sign for diffuse swelling and the evolution of DME even in well-controlled .© 2019 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31652543>Improving Health-Promoting Effects of Food-Derived Bioactive Peptides through Rational Design and Oral Delivery Strategies.</a></h2><p>Over the last few decades, scientific interest in food-derived bioactive peptides has grown as an alternative to pharmacological treatments in the control of lifestyle-associated diseases, which represent a serious health problem worldwide. Interest has been directed towards the control of hypertension, the management of type 2  and oxidative stress. Many food-derived antihypertensive peptides act primarily by inhibiting angiotensin I-converting enzyme (ACE), and to a lesser extent, renin enzyme activities. Antidiabetic peptides mainly inhibit dipeptidyl peptidase-IV (DPP-IV) activity, whereas antioxidant peptides act through inactivation of reactive oxygen species, free radicals scavenging, chelation of pro-oxidative transition metals and promoting the activities of intracellular antioxidant enzymes. However, food-derived bioactive peptides have intrinsic weaknesses, including poor chemical and physical stability and a short circulating plasma half-life that must be addressed for their application as nutraceuticals or in functional foods. This review summarizes the application of common pharmaceutical approaches such as rational design and oral delivery strategies to improve the health-promoting effects of food-derived bioactive peptides. We review the structural requirements of antihypertensive, antidiabetic and antioxidant peptides established by integrated computational methods and provide relevant examples of effective oral delivery systems to enhance solubility, stability and permeability of bioactive peptides.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31651275>Study protocol of  LEAP: a longitudinal study examining emotional problems in adolescents with type 1  and their parents/caregivers.</a></h2><p>Type 1  (T1D) is a chronic metabolic condition requiring intensive daily self-care to avoid both high and low blood glucose levels. Self-care and glycemic outcomes are particularly problematic in adolescence, a period known for its increased risk of emotional problems. However, the true scope of mood and anxiety disorders in adolescents with T1D is unknown. Earlier studies are limited by a small sample size, lack of diagnostic interview data, a focus on depression only, non-adolescent specific estimates, lack of information about parental emotional problems and/or a cross-sectional design.  LEAP is a two-year prospective observational cohort study examining (a) the prevalence and course of depression and anxiety in adolescents with T1D and their parents/caregivers, () the risk factors predicting the presence of these emotional problems, (c) their longitudinal relation with  outcomes, and (d) the psychosocial care currently in place.Adolescents (12-18 years) from 8 Dutch pediatric  clinics are interviewed using the DISC-IV to establish the presence of mood and anxiety disorders in the previous 4 weeks, the previous 12 months, and lifetime. They also complete questionnaires, including CDI-2, GAD-7, and PAID-T. Parents/caregivers complete PHQ-9, GAD-7, and PAID-PR. Follow-up assessments take place after 1 and 2 years.This longitudinal study with diagnostic interviews in a large cohort of adolescents with T1D in the Netherlands will provide much needed information regarding the prevalence and course of depression and anxiety in this group, thereby opening avenues for proper recognition, prevention and timely treatment.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31653476>The importance of relationship processes for lowering BMI over time in women with type 2  in a randomized controlled trial.</a></h2><p>Weight change may be affected by dyadic processes within couple relationships. The aim of this secondary data analysis was to explore trends in BMI across time, and assess whether relationship processes (i.e., relationship satisfaction, positive problem-solving), predict BMI trajectories in men and women.Data are from 268 participants in the  Support Project, a randomized trial of behavioral intervention for individuals with type 2  (T2D) in poor glycemic control. For secondary analyses, BMI was measured at pre-treatment (baseline), 4 months (post-treatment), 8 months, and 12 months. Multiple relationship variables were measured at all time points and were modeled as predictors and correlates of change in BMI across time.In general, BMI trajectories had higher starting values (intercepts) for females than for males in the sample ( = -2.51, p < .05), and slopes trended downward from pre-treatment to 12 months ( = -.09, p <  .05). Downward trajectories of BMI were more pronounced for women with higher relationship satisfaction ( = .05, p <  .05) and higher positive problem solving skills ( = .06, p < .05) at baseline. Change in relationship processes were not correlated with change in BMI across time.For women with T2D in this behavioral intervention study, relationship process scores at the beginning of treatment predicted changes in BMI over time, with better problem solving and higher relationship satisfaction at baseline related to steeper decreases in BMI across treatment. Additional research is needed to understand how improving relationship interaction prior to  treatment may positively influence weight loss during treatment.Copyright © 2019. Published by Elsevier Ltd.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31644724>Brazilian generics market change after Farmácia Popular program.</a></h2><p>To evaluate trends in the use of generic and non-generic medicines to treat hypertension and  under the Farmácia Popular Program (FP) and its impact on generic medicines sales volume and market share in the Brazilian pharmaceutical market.This longitudinal, retrospective study used interrupted time series design to analyze changes in monthly sales volume and proportion of medicines sales (market share) for oral antidiabetic and antihypertensive medicines for generic versus non-generic products. Analyses were conducted in a combined dataset that aggregate monthly sales volumes from the Farmácia Popular program and from the QuintilesIMS™ (IQVIA) national market sales data from January 2007 to December 2012. The Farmácia Popular program phases analyzed included: a) 2009 reductions in medicines reference prices (AFP-II) and ) 2011 implementation of free medicines program for hypertension and , the Saúde não tem preço (SNTP - Health has no price).Patterns of use for FP-covered antidiabetic and antihypertensive medicines were similar to their use in the market in general. After one year of the decreases in government subsidies in April 2010, market share of antidiabetic and antihypertensive medicines experienced relative declines of -54.5% and -59.9%, respectively. However, when FP-covered medicines were made free to patients, overall market volume for antidiabetic and antihypertensive generics increased dramatically, with 242.6% and 277.0% relative increases by February 2012, as well as non-generics with relative increase of 209.7% and 279% for antidiabetic and antihypertensive medicines, respectively.Ministry of Health policies on the amount of patient cost sharing and on the choice of medicines on coverage lists have substantial impacts on overall generic sales volume in retail pharmacies.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31653516>Plaque calcification is driven by different mechanisms of mineralization associated with specific cardiovascular risk factors.</a></h2><p>The aim of this study was to investigate possible associations among markers of mineralization, plaque instability and the main risk factors of atherosclerosis.A Tissue MicroArray containing 52 samples of calcified carotid plaques from 52 symptomatic and asymptomatic patients were built. TMA serial sections were used to study the expression of inflammatory and mineralization markers (BMP-2, BMP-4, VDR, RANKL, Osteopontin, Sclerostin, β-catenin and calmodulin) by immunohistochemistry. Our data clearly demonstrated the expression of mineralization markers in atheromatic plaques. Indeed, with the exception of RANKL, all investigated markers were expressed in at least 60% of cases. Specifically, multivariate analysis displayed significant associations between both the expression of BMP-2 and the presence of unstable plaques as well as between the expression of β-catenin and the presence of stable plaques. We also found a significant inverse association between both a) the presence of hypertension and VDR and ) smoking habits and calmodulin expression. Finally, we noted a higher density of RANKL positive cells in plaques from diabetic patients as compared to non-diabetic ones and a significant positive association between hypertriglyceridemia and BMP-4 expression.Our results support the hypothesis that the process of atherosclerotic plaque calcification presents a number of similarities with the physiological processes that occur in bone, involving both osteoblasts- and osteoclasts-like arterial cells. Finally, the present study suggests that risk factors, such as hypertension, cigarette smoke and , can cause the destabilization of the atheromatic plaque acting on calcification process as well as inflammation.Copyright © 2019 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier .V. All rights reserved.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31642143>Utility of the plasma pancreatic polypeptide response to modified sham feeding in diabetic gastroenteropathy and non-ulcer dyspepsia.</a></h2><p>The relationship between cardiovascular and gastrointestinal (ie, plasma pancreatic polypeptide [PP] response to modified sham feeding [MSF]) indices of vagal function is unclear. Hyperglycemia inhibits PP secretion via vagally mediated mechanisms. Our aims were to (a) compare the PP response, () its relationship with glycemia, and (c) the relationship between PP response to MSF, gastric emptying (GE) of solids, and symptoms during GE study in healthy controls, patients with diabetic gastroenteropathy (DM), and non-ulcer dyspepsia (NUD).In 24 healthy controls, 40 DM, and 40 NUD patients, we measured plasma PP concentrations during MSF, cardiovagal functions, GE, and symptoms during a GE study.Baseline PP concentrations were higher in DM than in controls and NUD (P = .01), and in type 2 than in type 1 DM patients (P < .01). The PP increment during MSF was normal (≥20 pg/mL) in 70% of controls, 54% of DM, and 47% of NUD patients. Overall, the PP response and cardiovagal tests were concordant (P = .01). Among patients with a reduced PP increment with MSF, 7/10 of T1DM and 1/7 of T2DM patients had moderate or severe cardiovagal dysfunctions (P < .05). The PP response to MSF was not associated with GE.Up to 30% of healthy controls have a reduced PP increment during MSF, limiting the utility of this test to detect vagal injury. The PP response is more useful when it is normal than abnormal. A reduced PP response is more likely to be associated with cardiovagal dysfunctions in T1DM than in T2DM.© 2019 John Wiley & Sons Ltd.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31658127>Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis  and Low-Level Viremia.</a></h2><p>Patients with hepatitis  early antigen (HBeAg)-negative chronic hepatitis  (CHB) and low-level viremia are a heterogeneous group. Identifying those at risk of developing active CHB requiring antiviral therapy is important. In this study, we prospectively characterize incidence rates and predictors of transitioning from inactive to active CHB in a North American adult cohort.Participants in the multicenter National Institute of  and Digestive and Kidney Diseases Hepatitis  Research Network cohort who were HBeAg negative with baseline hepatitis  virus (HBV) DNA ≤ 10,000 IU/mL were included in the study. Cox regression models were used to estimate the proportion of individuals in 3 baseline HBV DNA categories (≤100, 101 to ≤2,000, and 2,001 to ≤10,000 IU/mL) who developed phase transition defined by HBV DNA > 10,000 IU/mL and alanine aminotransferase (ALT) > 2× upper limit of normal or initiated treatment during follow-up.Of 970 participants meeting inclusion criteria, 15% experienced phase transition or initiated treatment over a median follow-up of 4 years: 9% of those with baseline HBV DNA ≤ 100 IU/mL, 14% with HBV DNA 101 to ≤2,000 IU/mL, and 24% with HBV DNA 2,001 to ≤10,000 IU/mL (P < 0.001). The overall rate of phase transition or treatment initiation was 7.6 per 100 person-years: 4.6 in those with HBV DNA ≤ 100 IU/mL, 6.8 in those with HBV DNA 101 to ≤2,000 IU/mL, and 12.2 in those with HBV DNA 2,001 to ≤10,000 IU/mL (P < 0.001). Factors independently associated with higher rate of phase transition or treatment initiation included HBV genotype  or C, higher baseline ALT and HBV DNA levels, lower platelet count, quantitative hepatitis  surface antigen > 1,000 IU/mL, and hyperlipidemia. Only higher ALT, higher HBV DNA, and lower platelets were associated with phase transition when patients starting treatment were censored.Most adults in this North American cohort with HBeAg-negative CHB and low-level viremia remained inactive and off treatment over 4 years. Transition from inactive to active CHB is infrequent and predominantly associated with viral rather than host factors.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31639240>An observational study on long-term renal outcome in patients with chronic hepatitis  treated with tenofovir disoproxil fumarate.</a></h2><p>In patients with chronic hepatitis  (CHB), long-term effects of tenofovir disoproxil fumarate (TDF) on renal function have been controversial. This study aimed to analyze the real-world long-term effects of TDF on renal function in Korean patients with CHB. We analyzed a cohort of 640 treatment-naïve patients with CHB who were treated with TDF between May 2012 and December 2015 at Severance Hospital, Seoul, Republic of Korea. The mean age was 48.3 years old, and 59.5% were male. The proportions of hypertension and  (DM) were 11.6% and 14.2%, respectively, and that of liver cirrhosis was 20.8%. During the 5 year follow up, using a linear mixed model, serum creatinine increased from 0.77 ± 0.01 mg/dL to 0.85 ± 0.02 mg/dL (P<0.001), and eGFR decreased from 102.6 ± 0.6 mL/min/1.73m to 93.4 ± 1.4 mL/min/1.73m (P<0.001). In subgroup analysis, eGFR was statistically more decreased in patients with age >60 than ≦60 years old (P=0.027), and in patients with diuretic use than without diuretic use (P=0.008). In multivariate analysis, the independent risk factors for eGFR decrease >20% were baseline eGFR <60mL/min/1.73m (P=0.034) and the use of diuretics (P<0.001). CHB patients on TDF experienced greater reduction in renal function with age >60 and with diuretic use compared to those without these characteristics. Baseline eGFR <60mL/min/1.73m and use of diuretics were independent risk factors of eGFR decline of more than 20% on TDF therapy.© 2019 John Wiley & Sons Ltd.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31661991>Pyrroloquinoline quinone protected autophagy-dependent apoptosis induced by mono(2-ethylhexyl) phthalate in INS-1 cells.</a></h2><p>Mono(2-ethylhexyl) phthalate (MEHP) is the main metabolite of di(2-ethylhexyl) phthalate (DEHP) in organisms and is commonly used as a plasticizer. Exposure to DEHP impairs the function of islet beta cells (INS-1 cells), which is related to insulin resistance and type 2 . At present, some research data have also confirmed that MEHP has a certain damage effect on INS-1 cells. In our experiment, we found that MEHP would lead to the increase of reactive oxygen species (ROS) and the upregulation of autophagy. And downregulated ROS production by -acetyl-l-cysteine could also reduce autophagy. In addition, MEHP-induced lysosomal membrane permeability (LMP) subsequently released cathepsin D. Additionally, MEHP induced the collapse of mitochondrial transmembrane potential and release of cytochrome . Addition of autophagy inhibitor 3-methyladenine relieved MEHP-induced apoptosis as assessed by the expression of cleaved caspase 3, cleaved caspase 9, and terminal deoxynucleotidyl transferase dUTP nick end labeling assay, indicating that MEHP-induced apoptosis was autophagy dependent. Cathepsin D inhibitor, pepstatin A, suppressed MEHP-induced mitochondria release of cytochrome  and apoptosis as well. Meanwhile, pyrroloquinoline quinone (PQQ), a new  vitamin, improved the above phenomenon. Taken together, our results indicate that MEHP induces autophagy-dependent apoptosis in INS-1 cells by lysosomal-mitochondrial axis. PQQ improved this process by downregulating ROS and provided a degree of protection. Our study provides a new perspective for MEHP on the cytotoxic mechanism and PQQ protection in INS-1 cells.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31654916>Associations of long-term exposure to PM, PM, NO with type 2  prevalence and fasting blood glucose levels in Chinese rural populations.</a></h2><p>To evaluate the associations between long-term exposure to particulate matter with an aerodynamic diameter ≤1.0 μm and ≤2.5 μm (PM and PM), nitrogen dioxide (NO) and type 2  prevalence and fasting blood glucose levels in Chinese rural populations.A total of 39, 259 participants were enrolled in The Henan Rural Cohort study. Questionnaires and medical examination were conducted from July 2015 to September 2017 in rural areas of Henan province, China. Three-year average residential exposure levels of PM, PM, NO for each subject were estimated by a spatiotemporal model. Logistic regression and linear regression models were applied to estimate the associations between PM, PM, NO exposure and type 2  prevalence and fasting blood glucose levels.The mean 3-year residential exposure concentrations of PM, PM and NO was 57.4 μg/m, 73.4 μg/m and 39.9 μg/m, respectively. Higher exposure concentrations of PM, PM, NO by 1 μg/m was positively related to a 4.0% (95%CIs: 1.026, 1.054), 6.8% (1.052, 1.084) and 5.0% (1.039, 1.061) increase in odds of type 2  in the final adjusted models. Besides, a 1 μg/m increase of PM, PM and NO was related to a 0.020 mmol/L (95%CIs: 0.014, 0.026), 0.036 mmol/L (95%CIs: 0.030, 0.042) and 0.030 mmol/L (95%CIs: 0.026, 0.034) mmol/L higher fasting blood glucose levels.Higher exposure concentrations of air pollutants were positively related to the increased odds of type 2 , as well as higher fasting blood glucose levels in Chinese rural populations.Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31651649>Hepatitis  virus infection and the risk of liver disease progression in type 2 diabetic patients with potential nonalcoholic fatty liver disease: a retrospective, observational, cohort study in the United Kingdom Clinical Practice Research Datalink.</a></h2><p>Assess the risk of progression to cirrhosis and hepatocellular carcinoma (HCC) due to hepatitis  virus (HBV)-infection in patients with nonalcoholic fatty liver disease (NAFLD) and type 2  (T2DM).Retrospective cohort study in the UK Clinical Practice Research Datalink with three cohorts: subjects with T2DM and HBV infection (T2DM+HBV cohort; N = 297), with T2DM without HBV-infection (T2DM cohort; N = 261 865), and with HBV-infection without T2DM (HBV cohort; N = 3630). Primary analyses were performed on the three cohorts and secondary analyses on subcohorts including patients with NAFLD diagnosis code (N = 6599). Case/outcome definitions were formulated with International Classification of Diseases/Read codes/laboratory results and classified using validated algorithms. Adjusted incidence rate ratios (IRR) were estimated with a Poisson regression model.When comparing the T2DM+HBV and T2DM cohorts, adjusted IRRs were 14.06 (95% confidence interval: 4.47-44.19) for cirrhosis and 2.83 (1.06-7.55) for HCC. When comparing the T2DM+HBV and HBV cohorts, adjusted IRRs were 0.68 (0.21-2.27) for cirrhosis and 1.39 (0.46-4.20) for HCC. No cirrhosis cases were identified in T2DM+NAFLD+HBV patients; IRs were 16.92/10 000 person-years (12.97-21.69) and 85.24/10 000 person-years (10.32-307.91) in the T2DM+NAFLD and NAFLD+HBV cohorts.HBV-infection increased significantly the risk for cirrhosis among T2DM patients, however, not beyond the expected incremental risk among infected non-T2DM subjects. Our approach to evaluate the role of T2DM/NAFLD and HBV-infection in liver disease progression could be applied to other settings with higher HBV prevalence.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31669498>Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.</a></h2><p>Familial hypercholesterolemia (FH) is a frequent genetic disorder characterized by elevated low-density lipoprotein (LDL)-cholesterol (LDL-C) levels and early onset of atherosclerotic cardiovascular disease. FH is caused by mutations in genes that regulate LDL catabolism, mainly the LDL receptor (LDLR), apolipoprotein  (APOB) and gain of function of proprotein convertase subtilisin kexin type 9 (PCSK9). However, the phenotype may be encountered in individuals not carrying the latter monogenic defects, in approximately 20% of these effects of polygenes predominate, and in many individuals no molecular defects are encountered at all. These so-called FH phenocopy individuals have an elevated atherosclerotic cardiovascular disease risk in comparison with normolipidemic individuals but this risk is lower than in those with monogenic disease. Individuals with FH are exposed to elevated LDL-C levels since birth and this explains the high cardiovascular, mainly coronary heart disease, burden of these subjects. However, recent studies show that this risk is heterogenous and depends not only on high LDL-C levels but also on presence of previous cardiovascular disease, a monogenic cause, male sex, smoking, hypertension, , low HDL-cholesterol, obesity and elevated lipoprotein(a). This heterogeneity in risk can be captured by risk equations like one from the SAFEHEART cohort and by detection of subclinical coronary atherosclerosis. High dose high potency statins are the main stain for LDL-C lowering in FH, however, in most situations these medications are not powered enough to reduce cholesterol to adequate levels. Ezetimibe and PCSK9 inhibitors should also be used in order to better treat LDL-C in FH patients.Copyright © 2019. Published by Elsevier Inc.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31638358>The utility of MODY Probability Calculator in probands of families with early-onset autosomal dominant  from Poland.</a></h2><p>Maturity-Onset  of the Young (MODY) accounts for 1-2% of all  cases. Unfortunately, ca. 90% of MODY cases are misdiagnosed as type 1 or type 2 . A proper genetic diagnosis based on automatic sequencing is crucial for the use of a tailored treatment. However, this method is still expensive and, thus, patients selection for testing should be performed precisely. In 2012, an easy-to-use tool was developed in Exeter, UK, to support genetic testing for MODY in the British population. The aim of the study was to assess the utility of MODY Probability Calculator in probands from Polish families with early-onset autosomal dominant .We have performed a retrospective analysis of 155 probands who were qualified for genetic testing between 2006 and 2018. Probands were recruited for MODY testing based on the following criteria: a) early age of diagnosis (≤35 years); ) a positive, multigenerational family history of . Automatic sequencing, Sanger and, in case of initial negative results, New Generation Sequencing (NGS) of a set of 28 genes, were performed. MODY Probability was calculated on the website: www.diabetesgenes.org.The group of probands consisted of 64 GCK-, 37 HNF1A- and 3 HNF4A-MODY patients and 51 NGS-negative subjects. The median positive predictive value (PPV) was 75.5% (75.5- 75.5), 49.4% (24.4-75.5), 45.5% (21.0-75.5) and 49.4% (32.9-75.5)for GCK-, HNF1A-, HNF4A-MODY and NGS-negative, respectively. The discriminative accuracy, as expressed by AUC, of PPV between MODY and NGS negative groups was 0.62 (95% CI: 0.52-0.71) with the corresponding sensitivity of 71.2% and specificity of 51.0%.In this highly pre-selected group of probands that were qualified for genetic testing based on clinical features, the use of MODY Probability Calculator would not substantially improve the patients selection process for genetic testing. Further efforts to improve this tool are desirable.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31671770>Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain.</a></h2><p>Second-generation antipsychotics (SGAs) are the cornerstone of treatment for schizophrenia because of their high clinical efficacy. However, SGA treatment is associated with severe metabolic alterations and body weight gain, which can increase the risk of type 2  and cardiovascular disease, and greatly accelerate mortality. Several underlying mechanisms have been proposed for antipsychotic-induced weight gain (AIWG), but some studies suggest that metabolic changes in insulin-sensitive tissues can be triggered before the onset of AIWG. In this review, we give an outlook on current research about the metabolic disturbances provoked by SGAs, with a particular focus on whole-body glucose homeostasis disturbances induced independently of AIWG, lipid dysregulation or adipose tissue disturbances. Specifically, we discuss the mechanistic insights gleamed from cellular and preclinical animal studies that have reported on the impact of SGAs on insulin signaling, endogenous glucose production, glucose uptake and insulin secretion in the liver, skeletal muscle and the endocrine pancreas. Finally, we discuss some of the genetic and epigenetic changes that might explain the different susceptibilities of SGA-treated patients to the metabolic side-effects of antipsychotics.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643715>Antifungal Agents.</a></h2><p>Antifungal drugs are a diverse group of medications used to treat fungal infections ranging from ringworm and athletes foot to esophageal candidiasis, coccidiomycosis, and cryptococcal meningitis. The antifungals are classified into several groups based on their structure and mechanisms of action. These classes include the polyenes, imidazoles, triazoles, allylamines, and echinocandins, as well as miscellaneous agents. Polyene antifungals have an amphiphilic structure which binds to ergosterol, converting the fluid cell membrane of the fungal cell into a more crystalline state increasing permeability and precipitating cell lysis. Examples of polyenes (with date of approval and common brand names) include nystatin (1971: Mycostatin, Nystat) and amphotericin  (1971: Amphocin, Fungizone). Imidazole and triazole antifungal drugs inhibit cytochrome P450 14α-demethylase which is responsible for converting lanosterol to ergosterol, which blocks cell membrane synthesis in fungi. Examples of imidazoles include ketoconazole (1981: Nizoral) and clotrimazole (1975: Mycelex). Examples of triazoles include fluconazole (1990: Diflucan), itraconazole (1992: Sporanox), posaconazole (2006: Noxafil) and voriconazole (2002: Vfend). Isavuconazonium (Cresemba: 2016) is a prodrug of isavuconazole and is available in both intravenous and oral forms, its indications restricted for serious, invasive fungal infections such as aspergilosis and mucormycosis. The triazoles are perhaps the most commonly used antifungal agents having excellent oral absorption, tolerance and tissue penetration.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643701>Romidepsin.</a></h2><p>Romidepsin is an intravenously administered histone deacetylase inhibitor and antineoplastic agent that is approved for use in refractory or relapsed cutaneous and peripheral T cell lymphomas. Romidepsin is associated with modest rate of minor serum enzyme elevations during therapy but has not been linked to cases of clinically apparent liver injury, although it has been reported to cause reactivation of hepatitis .</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643852>Ruxolitinib.</a></h2><p>Ruxolitinib is a Janus kinase inhibitor that is used in the treatment of intermediate or high risk myelofibrosis. Ruxolitinib is associated with transient and usually mild elevations in serum aminotransferase during therapy, but has not been linked to cases of clinically apparent idiosyncratic acute liver injury but has been shown to be a cause of reactivation of hepatitis .</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31618895>The Mechanistic Differences in HLA-Associated Carbamazepine Hypersensitivity.</a></h2><p>Drug hypersensitivity reactions that resemble acute immune reactions are linked to certain human leucocyte antigen (HLA) alleles. Severe and life-threatening Stevens Johnson Syndrome and Toxic Epidermal Necrolysis following treatment with the antiepileptic and psychotropic drug Carbamazepine are associated with HLA-*15:02; whereas carriers of HLA-A*31:01 develop milder symptoms. It is not understood how these immunogenic differences emerge genotype-specific. For HLA-*15:02 an altered peptide presentation has been described following exposure to the main metabolite of carbamazepine that is binding to certain amino acids in the F pocket of the HLA molecule. The difference in the molecular mechanism of these diseases has not been comprehensively analyzed, yet; and is addressed in this study. Soluble HLA-technology was utilized to examine peptide presentation of HLA-A*31:01 in presence and absence of carbamazepine and its main metabolite and to examine the mode of peptide loading. Proteome analysis of drug-treated and untreated cells was performed. Alterations in sA*31:01-presented peptides after treatment with carbamazepine revealed different half-life times of peptide-HLA- or peptide-drug-HLA complexes. Together with observed changes in the proteome elicited through carbamazepine or its metabolite these results illustrate the mechanistic differences in carbamazepine hypersensitivity for HLA-A*31:01 or *15:02 patients and constitute the bridge between pharmacology and pharmacogenetics for personalized therapeutics.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31615341>Circulatory miR-98-5p levels are deregulated during  and it inhibits proliferation and promotes apoptosis by targeting PPP1R15B in keratinocytes.</a></h2><p>Although deregulated circulatory miRNA signatures during  have been identified for some years now, the effects of such miRNAs on several target tissues are not yet thoroughly investigated. The skin that is nourished by components present in the circulation exhibits several notable abnormal features during . We, therefore, hypothesized that such altered circulatory miRNA levels might be critical in the onset and progression of impaired skin health during . RNA sequencing from blood samples of normal and type 2 diabetic human subjects identified 9 upregulated and 19 downregulated miRNAs. miR-98-5p was significantly downregulated and its overexpression down-regulated PPP1R15B levels in HaCaT cells and this was prevented by the miR-98-5p inhibitor. This was validated in human primary epidermal keratinocytes and further supported by a dual reporter luciferase assay of the PPP1R15B 3'UTR where miR-98-5p significantly decreased the luciferase activity which was prevented in the presence of the miRNA inhibitor and by mutation in the miRNA binding site. By targeting PPP1R15B, miR-98-5p increases levels of p-eIF2α, BiP and CHOP. Consequently, there was induction of apoptosis accompanied with decreased proliferation in the presence of miR-98-5p. Conversely, miR-98-5p inhibition alone inhibited apoptosis and promoted proliferation. Taken together, our data suggest that by targeting PPP1R15B, miR-98-5p induces apoptosis and decreases proliferation. As opposed to this since circulatory miR-98-5p levels are decreased in , we believe that this decrease in the circulation that feeds the skin layers might be a major contributor of hyperproliferation as seen in the skin during .  miRNAs: MicroRNAs; PPP1R15B: PPP1R15B: Protein Phosphatase 1 Regulatory Subunit 15B; TGFβR1: Transforming Growth Factor Beta Receptor 1; ER: Endoplasmic Reticulum; Bip: Binding Immunoglobulin Protein; Chop: CCAAT-enhancer-binding protein homologous protein; p-eIF2α: Eukaryotic Translation Initiation Factor 2a; Bax: Bcl2-associated X protein; Bcl-2: -cell CLL/lymphoma 2; PCNA: Proliferating Cell Nuclear Antigen; K5: Cytokeratin 5; qRT-PCR: Quantitative Real-Time PCR; ESCC: Oesophageal squamous cell carcinoma; HCC: Hepatocellular carcinoma; CTHRC1: Collagen triple helix repeat containing 1; SALL4: Sal-like protein 4; TNFα: Tumour Necrosis Factor alpha; PGC-1β: Peroxisome Profilerator-activated receptor-γ coactivator-1β; IGF2BP1: Insulin-like growth factor 2 mRNA binding protein 1.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31653894>IL-21 regulates SOCS1 expression in autoreactive CD8 T cells but is not required for acquisition of CTL activity in the islets of non-obese diabetic mice.</a></h2><p>In type 1 , maturation of activated autoreactive CD8 T cells to fully armed effector cytotoxic T lymphocytes (CTL) occurs within the islet. At present the signals required for the maturation process are poorly defined. Cytokines could potentially provide the necessary "third signal" required to generate fully mature CTL capable of killing insulin-producing β-cells. To determine whether autoreactive CTL within islets respond to cytokines we generated non-obese diabetic (NOD) mice with a reporter for cytokine signalling. These mice express a reporter gene, hCD4, under the control of the endogenous regulatory elements for suppressor of cytokine signalling (SOCS)1, which is itself regulated by pro-inflammatory cytokines. In NOD mice, the hCD4 reporter was expressed in infiltrated islets and the expression level was positively correlated with the frequency of infiltrating CD45 cells. SOCS1 reporter expression was induced in transferred β-cell-specific CD8 8.3T cells upon migration from pancreatic draining lymph nodes into islets. To determine which cytokines induced SOCS1 promoter activity in islets, we examined hCD4 reporter expression and CTL maturation in the absence of the cytokine receptors IFNAR1 or IL-21R. We show that IFNAR1 deficiency does not confer protection from  in 8.3 TCR transgenic mice, nor is IFNAR1 signalling required for SOCS1 reporter upregulation or CTL maturation in islets. In contrast, IL-21R-deficient 8.3 mice have reduced  incidence and reduced SOCS1 reporter activity in islet CTLs. However IL-21R deficiency did not affect islet CD8 T cell proliferation or expression of granzyme  or IFNγ. Together these data indicate that autoreactive CD8 T cells respond to IL-21 and not type I IFNs in the islets of NOD mice, but neither IFNAR1 nor IL-21R are required for islet intrinsic CTL maturation.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31659016>UBASH3A Regulates the Synthesis and Dynamics of TCR-CD3 Complexes.</a></h2><p>The TCR-CD3 complex is a multicomponent membrane receptor, the expression of which is tightly regulated in thymocytes, as well as in mature T cells both at steady state and upon stimulation. In this study, we report novel roles for UBASH3A in TCR-CD3 synthesis and turnover. UBASH3A is a negative regulator of T cell function and plays a broad role in autoimmunity. We show that modulation of UBASH3A levels in unstimulated Jurkat cells leads to altered amounts of total cellular CD3 chains and of cell-surface TCR-CD3 complexes; in contrast, UBASH3A does not affect the level of cell-surface CD28, an important T cell costimulatory receptor. Upon TCR engagement, UBASH3A enhances the downmodulation of cell-surface TCR-CD3. Mass spectrometry and protein-protein interaction studies uncover novel associations between UBASH3A and components of several cellular pathways involved in the regulation of TCR-CD3 turnover and dynamics, including endoplasmic reticulum-associated protein degradation, cell motility, endocytosis, and endocytic recycling of membrane receptors. Finally, we demonstrate that the SH3 domain of UBASH3A mediates its binding to CBL-, an E3 ubiquitin ligase that negatively regulates CD28-mediated signaling and, hence, T cell activation. In summary, this study provides new mechanistic insights into how UBASH3A regulates T cell activation and contributes to autoimmunity. The interaction between UBASH3A and CBL- may synergistically inhibit T cell function and affect risk for type 1 , as both genes have been shown to be associated with this autoimmune disease.Copyright © 2019 by The American Association of Immunologists, Inc.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31635133>Pharmacological Enhancement of Regeneration-Dependent Regulatory T Cell Recruitment in Zebrafish.</a></h2><p>Regenerative capacity varies greatly between species. Mammals are limited in their ability to regenerate damaged cells, tissues and organs compared to organisms with robust regenerative responses, such as zebrafish. The regeneration of zebrafish tissues including the heart, spinal cord and retina requires  zebrafish regulatory T cells (zTregs). However, it remains unclear whether the muted regenerative responses in mammals are due to impaired recruitment and/or function of homologous mammalian regulatory T cell (Treg) populations. Here, we explore the possibility of enhancing zTreg recruitment with pharmacological interventions using the well-characterized zebrafish tail amputation model to establish a high-throughput screening platform. Injury-infiltrating zTregs were transgenically labelled to enable rapid quantification in live animals. We screened the NIH Clinical Collection (727 small molecules) for modulators of zTreg recruitment to the regenerating tissue at three days post-injury. We discovered that the dopamine agonist pramipexole, a drug currently approved for treating Parkinson's Disease, specifically enhanced zTreg recruitment after injury. The dopamine antagonist SCH-23390 blocked pramipexole activity, suggesting that peripheral dopaminergic signaling may regulate zTreg recruitment. Similar pharmacological approaches for enhancing mammalian Treg recruitment may be an important step in developing novel strategies for tissue regeneration in humans.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31638359>The cholesterol paradox may be attenuated in heart failure patients with .</a></h2><p>In heart failure (HF) patients, a lower total cholesterol (TC) appears to portend an ominous prognosis. We studied if the prognostic impact of TC was different according to  (DM) status in a chronic HF population.Patients with systolic HF under optimized and stable evidence-based therapy were prospectively recruited from our HF clinic. We excluded patients on renal replacement therapy and those hospitalized in the previous 2 months. A venous blood sample was collected. Patients were followed for up to 5 years and all-cause mortality was the endpoint under analysis. The prognostic impact of TC was analysed using a Cox-regression analysis. Analysis was stratified according to coexistence of DM.We studied 262 chronic HF patients, 182 males, mean age 69 years, 98 (37.4%) diabetic and 62.2% with severe left ventricular systolic dysfunction. Median - type natriuretic peptide: 237.8pg/mL; median TC: 169mg/dL. During follow-up 121 (46.2%) patients died. Patients with TC>200mg/dL had better survival than those with lower TC; however, this protective effect was mostly observed in non-diabetic HF patients. In non-diabetics the multivariate adjusted 5-year mortality hazard ratio (HR) was 0.36 (95% CI: 0.16-0.79) for those with TC>200mg/dL. In diabetic HF patients, there was non-significant survival benefit of TC>200mg/dL; HR 0.51 (95% CI: 0.20-1.30).Non-diabetic chronic HF patients with TC>200mg/dL have a 64% lower risk of 5-year death. In diabetics, there is a non-significant 49% protective effect of elevated TC. The cholesterol paradox may be attenuated in diabetic HF patients.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643258>Baloxavir.</a></h2><p>Baloxavir is an inhibitor of the influenza cap-dependent endonuclease enzyme and is used as therapy of influenza A and . Baloxavir is given as a single, one-time dose and has not been associated with serum enzyme elevations or with clinically apparent liver injury.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31654056>BCL11A, a potential diagnostic biomarker and therapeutic target in human diseases.</a></h2><p>Transcription factor -cell lymphoma/leukemia 11A (BCL11A) gene encodes a zinc-finger protein that is predominantly expressed in brain and hematopoietic tissue. BCL11A functions mainly as a transcriptional repressor that is crucial in brain, hematopoietic system development, as well as fetal-to-adult hemoglobin switching. The expression of this gene is regulated by microRNAs, transcription factors and genetic variations. A number of studies have recently shown that BCL11A is involved in β-hemoglobinopathies, hematological malignancies, malignant solid tumors, 2p15-p16.1 microdeletion syndrome, and type II . It has been suggested that BCL11A may be a potential prognostic biomarker and therapeutic target for some diseases. In this review, we summarize the current research state of BCL11A, including its biochemistry, expression, regulation, function and its possible clinical application in human diseases.Copyright 2019 The Author(s).</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31638601>Hyperuricemia and gout caused by missense mutation in d-lactate dehydrogenase.</a></h2><p>Gout is caused by deposition of monosodium urate crystals in joints when plasma uric acid levels are chronically elevated beyond the saturation threshold, mostly due to renal underexcretion of uric acid. Although molecular pathways of this underexcretion have been elucidated, its etiology remains mostly unknown. We demonstrate that gout can be caused by a mutation in LDHD within the putative catalytic site of the encoded d-lactate dehydrogenase, resulting in augmented blood levels of d-lactate, a stereoisomer of l-lactate, which is normally present in human blood in miniscule amounts. Consequent excessive renal secretion of d-lactate in exchange for uric acid reabsorption culminated in hyperuricemia and gout. We showed that LDHD expression is enriched in tissues with a high metabolic rate and abundant mitochondria and that d-lactate dehydrogenase resides in the mitochondria of cells overexpressing the human LDHD gene. Notably, the p.R370W mutation had no effect on protein localization. In line with the human phenotype, injection of d-lactate into naive mice resulted in hyperuricemia. Thus, hyperuricemia and gout can result from the accumulation of metabolites whose renal excretion is coupled to uric acid reabsorption.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31658863>Cognitive-Motor Impairment in Manual Tasks in Adults With Type 2 .</a></h2><p>Adults with type 2  (T2D) experience decline in cognitive function compared with controls. Cognitive function is a major component in the performance of daily activities that involve motor components. The aim of this project was to evaluate working memory cognitive deficits and sensorimotor deficits in adults with T2D versus healthy participants. Ten community-dwelling persons with T2D and 10 age- and sex-matched healthy controls were recruited. Cognitive function, tactile function, motor function, and health state measures were evaluated. Reduced cognitive function, tactile function, and motor function were exhibited in the T2D group. Cognitive and motor functions remained impaired versus controls during tasks with both cognitive and motor components (dual tasks). Health state measures were found to covary with measures of interest. The conclusions of this article are as follows: (a) systemic deficits beyond tactile dysfunction contribute to reduced hand/finger function in T2D, and () participants with T2D demonstrate impairments in working memory, tactile function, and motor function.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31645830>: A Friend or Foe in ICU (A Case Report with Solution).</a></h2><p> or , also known as baker's yeast or brewer's yeast, is normally a nonpathogenic microbe. It is commonly used as a probiotic to prevent antibiotic-associated diarrhea. We present a case of a 77-year-old woman with uncontrolled  who developed  with use of  containing probiotic after 5 days of treatment. The probiotic was immediately discontinued. The indwelling central line was removed, she was started on amphotericin  and the fungemia resolved. This case report highlights this peculiar complication of probiotic use. We also find it important to increase the awareness amongst the healthcare providers about this likely risk while prescribing probiotics, especially for critically ill patients.  Gupta P, Singh YP, Taneja A. : A Friend or Foe in ICU (A Case Report with Solution). Indian J Crit Care Med 2019;23(9):430-431.Copyright © 2019; Jaypee Brothers Medical Publishers (P) Ltd.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643528>Infliximab.</a></h2><p>Infliximab is a monoclonal antibody to human tumor necrosis factor alpha (TNFα) which has potent antiinflammatory activity and is used in the therapy of severe inflammatory bowel disease and rheumatoid arthritis. Infliximab has been linked to many instances of idiosyncratic acute liver injury and is a well known cause of reactivation of hepatitis .</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31649987>Evaluation of  Care parameters in capillary blood collected with a novel sampling device.</a></h2><p>The aim of this study was to determine whether the Hem-Col method of obtaining and storing blood is an acceptable alternative to venepuncture for measuring  Care parameters.  : Hem-Col is a novel blood collection device that is designed to collect capillary blood drawn with a finger prick. Hem-Col is a microtube containing an anticoagulant and a preservation buffer to enhance analyte stability in whole blood. The  Care parameters cholesterol, creatinine, HbA1c, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, and triglycerides were measured both in blood/plasma collected via Hem-Col and blood/plasma collected with venepuncture. The results were compared to assess the agreement between the two methods.  : HbA1c shows agreement after storage for up to 120 hours at temperatures ranging from 4 to 37 °C. Cholesterol, HDL cholesterol, LDL cholesterol, triglycerides and creatinine can be measured after 120 hours of storage in Hem-Col buffer, if high temperatures are avoided, and with the use of correction factors or adaptations to reported reference intervals.  : Hem-Col is suitable for the measurement of HbA1c after storage for up to 120 hours at temperatures ranging from 4 to 37 °C. Cholesterol, creatinine, HDL cholesterol, LDL cholesterol and triglycerides can be measured after 120 hours of storage in Hem-Col buffer, if high temperatures are avoided. Further studies are required to determine whether Hem-Col can replace the venepuncture for the  Care parameters.© 2019 The Authors.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31644910>MALT1 Phosphorylation Controls Activation of T Lymphocytes and Survival of ABC-DLBCL Tumor Cells.</a></h2><p>The CARMA1/CARD11-BCL10-MALT1 (CBM) complex bridges T and  cell antigen receptor (TCR/BCR) ligation to MALT1 protease activation and canonical nuclear factor κ (NF-κ) signaling. Using unbiased mass spectrometry, we discover multiple serine phosphorylation sites in the MALT1 C terminus after T cell activation. Phospho-specific antibodies reveal that CBM-associated MALT1 is transiently hyper-phosphorylated upon TCR/CD28 co-stimulation. We identify a dual role for CK1α as a kinase that is essential for CBM signalosome assembly as well as MALT1 phosphorylation. Although MALT1 phosphorylation is largely dispensable for protease activity, it fosters canonical NF-κ signaling in Jurkat and murine CD4 T cells. Moreover, constitutive MALT1 phosphorylation promotes survival of activated  cell-type diffuse large  cell lymphoma (ABC-DLBCL) cells addicted to chronic BCR signaling. Thus, MALT1 phosphorylation triggers optimal NF-κ activation in lymphocytes and survival of lymphoma cells.Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643845>Zanamivir.</a></h2><p>Zanamivir is an inhibitor of the influenza neuramidase enzyme and is given by inhalation as therapy and prophylaxis against influenza A and . Zanamivir has not been associated with clinically apparent liver injury, at least when given by inhalation.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31670082>Human epidemiological evidence about the association between air pollution exposure and gestational : Systematic review and meta-analysis.</a></h2><p>Previous studies have shown that ambient air pollution exposure can increase the risk of type 2  (T2DM) significantly. In consideration of the common underlying pathophysiologic mechanisms, exposure to air pollution may also increase the risk of gestational  (GDM), but the current evidence was inconsistent and has not well been systematically reviewed. Our goal was to perform a systematic review and meta-analysis assessing the association between air pollution exposure and GDM.An extensive literature search was conducted in selected electronic databases for related human epidemiological studies published in English language. Summary effect estimates were calculated using random-effect models for a) risk per unit increase in continuous air pollutant concentration and ) risk of high versus low exposure level in individual study if each exposure that had been examined in ≥2 studies. We evaluated the heterogeneity using Cochran's Q test and quantified it by I statistic. Publication bias was also evaluated through the funnel plot when sufficient number of studies are available.A total of 11 studies evaluating the association between GDM and exposure to air pollution were identified finally. The summary odds ratio (OR) for incidence of GDM following a 10 μg/m increase in PM exposure during the second trimester was 1.04 (95% Confidence Interval (CI): 1.01, 1.09) and in NO during the first trimester was 1.03 (95%CI: 1.00, 1.07) per 10 ppb increase, while for high versus low SO exposure during the second trimester was 1.25 (95%CI: 1.02, 1.53). High heterogeneity among study-specific results in majority of the analyses were observed, and attributed to different exposure assessment methods, populations, study locations, and covariates adjustment. Publication bias cannot be excluded because of the inclusion of small number of studies.The present study supports the evidence that air pollution exposure increases the risk the GDM, albeit the existence of high heterogeneity. Further studies are necessary to elaborate the suggestive associations. These results are of public health significance since worsening air pollution in developing countries has been expected to increase the risk of GDM development.Copyright © 2019 Elsevier Inc. All rights reserved.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643475>Ocrelizumab.</a></h2><p>Ocrelizumab is a humanized monoclonal antibody to CD20 which is used as therapy of multiple sclerosis. Ocrelizumab has not been associated with serum enzyme elevations during therapy nor with instances of clinically apparent liver injury, but is likely to cause reactivation of hepatitis  in susceptible patients.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31655001>Hypoglycaemic episodes increase the risk of ventricular arrhythmia and sudden cardiac arrest in patients with type 2 -A nationwide cohort study.</a></h2><p>The impact of hypoglycaemic episode (HE) on the risk of ventricular arrhythmia (VA) and sudden cardiac arrest (SCA) remains unclear. We hypothesized that HE increases the risk of both VA and SCA and that glucose-lowering agents causing HE also increase the risk of VA/SCA in patients with type 2  (T2D).Patients aged 20 years or older with newly diagnosed T2D were identified using the Taiwan National Health Insurance Database. HE was defined as the presentation of hypoglycaemic coma or specified/unspecified hypoglycaemia. The control group consisted of T2D patients without HE. The primary outcome was the occurrence of VA (including ventricular tachycardia and fibrillation) and SCA during the defined follow-up periods. A multivariate Cox hazards regression model was used to evaluate the hazard ratio (HR) for VA or SCA.A total of 54 303 patients were screened, with 1037 patients with HE assigned to the HE group and 4148 frequency-matched patients without HE constituting the control group. During a mean follow-up period of 3.3 ± 2.5 years, 29 VA/SCA events occurred. Compared with the control group, HE group had a higher incidence of VA/SCA (adjusted HR: 2.42, P = .04). Patients who had used insulin for glycaemic control showed an increased risk of VA/SCA compared with patients who did not receive insulin (adjusted HR: 3.05, P = .01).The HEs in patients with T2D increased the risk of VA/SCA, compared with those who did not experience HEs. Use of insulin also independently increased the risk of VA/SCA.© 2019 John Wiley & Sons, Ltd.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643663>Tositumomab.</a></h2><p>Tositumomab is the combination of a monoclonal antibody to CD20 and iodine-131 which is used to treat refractory, advanced non-Hodgkin lymphoma. Tositumomab has not been associated with significant serum enzyme elevations during therapy or to cases of idiosyncratic, clinically apparent liver injury. However, tositumomab has potent immunosuppressive activity and is probably capable of causing reactivation of hepatitis  in susceptible patients.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31644130>Sofosbuvir.</a></h2><p>Sofosbuvir is an oral nucleoside analogue and potent inhibitor of the hepatitis C virus (HCV) RNA polymerase that is used in combination with other antiviral agents to treat chronic hepatitis C. Elevations in serum enzyme levels during sofosbuvir therapy are uncommon, and it has not been implicated convincingly in cases of clinically apparent liver injury with jaundice. Nevertheless, and for unknown reasons, successful antiviral therapy of hepatitis C with sofosbuvir and other direct acting agents in patients with cirrhosis is occasionally complicated by hepatic decompensation; furthermore, treatment can cause reactivation of hepatitis  in susceptible patients coinfected with the hepatitis  virus (HBV).</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31640424>System Accuracy Assessment of a Combined Invasive and Noninvasive Glucometer.</a></h2><p>The pain associated with pricking the fingertip for blood glucose self-testing is considered to be a major burden in  treatment. This study was performed to evaluate the system accuracy of the invasive TensorTip Combo Glucometer (CoG) device component in accordance with ISO15197:2015 requirements and to explore the accuracy of the noninvasive tissue glucose prediction component.One hundred samples were obtained from people with type 1 and type 2  and healthy volunteers (43 females, 57 males; age: 53 ± 16 years), with glucose distribution as requested by the ISO standard. Three strip lots were tested twice by healthcare professionals in comparison to YSI 2300 Stat Plus reference method followed by a noninvasive tissue glucose reading (NI-CoG). Mean Absolute (Relative) Difference (MARD) was calculated and a consensus error grid (CEG) analysis was performed.The ISO system accuracy criteria were met with the invasive strip technology by 586/600 of the data points (97.1%) and for each strip lot separately. All invasive results (100%) were within CEG-zone A and total MARD was calculated to be 7.1%. With the noninvasive reading, 99% of raw data points were in A +  (91.1% and 7.8%), and the total MARD was calculated to be 18.1%.The invasive component of the CoG device was shown to be in full compliance with the current ISO15197 criteria. Good results were also obtained with the NI-CoG tissue glucose prediction. This noninvasive technology would potentially be suitable for frequent pain-free glucose monitoring in many people with .</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31641666>In-Vitro Biofilm Formation and Antimicrobial Resistance of  in Diabetic and Nondiabetic Patients.</a></h2><p>Diabetic patients are more susceptible to urinary tract infection compared to nondiabetic patients,  being the most common uropathogen causing UTI. Unreasonable and incorrect antibiotic prescription for UTI in these patients may induce the development of antibiotic-resistant urinary pathogens resulting in delayed recovery and longer hospitalization. In addition to these, biofilm forming capacity of the pathogen may worsen the problem. The main aim of this cross-sectional study (conducted from March to September 2015) is to detect the biofilm forming capacity of UTI causing micro-organisms and compare the antibiotic resistance pattern of , the most common cause of UTI, which will help the physician in choosing the best antibiotic.Total of 1,099 clean-catch mid stream urine (CCMSU) was processed by standard microbiological technique; 182 were from the diabetic group and 917 nondiabetic. Following identification, all isolates were subjected to antibiotic susceptibility testing using modified Kirby-Bauer disc diffusion method. In-vitro biofilm forming capacity of the isolates were detected by Microtitre plate method. The data were analyzed using SPSS software 16.Urinary tract infection was found to be significantly higher in diabetic patients (42.9%) compared to nondiabetic patients (17.4%) with  as the most common uropathogen in both diabetic and nondiabetic groups. Similarly, UTI was more common in elderly population (29.5%). Imipenem, nitrofurantoin and amikacin were found to be the most effective drug for uropathogenic  in both diabetic and nondiabetic patients, whereas amoxicillin, ciprofloxacin, and cotrimoxazole were least effective. Of the total bacterial isolates, 43.3% showed positive results for in-vitro biofilm production by the Microtitre plate method. A significantly higher resistance rate was observed among biofilm producing  for quinolones, cotrimoxazole, and third generation cephalosporin ceftriaxone. Most of the biofilm producers (79.5%) were found to be MDR (-value 0.015).Elderly populations with  are at a higher risk of UTI. Higher biofilm production and resistance to in-use antimicrobial agents in this study render its inefficacy for empirical treatment and point out the importance of biofilm screening to ensure the effective management of infection.Copyright © 2019 Sunayana Raya et al.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31644050>Vedolizumab.</a></h2><p>Vedolizumab is a humanized monoclonal antibody to integrin α4β7 which is used in the treatment of inflammatory bowel disease. Vedolizumab has been linked to a low rate of serum enzyme elevations during therapy, but has not been linked to cases of idiosyncratic, clinically apparent liver injury with jaundice. Because vedolizumab is a potent inhibitor of lymphocyte function, it may cause reactivation of chronic hepatitis  in susceptible patients.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31658492>Rosiglitazone alleviates α-naphthylisothiocyanate-induced intrahepatic cholestasis in mice - The role of circulating 15d-PGJ and Nogo.</a></h2><p>Intrahepatic cholestasis is mainly caused by dysfunctions of molecules for bile secretion with limited treatment. Rosiglitazone is a synthetic ligand while 15-deoxy-Δ -prostaglandin J (15d-PGJ ) is the endogenous agonist of PPARγ. Reticulon 4B (Nogo-) is the detectable Nogo protein family member in the liver and secreted into circulation. Herein, we determined if rosiglitazone can alleviate intrahepatic cholestasis in mice.Wild type, hepatocyte-specific PPARγ or Nogo- knockout mice received intragastric administration of α-naphthylisothiocyanate (ANIT) and/or rosiglitazone, followed by determination of intrahepatic cholestasis and the involved mechanisms. Serum samples were collected from PBC patients and non-PBC controls to analyze cholestasis-related serum parameters.Rosiglitazone prevented wild type but not hepatocyte-specific PPARγ deficient mice from ANIT-induced intrahepatic cholestasis by activating expression of bile homeostatic molecules, reducing hepatic necrosis, and correcting abnormal serum parameters and bile enterohepatic circulation. Nogo- deficiency had similar protections to rosiglitazone. ANIT-induced intrahepatic cholestasis reduced 15d-PGJ but increased Nogo- in serum, and both were corrected by rosiglitazone. Nogo- deficiency in the liver boosted 15d-PGJ production, thereby activating expression of PPARγ and bile homeostatic molecules. Rosiglitazone and Nogo- deficiency also alleviated cholestasis-associated dyslipidemia. Furthermore, reduced 15d-PGJ and increased Nogo- in PBC patients' serum were determined, with a negative or positive correlation to classical cholestatic parameters. In addition, rosiglitazone reduced symptoms of the established intrahepatic cholestasis.Our study demonstrates that 15d-PGJ and Nogo are important biomarkers for intrahepatic cholestasis. Synthetic PPARγ ligands can be used for treatment of intrahepatic cholestasis and cholestasis-associated dyslipidemia potentially.This article is protected by copyright. All rights reserved.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31635118>Periodontal Treatment Experience Associated with Oral Health-Related Quality of Life in Patients with Poor Glycemic Control in Type 2 : A Case-Control Study.</a></h2><p>Severe periodontitis is a risk factor for poor glycemic control. The appropriate medicaltreatment and plaque control of periodontitis positively affects blood-sugar control in diabetespatients. We aimed to identify the factors associated with glycemic control and examine theperiodontal treatment (PT) experience and oral health-related quality of life (OHQoL) for patientswith poor glycemic control in type 2  (T2DM). This multicenter case-control studyrecruited 242 patients with poor glycemic control and 198 patients with good glycemic control. Wecollected patients' information through face-to-face interviews using a structured questionnaire.The Oral Health Impact Profile-14 (OHIP-14) was used to measure OHQoL. Based on PT status, thepatients were classified into three groups: a non-periodontal disease group, a PT group, and a non-PT (NPT) group. Regression models were used to analyze the data. No interdental cleaning(adjusted odds ratio (aOR) = 1.78) and positive attitudes toward periodontal health (aOR = 1.11)were significantly more likely to be associated with poor glycemic control in patients with T2DM.The PT group had a significantly lower OHIP-14 score than the NPT group (6.05 vs. 9.02, p < 0.001),indicating a better OHQoL among patients with poorly controlled T2DM. However, the OHQoLdid not differ significantly in patients with well-controlled T2DM between the PT and NPT groups.This suggested that diabetic patients with poor glycemic control must improve periodontal carepractices and receive proper PT, if necessary, to improve their OHQoL.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31633724>A STUDY OF METABOLIC PARAMETERS IN NON DIABETIC PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE - IMPORTANCE OF DYSLIPIDEMIA.</a></h2><p>Metabolic risk factors of non alcoholic fatty liver disease (NAFLD) in non diabetic teetotallers who constitute a definite group are not well defined.To identify the metabolic risk factors of NAFLD if any in non diabetic subjects who do not consume alcohol.In a cross sectional study the effect of metabolic parameters (BMI, individual lipid levels, hemoglobinA1c (HbA1c), HOMA IR and the metabolic syndrome components) of 150 consecutive non diabetic teetotallers (90 with normal glucose tolerance and 60 prediabetics) on their NFS (quantifiable severity parameter of NAFLD) was studied by linear regression analysis. Similar study was done in the normal glucose tolerance and prediabetes groups separately. These parameters were then compared with those of 75 matched diabetic teetotallers with NAFLD. To analyse further the difference between normal glucose tolerance, prediabetic and overt diabetic groups, binary logistic regression of the factors was carried out taking prediabetes and  as outcome variable.All the metabolic parameters were significantly higher in diabetics compared to non diabetics and in prediabetics compared to those with normal glucose tolerance except high-density lipoprotein cholesterol. Triglyceride, high-density lipoprotein cholesterol and BMI significantly predicted NFS in the overall (adjusted R2 68.7%, P=0.000) and normal glucose tolerance groups (adjusted R2 73.2%, P=0.000) whereas BMI, triglyceride, low-density lipoprotein cholesterol and HbA1c did in prediabetics (adjusted R2 89%, P=0.000). The metabolic syndrome was significantly associated with NFS in the overall and prediabetic groups. High triglyceride (odds ratio1.08), low-density lipoprotein cholesterol (odds ratio1.03) and HbA1c (odds ratio 11.54) were positively associated with prediabetes compared to normal glucose tolerance group.In nondiabetic teetotallers dyslipidemias are the prime contributors to the development of NAFLD.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31626467>[The faces of migrant health in France].</a></h2><p>The pathologies encountered by migrants are varied and depend on many factors such as sex, age, country of origin, migration conditions, administrative status, living conditions in France and the year of arrival. There are imported diseases such as tuberculosis or chronic hepatitis , congenital as sickle cell disease, consequent to the difficulties encountered during the migration course -psychological disorders and malnutrition in particular-, acquired on the French territory in connection with hardship like scabies or nearly one in two HIV infections, but also related to the adoption of deleterious dietary habits and the consumption of tobacco and alcohol that can potentiate certain diseases such as  and hypertension. There is no clinical specificity of migrants' health but reflexes to be acquired in relation to the epidemiological and clinical knowledge that varies from one group to another. The frequency of certain often asymptomatic diseases such as hepatitis , schistosomiasis or hypertension justifies the proposal of a systematic health check-up for all migrants and immigrants. Migration for health reasons remains, for its part, a minority reason for migration to France.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31647489>Fundamentals of cross-seeding of amyloid proteins: an introduction.</a></h2><p>Misfolded protein aggregates formed by the same (homologous) or different (heterologous/cross) sequences are the pathological hallmarks of many protein misfolding diseases (PMDs) including Alzheimer's disease (AD) and type 2  (T2D). Different from homologous-amyloid aggregation that is solely associated with a specific PMD, cross-amyloid aggregation (i.e. cross-seeding) of different amyloid proteins is more fundamentally and biologically important for understanding and untangling not only the pathological process of each PMD, but also a potential molecular cross-talk between different PMDs. However, the cross-amyloid aggregation is still a subject poorly explored and little is known about its sequence/structure-dependent aggregation mechanisms, as compared to the widely studied homo-amyloid aggregation. Here, we review the most recent and important findings of amyloid cross-seeding behaviors from in vitro, in vivo, and in silico studies. Some typical cross-seeding phenomena between Aβ/hIAPP, Aβ/tau, Aβ/α-synuclein, and tau/α-synuclein are selected and presented, and the underlying specific or general cross-seeding mechanisms are also discussed to better reveal their sequence-structure-property relationships. The potential use of the cross-seeding concept to design amyloid inhibitors is also proposed. Finally, we offer some personal perspectives on current major challenges and future research directions in this less-studied yet important field, and hopefully this work will stimulate more research to explore all possible fundamental and practical aspects of amyloid cross-seeding.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31654609>GDM: More , more good or more harm?</a></h2><p>In this issue of BJOG, Shah and Sharif report an increased risk of adverse perinatal outcomes in women meeting IADPSG, but not "2-step" criteria for GDM (Shah , et al. BJOG 2019). These women were not considered to have GDM and were not treated for the condition. The authors used a clever study design leveraging population-based data and their findings are consistent with other studies.© 2019 Royal College of Obstetricians and Gynaecologists.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31665403>Evaluation of Systematic Blood Testing at the Time of Recruitment to the Armed Forces: Retrospective Monocentric Study Among 726 French Army Soldiers.</a></h2><p>In the French armed forces, the biological checkup required during the recruitment process comprises a urinalysis (urinary dipstick), a complete blood count (CBC), and measurement of serum levels of aspartate aminotransferase, alanine aminotransferase, fasting blood glucose, and creatinine. This study aimed to evaluate the benefits of this biological checkup and to determine the most relevant parameters.We conducted a monocentric retrospective study of all standardized and systematically conducted blood tests (CBC and measurement of aspartate aminotransferase, alanine aminotransferase, fasting blood glucose, and creatinine) over a 15-month period among 726 French Army recruits.The population included mainly young males (85.4%, mean age 21.6 years). More than half (54.1%) of the blood tests had at least one abnormal parameter, most often concerning the CBC. Anemia occurred in 5.3% of the population and was mostly normocytic. Microcytosis was mostly not associated with anemia (72.3% of cases). Lymphopenia occurred in 20.1% of the population and was mostly mild. Eosinophilia was present in 5.1% of the population and was never severe. Thrombocytopenia occurred in 0.7% of the population and was never severe. Serum levels of aminotransferases were elevated in 8.1% of the population. Fasting plasma glucose averaged 84 mg/dL (SD: 0.07) ranging from 64 to 123 mg/dL, was abnormal in 0.4% of the population, and one case of  was diagnosed. Serum creatinine concentration was elevated in 0.7% of the population.CBCs gave useful information but iron deficiency was common and insufficiently detected by this single analysis. Assessing aminotransferase levels without screening for viral hepatitis and systematic measurement of fasting plasma glucose levels did not appear to be efficient. In addition, the only interest in systematic measurement of creatinine serum levels was to obtain a reference level for long-term follow-up. In addition to the urinary dipstick, the systematic biological checkup at recruitment could be limited to a CBC with measurement of plasma ferritin levels and Hepatitis  virus serology, providing that any CBC abnormalities, in particular cytopenia, eosinophilia, and microcytosis, are systematically investigated. For a public health approach, systematic screening for other sexually transmitted infections could be proposed.© Association of Military Surgeons of the United States 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31614775>Musclin, A Myokine Induced by Aerobic Exercise, Retards Muscle Atrophy During Cancer Cachexia in Mice.</a></h2><p>Physical activity improves the prognosis of cancer patients, partly by contrasting the associated muscle wasting (cachexia), through still unknown mechanisms. We asked whether aerobic exercise causes secretion by skeletal muscles of proteins (myokines) that may contrast cachexia. Media conditioned by peroxisome proliferator-activated receptor γ coactivator 1α (PGC1α)-expressing myotubes, reproducing some metabolic adaptations of aerobic exercise, as increased mitochondrial biogenesis and oxidative phosphorylation, restrained constitutively active Forkhead box-containing subfamily O3 (caFoxO3)-induced proteolysis. Microarray analysis identified amphiregulin (AREG), natriuretic peptide precursor  (NppB), musclin and fibroblast growth factor 18 (FGF18) as myokines highly induced by PGC1α. Notably, only musclin tended to be low in muscle of mice with a rare human renal carcinoma; it was reduced in plasma and in muscles of C26-bearing mice and in atrophying myotubes, where PGC1α expression is impaired. Therefore, we electroporated the Tibialis Anterior (TA) of C26-bearing mice with musclin or (its receptor) natriuretic peptide receptor 3 (Npr3)-encoding plasmids and found a preserved fiber area, as a result of restrained proteolysis. Musclin knockout (KO) mice lose more muscle tissue during growth of two distinct cachexia-causing tumors. Running protected C26-bearing mice from cachexia, not changing tumor growth, and rescued the C26-induced downregulation of musclin in muscles and plasma. Musclin expression did not change in overloaded plantaris of mice, recapitulating partially muscle adaptations to anaerobic exercise. Musclin might, therefore, be beneficial to cancer patients who cannot exercise and are at risk of cachexia and may help to explain how aerobic exercise alleviates cancer-induced muscle wasting.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31634466>Nutrient metabolism, subcellular redox state and oxidative stress in pancreatic islets and β-cells.</a></h2><p>Insulin-secreting pancreatic β-cells play a critical role in blood glucose homeostasis and the development of type 2  (T2D) in the context of insulin resistance. Based on data obtained at the whole cell level using poorly specific chemical probes, reactive oxygen species (ROS) like superoxide and hydrogen peroxide have been proposed to contribute to the stimulation of insulin secretion by nutrients (positive role) and to the alterations of cell survival and secretory function in T2D (negative role). This raised the controversial hypothesis that any attempt to decrease β-cell oxidative stress and apoptosis in T2D would further impair insulin secretion. Over the last decade, the development of genetically-encoded redox probes that can be targeted to cellular compartments of interest and are specific of redox couples allowed the evaluation of short- and long-term effects of nutrients on β-cell redox changes at the subcellular level. The data indicated that the nutrient regulation of β-cell redox signaling and ROS toxicity is far more complex than previously thought, and that the subcellular compartmentation of these processes cannot be neglected when evaluating the mechanisms of ROS production or the efficacy of antioxidant enzymes and antioxidant drugs under glucolipotoxic conditions and in T2D. In this review, we present what is currently known about the compartmentation of redox homeostatic systems and tools to investigate it. We then review data about the effects of nutrients on β-cell subcellular redox state under normal conditions and in the context of T2D, and discuss challenges and opportunities in the field.Copyright © 2019 Elsevier Ltd. All rights reserved.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31648630>Disparities in Antihypertensive Prescribing After Stroke: Linked Data From the Australian Stroke Clinical Registry.</a></h2><p>Background and Purpose- Despite evidence to support the prescription of antihypertensive medications before hospital discharge to promote medication adherence and prevent recurrent events, many patients with stroke miss out on these medications at discharge. We aimed to examine patient, clinical, and system-level differences in the prescription of antihypertensive medications at hospital discharge after stroke. Methods- Adults with acute ischemic stroke or intracerebral hemorrhage alive at discharge were included (years 2009-2013) from 39 hospitals participating in the Australian Stroke Clinical Registry. Patient comorbidities were identified using the  () codes from the hospital admissions and emergency presentation data. The outcome variable and other system factors were derived from the Australian Stroke Clinical Registry dataset. Multivariable, multilevel logistic regression was used to examine factors associated with the prescription of antihypertensive medications at hospital discharge. Results- Of the 10 315 patients included, 79.0% (intracerebral hemorrhage, 74.1%; acute ischemic stroke, 79.8%) were prescribed antihypertensive medications at discharge. Prescription varied between hospital sites, with 6 sites >2 SDs below the national average for provision of antihypertensives at discharge. Prescription was also independently associated with patient and clinical factors including history of hypertension, , management in an acute stroke unit, and discharge to rehabilitation. In patients with acute ischemic stroke, females (odds ratio, 0.85; 95% CI, 0.76-0.94), those who had greater stroke severity (odds ratio, 0.81; 95% CI 0.72-0.92), or dementia (odds ratio, 0.65; 95% CI, 0.52-0.81) were less likely to be prescribed. Conclusions- Prescription of antihypertensive medications poststroke varies between hospitals and according to patient factors including age, sex, stroke severity, and comorbidity profile. Implementation of targeted quality improvement initiatives at local hospitals may help to reduce the variation in prescription observed.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31652867>Identifying Phlorofucofuroeckol-A as a Dual Inhibitor of Amyloid-β Self-Aggregation and Insulin Glycation: Elucidation of the Molecular Mechanism of Action.</a></h2><p>Both amyloid-β (Aβ) and insulin are amyloidogenic peptides, and they play a critical role in Alzheimer's disease (AD) and type-2  (T2D). Misfolded or aggregated Aβ and glycated insulin are commonly found in AD and T2D patients, respectively, and exhibit neurotoxicity and oxidative stress. The present study examined the anti-Aβ aggregation and anti-insulin glycation activities of five phlorotannins isolated from  . Thioflavin-T assay results suggest that eckol, dioxinodehydroeckol, dieckol, and phlorofucofuroeckol-A (PFFA) significantly inhibit Aβ self-assembly. Molecular docking and dynamic simulation analyses confirmed that these phlorotannins have a strong potential to interact with Aβ peptides and interrupt their self-assembly and conformational transformation, thereby inhibiting Aβ aggregation. In addition, PFFA dose-dependently inhibited d-ribose and d-glucose induced non-enzymatic insulin glycation. To understand the molecular mechanism for insulin glycation and its inhibition, we predicted the binding site of PFFA in insulin via computational analysis. Interestingly, PFFA strongly interacted with the Phe1 in insulin chain-, and this interaction could block d-glucose access to the glycation site of insulin. Taken together, our novel findings suggest that phlorofucofuroeckol-A could be a new scaffold for AD treatment by inhibiting the formation of β-sheet rich structures in Aβ and advanced glycation end-products (AGEs) in insulin.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643573>Rituximab.</a></h2><p>Rituximab is a chimeric mouse/human monoclonal antibody to CD20 a cell surface antigen found on pre- and mature  lymphocytes and which is approved for use in non-Hodgkin lymphoma and chronic lymphocytic leukemia as well as in several autoimmune conditions, including rheumatoid arthritis and Wegener granulomatous. Rituximab has been linked to many cases of severe and even fatal liver injury as a result of reactivation of inactive or previously resolved hepatitis .</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31630574>Impact of Immigration on Body Mass Index and Blood Pressure among Adolescent Males and Females: A Nationwide Study.</a></h2><p>Immigration from one cultural milieu to another has been associated with a greater risk for incident cardio-metabolic morbidity among adults. In this nationwide, population-based, cross-sectional study of data recorded from 1992 to 2016, we assessed the association between body mass index and blood pressure levels among adolescent immigrants, aged 16 to 19 years, of Ethiopian origin, and their secular trend of overweight and obesity. Adolescents of Ethiopian origin were classified as Israeli-born (n=16 153) or immigrants (N=23 487), with stratification by age at immigration. Adolescents whose fathers were at least 3 generations in Israel (n=277 789) served as a comparative group. Hypertensive-range blood pressure values adjusted for age, sex, and height served as outcome. Among adolescents of Ethiopian origin, overweight and obesity (body mass index ≥85th percentile), increased by 2.5 and 4-fold in males and females, respectively, during the study period, compared with a 1.5-fold increase among native Israeli-born males and females. The odds for hypertensive-range measurements increased with the length of residence in Israel: 7.3%, 10.6%, and 14.4% among males who immigrated at ages 12 to 19, 6 to 11.9, and 0 to 5.9 years, respectively; and 11.5%, 16.7%, and 19.3%, respectively, among females. Israeli-born Ethiopians had a significantly higher risk for hypertensive-range measurements at any body mass index level compared with native Israeli-born examinees, after adjusting for sociodemographic factors and health status. In conclusion, among Ethiopian Israeli adolescents, abnormal blood pressure correlates directly with the time-lapse since immigration. Immigrant populations require targeted surveillance and appropriate intervention.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31635395>Anti-Oxidant and Anti- Potential of Water-Soluble Chitosan-Glucose Derivatives Produced by Maillard Reaction.</a></h2><p>Chitosan-sugar derivatives demonstrate some useful biology activities (for example anti-oxidant and anti-microbial activities). In this study, water-soluble chitosan-glucose derivatives (WSCGDs) were produced from a water-soluble chitosan hydrochloride (WSC) with 12.5 kDa of molecular weight and 24.05% of degree of acetylation (DA) via Maillard reaction with the heating temperatures of 100 °C and 121 °C. The Maillard reaction between WSC and glucose was investigated by measuring the absorbances at 420 nm and 294 nm, indicating that the reaction took place more effectively at 121 °C. All WSCGDs exhibited higher anti-oxidant activity than WSC, in which WSCGDs obtained at the treatment 121 °C for 2 h, 3 h, and 4 h expressed the highest ability (IC50 range from 1.90-1.05 mg/mL). Increased anti-α-amylase and anti-α-glucosidase activities were also observed in WSCGDs from the treatment at 121 °C. In detail, the highest IC50 values of anti-α-amylase activity were 18.02 mg/mL (121 °C, 3 h) and 18.37 mg/mL (121 °C, 4 h), whereas the highest IC50 values of anti-α-glucosidase activity were in range of 7.09-5.72 mg/mL (121 °C, for 1-4 h). According to the results, WSCGD obtained from 121 °C for 3 h was selected for further characterizing by high performance liquid chromatography size exclusion chromatography (HPLC SEC), colloid titration, FTIR, as well as 1H-NMR, indicating that the derivative of WSC and glucose was successfully synthesized with a molecular weight of 15.1 kDa and degree of substitution (DS) of 34.62 ± 2.78%. By expressing the excellent anti-oxidant and anti- activities, WSCGDs may have potential use in health food or medicine applications.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31648154>Indoor light pollution and progression of carotid atherosclerosis: A longitudinal study of the HEIJO-KYO cohort.</a></h2><p>Exposure to light at inappropriate times in relation to the solar cycle can disturb circadian endocrine and metabolic rhythms. Previous studies have suggested an association between light exposure at night (LAN) and obesity, an important risk factor of atherosclerosis, although it remains unclear whether LAN associates with progression of atherosclerosis. To evaluate the longitudinal association between bedroom LAN intensity and progression of carotid atherosclerosis, light intensity in the bedroom at baseline and carotid artery intima-media thickness (IMT) at baseline and follow-up were measured in 989 elderly participants (945 at baseline and 780 at a median follow-up time of 34 months). The mean age of the participants was 71.4 ± 6.9 years. The average mean and maximal carotid IMT at baseline were 0.88 ± 0.15 and 1.10 ± 0.32 mm, respectively. The median intensity of bedroom LAN was 0.68 lx (IQR, 0.07-3.29). In multivariable analysis adjusted for potential confounders, the highest LAN group exhibited a significant increase in mean carotid IMT (adjusted β, 0.028; 95% CI, 0.005-0.052; P = 0.019) compared with the lowest LAN quartile group. A similar relationship was found between LAN and maximal carotid IMT (adjusted β, 0.083; 95% CI, 0.037-0.129; P < 0.001). In conclusion, we found a clear and significant association between bedroom LAN intensity and progression of subclinical carotid atherosclerosis, which was independent of known risk factors for atherosclerosis, including age, obesity, smoking, economic status, hypertension, and . Indoor light pollution may be a potential risk factor for atherosclerosis in the general population.Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31644020>Vitamin .</a></h2><p>Vitamin  refers to several water soluble vitamins often found together in foods, all of which are necessary for normal growth and metabolism, but none of which are synthesized in adequate amounts by humans. The common forms of vitamin  include vitamin B1 (thiamine), B2 (riboflavin), B3 (niacin), B6 (pyridoxine) and B12 (cyanocobalamin). Except for niacin (when given in high doses), there is no evidence that the other  vitamins, in physiologic or even super-physiologic, high doses, cause liver injury or jaundice. The major forms of vitamin  and selected other water soluble vitamins (biotin, pantothenic acid, choline) are discussed briefly in this record.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31661471>Relationship Between  and Cirrhosis Risk in Chronic Hepatitis  Patients in Wuhan, China.</a></h2><p>BACKGROUND The objective of our research was to assess the possible link between  (DM) and liver cirrhosis in chronic hepatitis  (CHB) patients in Wuhan, China. MATERIAL AND METHODS Individuals with a diagnosis of both liver cirrhosis and chronic HBV infection (n=257), and CHB-only patients (n=514) were matched 1: 2 by age and sex. Demographic, lifestyle, laboratory, and clinical characteristics were reviewed. Univariate and the multiple logistic regression analysis were conducted to investigate the association between DM and HBV-related liver cirrhosis. RESULTS The prevalence of DM was higher among CHB patients with liver cirrhosis than in those without liver cirrhosis (22.2% vs. 12.8%, P=0.001), yielding an adjusted odds ratio (AOR) of 2.317 and a 95% confidence interval (CI) of 1.528-3.513. Among them, 87.7% of liver cirrhosis patients were diagnosed with DM before liver cirrhosis diagnosis, yielding an AOR (95% CI) of 2.386 (1.533-3.714). In comparison to patients with a DM duration of 2-5 years, the AOR (95% CI) for those with a DM duration >5 years was 2.073 (0.701-6.132). In DM treatment, the AOR (95% CI) for those treated with insulin was 4.746 (1.329-16.949). CONCLUSIONS DM was associated with cirrhosis risk in CHB patients in Wuhan, China.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643405>Entecavir.</a></h2><p>Entecavir is a guanosine nucleoside analogue used in the treatment of chronic hepatitis  virus (HBV) infection. Entecavir therapy can be associated with flares of the underlying hepatitis  during or after therapy, but has not been linked to cases of clinically apparent liver injury.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31640118>Anti-Diabetic Nephropathy Activities of Polysaccharides Obtained from  via Regulation of NF-κ Signaling in db/db Mice.</a></h2><p> is a kind of traditional Chinese edible fungus rich in nutrients and medicinal ingredients, and it has anti-oxidative, analgesic and anti-inflammatory effects. However, the hypoglycemic and nephroprotective effects of polysaccharides separated from  (PTA) have not been reported. The properties of PTA were analyzed in a BKS.Cg-Dock7 +/+ Lepr/JNju (db/db) mouse model of . After the administration of PTA for eight weeks, the hypoglycemic and hypolipidemic activities of PTA in the db/db mice were assessed. The results of a cytokine array combined with an enzyme-linked immunosorbent assay confirmed the anti-oxidative and anti-inflammatory activities of PTA. An eight-week administration of PTA caused hypoglycemic and hypolipidemic functioning, as indicated by suppressed plasma glucose levels, as well as the modulation of several cytokines related to glycometabolism, in the sera and kidneys of the mice. PTA treatment also had a protective effect on renal function, restoring renal structures and regulating potential indicators of nephropathy. In the kidneys of the db/db mice, PTA treatment reduced the activation of protein kinase , the inhibitor of κ kinase alpha and beta, and the inhibitor of κ alpha and nuclear factor-κ (NF-κ). We establish the hypoglycemic, hypolipidemic, and anti-diabetic nephropathy effects of PTA, and we find that the renal protection effects of PTA may be related to anti-inflammatory activity via the regulation of NF-κ signaling.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31647139>Does meal-time insulin dosing based on fat-protein counting give positive results in postprandial glycaemic profile after a high protein-fat meal in adolescents with type 1 : a randomised controlled trial.</a></h2><p>The present study investigated the effects of fat-protein (CFP) counting in addition to carbohydrate (CARB) counting for calculating prandial insulin dosage on blood glucose profile in patients with type 1  (T1D) on basal-bolus insulin therapy.In this single centre, cross-over, randomised, controlled study, control meal (SM: standard meal using a carbohydrate counting method) and three test meals (HPM: high protein meal using a carbohydrate counting method; HPFM-a: high protein-fat meal using a carbohydrate counting method; HPFM-: high protein-fat meal using a carbohydrate and fat-protein counting method) were compared on postprandial early (0-120 min), late (120-240 min) and total (0-240 min) glucose response in 30 patients with T1D, aged 16-18 years.The glucose levels of 0-90 min did not change after different meal consumptions (P > 0.05), whereas 120-240 min glucose levels were higher after HPFM-a consumption compared to HPFM- consumption (P < 0.05). There were no significant differences between meals with respect to the early postprandial glucose response (0-120 min) (P = 0.405). In late response (120-240 min), HPFM- [area under the curve (AUC) = 20 609 (582) mg dL  × dk] was significantly lower than SM [AUC = 24 092 (9015) mg dL  × dk], HPM [AUC = 24 072 (5853) mg dL  × dk] and HPFM-a [AUC = 25 986 (6979) mg dL  × dk] (P = 0.032).Meal-related insulin dosing based on carbohydrate plus fat/protein counting has given positive results in the postprandial glycaemic profile as a result of lower postprandial glycaemic levels compared to conventional carbohydrate counting in patients with T1D after a high protein-fat meal.© 2019 The British Dietetic Association Ltd.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31640125>Fetuin-A Inhibits Placental Cell Growth and Ciliogenesis in Gestational .</a></h2><p>Gestational  (GDM) is a type of unbalanced glucose tolerance that occurs during pregnancy, which affects approximately 10% of pregnancies worldwide. Fetuin-A is associated with insulin resistance, and the concentration of circulating fetuin-A increases in women with GDM, however, the role of fetuin-A in the placenta remains unclear. In this study, we enrolled placental samples from twenty pregnant women with GDM and twenty non-GDM pregnant women and found that the abundance of fetuin-A was upregulated in terms of mRNA and protein levels. Fetuin-A inhibited placental cell growth by inducing apoptosis and inhibiting S phase entry. Irregular alignment of mitotic chromosomes and aberrant mitotic spindle poles were observed. In addition, centrosome amplification was induced by fetuin-A treatment, and these amplified centrosomes nucleated microtubules with disorganized microtubule arrays in placental cells. Furthermore, fetuin-A inhibited autophagy, and thus blocked the growth of the primary cilium, a cellular antenna that regulates placenta development and differentiation. Thus, our study uncovered the novel function of fetuin-A in regulating placental cell growth and ciliogenesis.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31629839>MORTALITY, REAMPUTATION AND PRE-OPERATIVE COMORBIDITIES IN PATIENTS UNDERGOING DYSVASCULAR LOWER LIMB AMPUTATION.</a></h2><p>Historically, mortality rates after major lower limb amputation (LLA) have been very high. However, there are inconsistencies regarding the risk factors. Reamputation rate after major LLA is largely unknown. The aim of this study is to report the 30 days and 1 year mortality and 1 year reamputation rates after major LLA and to identify potential risk factors.Observational cohort study in which all patients undergoing dysvascular major LLA in 2012-2013 in 12 hospitals in the northern region of the Netherlands are included.In total 382 patients underwent major LLA, 65% were male, the mean age (SD) was 71.9 ± 12.5 years. Peripheral arterial disease was observed in 88% and  (DM) in 56% of patients. No revascularization or prior LLA on the amputated side was observed among 26%, whereas 56% had no minor or major LLA on either limb prior to the study period. The 30 days and 1 year mortality rates were 14% and 34%, respectively. Patients aged 75-84 and >85 years had 3-4 times higher odds of dying within 1 year. Transfemoral amputation (OR 2.2), history of heart failure (OR 2.3), myocardial infarction (OR 1.7), hemodialysis (OR 5.7), immunosuppressive medication (OR 2.8) and guillotine amputation (OR 5.1) were independently associated with 1 year mortality. Twenty-six percent underwent ipsilateral reamputation within 1 year, for which no risk factors were identified.Mortality rate in the first year after major LLA is high, particularly among those undergoing transfemoral amputation, which is likely to be indicative of more severe vascular disease. Higher mortality among the most elderly patients, those with more severe cardiac disease and hemodialysis reflects the frailty of this population. Interestingly DM, revascularization history and prior minor or major LLA were not associated with mortality rates.Copyright © 2019. Published by Elsevier Inc.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643438>Bendamustine.</a></h2><p>Bendamustine is a parenterally administered alkylating agent used alone and in combination with other antineoplastic agents in the treatment of chronic lymphocytic leukemia and refractory forms of non-Hodgkin lymphoma. Bendamustine therapy is associated with minor transient serum enzyme elevations during treatment and to rare instances of clinically apparent liver injury, with jaundice generally arising as a part of a generalized hypersensitivity syndrome. Bendamustine also has potent immunosuppressive activity and can cause reactivation of chronic hepatitis  that can be severe and even fatal.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31647676>A scalable self-assembling micellar system for enhanced oral bioavailability and efficacy of lisofylline for treatment of type-I .</a></h2><p>The study summarizes the development of an orally active nanoformulation of a potent but one of the least explored molecules, lisofylline (LSF) in T1D. LSF undergoes rapid metabolism resulting in poor oral bioavailability and short half-life. In this work, to improve its pharmacokinetic (PK) properties, LSF was encapsulated in the form of its ester prodrug (LSF-linoleic acid (LA) prodrug) into biodegradable self-assembling polymeric micelles (LSF-LA PLM, size: 149.3nm; PDI: 0.209; CMC; 5.95 µg/mL and Nagg: 14.82 at 10 CMC) of methoxypoly(ethylene glycol)--poly(carbonate-co-L-lactide) (mPEG--P(CB-co-LA) block copolymer. LSF-LA PLM was found to be equally effective as LSF-LA prodrug in cell culture studies in insulin secreting MIN6 cells and showed excellent stability in simulating biological fluids and plasma. Pharmacokinetics of LSF-LA PLM (10 mg/kg dose) revealed significant improvement in oral bioavailability of LSF (74.86%; 3.3 fold increase in comparison to free LSF) and drastic reduction in drug metabolism. Further, LSF-LA PLM showed a significant reduction in fasting glucose levels and increase in insulin levels by intraperitoneal (IP) as well oral route in streptozotocin (STZ) induced T1D rat model. Production of inflammatory cytokines (TNF-α and IFN-γ) and different biochemical markers for liver and kidney functions were much reduced in diabetic animals after treatment with LSF-LA PLM. LSF-LA PLM treated pancreatic sections showed minimal infiltration of CD4+ and CD8+ T-cells as indicated by H&E staining and immunohistochemical analysis.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31630401>Epidemiology, clinical features, and associated factors in 78 cases of lichen planus on black skin.</a></h2><p>The pathogenesis of lichen planus (LP) is mostly autoimmune, while psychological and infectious factors are recognized to trigger or aggravate the disease. An association with  is reported. Our objective was to determine the epidemio-clinical characteristics of LP and its associated factors.This multicentric, prospective study was conducted over a 6-month period. The histopathology was only performed for atypical forms. Patients with a notion of drug intake before the rash were excluded. Anti-hepatitis C Virus (HCV) antibodies screening was systematical in case of mucosal damage. The data were analyzed using the SPSS IBM 20 software.The average age was 38 years. Women represented 84.6% (n = 66) of the studied population. The patients were married in 61.5%. Obesity or overweight status was noted in 41%. A marital or relational conflict was found in 25.6%. History of LP was reported in 24.4% (n = 19). Pruritus was found in 96.2%. The locations were as follows: skin (97.4%), mucous membranes (15.4%), and hair and nails (5.1%). Lesions were diffuse in 56.4%. The clinical forms were as follows: typical (52.6%), erythematosquamous (17%), warty (14.5%), pigmented (14.5%), and blaschkolinear (one case). Histopathology confirmed the diagnosis of LP in 91.4%. Blood sugar level was high in one case. Hepatitis  surface antigen (HBsAg) was positive in 3.03%. Anti-HIV and anti-HCV antibodies were negative.Lichen planus is a relatively rare disease in sub-Saharan Africa and is seen more in adults. The clinical manifestations are polymorphic, but the mucosal damage is rarely isolated.© 2019 The International Society of Dermatology.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31646144>Characteristics of influenza in elderly patients with and without , hospitalized for severe acute respiratory infection in a tertiary care hospital from Bucharest Romania - a three-year prospective epidemiological surveillance study.</a></h2><p>Patients with  may be at a higher risk of developing complicated influenza. We report the characteristics of influenza in hospitalized elderly patients with and without , in three consecutive influenza seasons.The study included patients admitted for severe acute respiratory infection (SARI) in the National Institute for Infectious Diseases "Prof. Dr. Matei Balș", Bucharest, during a three-year active epidemiological surveillance study (2015/16, 2016/17, 2017/18), in the I-MOVE+ hospital network.A total of 349 patients were tested by PCR over the duration of the study. The percentage of patients with  was comparable throughout the seasons: 34.7%, 28.3% and 30.4% (p=0.587). Influenza A was the main viral type circulating in 2015/16 and 2016/17 (100% and 97.6%) in our study population, while in 2017/18,  viruses predominated (90.0%). Diabetics presented a higher median number of comorbidities (3 vs. 2) p<0.001, and two-fold higher odds of also associating obesity (OR=2.1, 95%CI:1.3-3.4, p=0.003), compared to those without . Diabetics also tested positive for influenza more often (p=0.296). Only 6 patients with  (5.4%) from our study had been vaccinated against influenza, and most (n=4) of those who had been vaccinated tested negative for influenza.Our study is the first to describe the circulation of influenza viral types in elderly diabetic patients hospitalized for SARI. The results reinforce the national and international recommendation to vaccinate against influenza all patients with .GERMS.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31637971>Intensive Blood Pressure Treatment Reduced Stroke Risk in Patients With Albuminuria in the SPRINT Trial.</a></h2><p>Background and Purpose- Albuminuria is associated with stroke risk among individuals with . However, the association of albuminuria with incident stroke among nondiabetic patients is less clear. Methods- We performed a post hoc analysis of the SPRINT (Systolic Blood Pressure Intervention Trial), which examined the effect of higher versus lower intensity blood pressure management on mortality in 8913 participants without . We fit unadjusted and adjusted Cox proportional hazards models to estimate the association of baseline albuminuria (urinary albumin-to-creatinine ratio ≥30 mg/g versus<30 mg/g) with stroke risk. We also assessed effect modification according to treatment arms. Results- Mean age was 68±9 years, 35% were female, and 30% were black. Median follow-up was 3.2 years, and 19% patients had baseline albuminuria. Incident stroke occurred in 129 individuals during follow-up. Albuminuria was associated with increased stroke risk (unadjusted hazard ratio, 2.24; 95% CI, 1.55-3.23; adjusted hazard ratio 1.73; 95% CI, 1.17-2.56). The association of albuminuria with incident stroke differed according to the randomized treatment arm ( interaction=0.03). In the intensive treatment arm, the association of albuminuria and stroke was nonsignificant (unadjusted hazard ratio, 1.25; 95% CI, 0.69-2.28), whereas, in the standard treatment arm, it was significant (unadjusted hazard ratio, 3.44; 95% CI, 2.11-5.61). Conclusions- In a post hoc analysis of SPRINT, baseline albuminuria (versus not) was associated with a higher risk of incident stroke, but this relationship appeared to be restricted to those in the standard treatment arm. Further studies are required to conclusively determine if reduction of albuminuria in itself is beneficial in reducing stroke risk. Clinical Trial Registration- URL: https://www.clinicaltrials.gov. Unique identifier: .</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31644223>Tenofovir.</a></h2><p>Tenofovir disoproxil fumarate is an acyclic nucleotide analogue of adenosine used in combination with other agents in the therapy of the human immunodeficiency virus (HIV) and as single agent in hepatitis  virus (HBV) infection. Tenofovir does not appear to be a significant cause of drug induced liver injury.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31618560>Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 .</a></h2><p>Closed-loop systems that automate insulin delivery may improve glycemic outcomes in patients with type 1 .In this 6-month randomized, multicenter trial, patients with type 1  were assigned in a 2:1 ratio to receive treatment with a closed-loop system (closed-loop group) or a sensor-augmented pump (control group). The primary outcome was the percentage of time that the blood glucose level was within the target range of 70 to 180 mg per deciliter (3.9 to 10.0 mmol per liter), as measured by continuous glucose monitoring.A total of 168 patients underwent randomization; 112 were assigned to the closed-loop group, and 56 were assigned to the control group. The age range of the patients was 14 to 71 years, and the glycated hemoglobin level ranged from 5.4 to 10.6%. All 168 patients completed the trial. The mean (±SD) percentage of time that the glucose level was within the target range increased in the closed-loop group from 61±17% at baseline to 71±12% during the 6 months and remained unchanged at 59±14% in the control group (mean adjusted difference, 11 percentage points; 95% confidence interval [CI], 9 to 14; P<0.001). The results with regard to the main secondary outcomes (percentage of time that the glucose level was >180 mg per deciliter, mean glucose level, glycated hemoglobin level, and percentage of time that the glucose level was <70 mg per deciliter or <54 mg per deciliter [3.0 mmol per liter]) all met the prespecified hierarchical criterion for significance, favoring the closed-loop system. The mean difference (closed loop minus control) in the percentage of time that the blood glucose level was lower than 70 mg per deciliter was -0.88 percentage points (95% CI, -1.19 to -0.57; P<0.001). The mean adjusted difference in glycated hemoglobin level after 6 months was -0.33 percentage points (95% CI, -0.53 to -0.13; P = 0.001). In the closed-loop group, the median percentage of time that the system was in closed-loop mode was 90% over 6 months. No serious hypoglycemic events occurred in either group; one episode of diabetic ketoacidosis occurred in the closed-loop group.In this 6-month trial involving patients with type 1 , the use of a closed-loop system was associated with a greater percentage of time spent in a target glycemic range than the use of a sensor-augmented insulin pump. (Funded by the National Institute of  and Digestive and Kidney Diseases; iDCL ClinicalTrials.gov number, .).Copyright © 2019 Massachusetts Medical Society.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31630575>Opposing Age-Related Trends in Absolute and Relative Risk of Adverse Health Outcomes Associated With Out-of-Office Blood Pressure.</a></h2><p>Participant-level meta-analyses assessed the age-specific relevance of office blood pressure to cardiovascular complications, but this information is lacking for out-of-office blood pressure. At baseline, daytime ambulatory (n=12 624) or home (n=5297) blood pressure were measured in 17 921 participants (51.3% women; mean age, 54.2 years) from 17 population cohorts. Subsequently, mortality and cardiovascular events were recorded. Using multivariable Cox regression, floating absolute risk was computed across 4 age bands (≤60, 61-70, 71-80, and >80 years). Over 236 491 person-years, 3855 people died and 2942 cardiovascular events occurred. From levels as low as 110/65 mm Hg, risk log-linearly increased with higher out-of-office systolic/diastolic blood pressure. From the youngest to the oldest age group, rates expressed per 1000 person-years increased (<0.001) from 4.4 (95% CI, 4.0-4.7) to 86.3 (76.1-96.5) for all-cause mortality and from 4.1 (3.9-4.6) to 59.8 (51.0-68.7) for cardiovascular events, whereas hazard ratios per 20-mm Hg increment in systolic out-of-office blood pressure decreased (≤0.0033) from 1.42 (1.19-1.69) to 1.09 (1.05-1.12) and from 1.70 (1.51-1.92) to 1.12 (1.07-1.17), respectively. These age-related trends were similar for out-of-office diastolic pressure and were generally consistent in both sexes and across ethnicities. In conclusion, adverse outcomes were directly associated with out-of-office blood pressure in adults. At young age, the absolute risk associated with out-of-office blood pressure was low, but relative risk high, whereas with advancing age relative risk decreased and absolute risk increased. These observations highlight the need of a lifecourse approach for the management of hypertension.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31644555>Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients.</a></h2><p>This study was conducted to evaluate de novo donor-specific anti-human leukocyte antigen (HLA) antibody (dnDSA) production leading to antibody-mediated rejection (ABMR) after rituximab induction in non-sensitized ABO-compatible living kidney transplantation (ABO-CLKTx). During 2008-2015, 318 ABO-CLKTx were performed at the Department of Surgery III at Tokyo Women's Medical University Hospital. To reduce confounding factors, we adopted a propensity score analysis, which was applied with adjustment for age, gender, duration of pretransplant dialysis, HLA mismatch count, preformed DSA, non-insulin-dependent , immunosuppressive treatment, and estimated glomerular filtration rate (eGFR) on postoperative day 7. Using a propensity score matching model (1:1, 115 pairs), we analyzed the long-term outcomes of 230 ABO-CLKTx recipients retrospectively. Recipients were classified into a rituximab-treated (RTX-KTx, N = 115) group and a control group not treated with rituximab (C-KTx, N = 115). During five years, adverse events, survival rates for grafts and patients, and incidence of biopsy-proven acute rejection (BPAR) and dnDSA production for the two groups were monitored and compared. All recipients in the RTX-KTx group received rituximab induction on preoperative day 4 at a single fixed low dose of 100 mg; the CD19+  cells were eliminated completely before surgery. Of those recipients, 13 (11.3%) developed BPAR; 1 (0.8%) experienced graft loss. By contrast, of C-KTx group recipients, 25 (21.7%) developed BPAR; 3 (2.6%) experienced graft loss. The RTX-KTx group exhibited a significantly lower incidence of BPAR (P = .041) and dnDSA production (13.9% in the RTX-KTx group vs. 26.9% in the C-RTx group, P = .005). Furthermore, lower incidence of CMV infection was detected in the RTX-KTx group than in the C-KTx group (13.9% in the RTX-KTx group vs. 27.0% in the C-KTx group, P = .014). No significant difference was found between groups for several other factors: renal function (P = .384), graft and patient survival (P = .458 and P = .119, respectively), and the respective incidences of BK virus infection (P = .722) and leukopenia (P = .207). During five-year follow-up, single fixed low-dose rituximab therapy is sufficient for ensuring safety, reducing rejection, and suppressing dnDSA production for immunological low-risk non-sensitized ABO-CLKTx.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643945>Adefovir.</a></h2><p>Adefovir dipivoxil is an acyclic nucleotide analogue of adenosine used either alone or in combination with other agents as therapy of chronic hepatitis . Adefovir does not appear to be a significant cause of drug induced liver injury, but initiation of therapy and sudden withdrawal of therapy can induce a transient exacerbation of the underlying hepatitis .</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31644151>Monoclonal Antibodies.</a></h2><p>Monoclonal antibodies are antibodies that have a high degree of specificity (mono-specificity) for an antigen or epitope. Monoclonal antibodies are typically derived from a clonal expansion of antibody producing malignant human plasma cells. The initial monoclonal antibodies were created by fusing spleen cells from an immunized mouse with human or mouse myeloma cells (malignant self-perpetuating antibody producing cells), and selecting out and cloning the hybrid cells (hybridomas) that produced the desired antibody reactivity. These initial monoclonal products were mouse antibodies and were very valuable in laboratory and animal research and diagnostic assays, but were problematic as therapeutic agents because of immune reactions to the foreign mouse protein. Subsequently, production of chimeric mouse-human monoclonal antibodies and means of further “humanizing” them and producing fully human recombinant monoclonal antibodies were developed. The conventions used in nomenclature of monoclonal antibodies indicate whether they are mouse (-omab), chimeric (-ximab), humanized (-zumab) or fully human (-umab). Monoclonal antibodies have broad clinical and experimental medical uses. Many of the initial monoclonal antibodies used in clinical medicine were immunomodulatory agents with activity against specific immune cells, such as CD4 or CD3 lymphocytes, which are important in the pathogenesis of rejection after solid organ transplantation. Subsequently, monoclonal antibodies were prepared against specific cytokines (anti-cytokines), which were believed to play a role in cell and tissue damage in immunologically mediated diseases such as rheumatoid arthritis, alkylosing spondylitis, inflammatory bowel disease, multiple sclerosis and psoriasis, among others. In addition, therapeutic monoclonal antibodies were developed, aimed at blocking or inhibiting the activity of specific enzymes, cell surface transporters or signaling molecules and have been used in cancer chemotherapy and to treat severe viral infections. Use of monoclonal antibodies is currently broadening to therapy of other severe, nonmalignant conditions including asthma, atopic dermatitis, migraine headaches, hypercholesterolemia, osteoporosis and viral or bacterial infections. Thus, the therapeutic monoclonal antibodies do not fall into a single class and have broad therapeutic uses. As of 2018, more than 60 therapeutic monoclonal antibodies are approved and in use in the United States. Monoclonal antibodies are generally well tolerated. Because they are large proteins (typically 150-200,000 daltons in size) they require parenteral, often intravenous, administration. Circulating proteins are metabolized by many cells, but particularly by hepatocytes. Proteins undergo hepatic uptake by endocytosis and are either degraded or recycled to the cell surface for secretion. The hepatic metabolism of antibodies often determines their half-life. Proteins are broken down by cellular proteases into small peptides and amino acids that can used to synthesize other proteins. Metabolism of proteins does not generate toxic intermediates and, therefore, monoclonal antibodies are unlikely to induce drug induced liver injury via production of toxic metabolites. On the other hand, the peptides that are generated by the metabolism of the exogenously administered protein may ultimately be presented as foreign epitopes and generate an immune response. In addition, the primary effect of the monoclonal antibody may generate a response, either immune or otherwise, that leads to an immune mediate hepatic injury. Finally, monoclonal antibodies that suppress the immune system may cause reactivation of latent infections, including tuberculosis and hepatitis .</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31653377>Preoperative biomarker evaluation for the prediction of cardiovascular events after major vascular surgery.</a></h2><p>The cause of perioperative myocardial infarction (PMI) is postulated to involve hemodynamic stress or coronary plaque destabilization. We aimed to evaluate perioperative factors in patients with peripheral artery disease (PAD) undergoing major vascular surgery to determine the likely mechanisms and predictors of PMI.This was a prospective cohort study of 133 patients undergoing major vascular surgery including open abdominal aortic aneurysm (AAA) repair (n = 40) and major suprainguinal or infrainguinal arterial bypasses (non-AAA; n = 93). Preoperative assessment with history, physical examination, and peripheral artery tonometry was performed in addition to plasma sampling of biomarkers associated with inflammation and coronary plaque instability. The primary outcome was occurrence of a 30-day cardiovascular event (CVE; composite of PMI [troponin I elevation >99th percentile reference of ≥0.1 μg/L], stroke, or death).Of 133 patients, 36 patients (27%) developed a 30-day CVE after vascular surgery, and all were PMI. Patients with 30-day CVE were older (75 ± 8 years vs 69 ± 10 years, mean ± standard deviation; P = .001), had higher prevalence of hypertension (94% vs 79%; P = .01) and preoperative beta-blocker therapy (50% vs 29%; P = .02), and had longer duration of surgery (5.1 ± 1.8 hours vs 4.0 ± 1.1 hours; P < .0001). Significant elevations in cystatin C, N-terminal pro--type natriuretic peptide (NT-proBNP), troponin I, high-sensitivity troponin T, matrix metalloproteinase 3, and osteoprotegerin occurred in those who developed 30-day CVE (all P < .05). Multivariate binary logistic regression identified AAA surgery and log-transformed NT-proBNP to be independent preoperative predictors of 30-day CVE (area under the receiver operating characteristic curve = 0.81).In patients with peripheral artery disease undergoing major vascular surgery, the likely mechanism of PMI appears to be the hemodynamic stress related to the type and duration of surgery. NT-proBNP was a useful independent predictor of CVE and thus may serve as an important biomarker of cardiovascular fitness for surgery.Copyright © 2019 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31620616>Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology.</a></h2><p>The paradigm of chronic liver diseases has been shifting. Although hepatitis  and C viral infections are still the main causes of liver cirrhosis and hepatocellular carcinoma (HCC), the introduction of effective antiviral drugs may control or cure them in the near future. In contrast, the burden of nonalcoholic fatty liver disease (NAFLD) has been increasing for decades, and 25 to 30% of the general population in Korea is estimated to have NAFLD. Over 10% of NAFLD patients may have nonalcoholic steatohepatitis (NASH), a severe form of NAFLD. NASH can progress to cirrhosis and HCC. NASH is currently the second leading cause to be placed on the liver transplantation list in the United States. NAFLD is associated with obesity, type 2 , dyslipidemia, and metabolic syndrome. The pathophysiology is complex and associated with lipotoxicity, inflammatory cytokines, apoptosis, and insulin resistance. The only proven effective treatment is weight reduction by diet and exercise. However, this may not be effective for advanced fibrosis or cirrhosis. Therefore, effective drugs are urgently needed for treating these conditions. Unfortunately, no drugs have been approved for the treatment of NASH. Many pharmaceutical companies are trying to develop new drugs for the treatment of NASH. Some of them are in phase 2 or 3 clinical trials. Here, pharmacologic therapies in clinical trials, as well as the basic principles of drug therapy, will be reviewed, focusing on pathophysiology.Copyright © 2019 Yeungnam University College of Medicine.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31660582>Circulating β-cell-specific CD8+ T cells restricted by high risk HLA class I molecules show antigen experience in children with and at risk of type 1 .</a></h2><p>In type 1  (T1D), autoreactive cytotoxic CD8+ T cells are implicated in the destruction of insulin-producing β-cells. The HLA-*3906 and HLA-A*2402 class I genes confer increased risk and promote early disease onset, suggesting that CD8+ T cells that recognize peptides presented by these class I molecules on pancreatic β-cells play a pivotal role in the autoimmune response. We examined the frequency and phenotype of circulating preproinsulin (PPI)-specific and Insulin  (InsB)-specific CD8+ T cells in HLA-*3906+ children newly diagnosed with T1D and in high-risk HLA-A*2402+ children before the appearance of disease-specific autoantibodies and before diagnosis of T1D. Antigen-specific CD8+ T cells were detected using HLA class I tetramers and flow cytometry was used to assess memory status. In HLA-*3906+ children with T1D, we observed an increase in PPI -specific transitional memory CD8+ T cells compared to non-diabetic, age- and HLA-matched subjects. Furthermore, PPI -specific CD8+ T cells in HLA-*3906+ children with T1D showed a significantly more antigen-experienced phenotype compared to polyclonal CD8+ T cells. In longitudinal samples from high-risk HLA-A*2402+ children, the percentage of terminal effector cells within the InsB -specific CD8+ T cells was increased before diagnosis relative to samples taken before the appearance of autoantibodies. This is the first study to report HLA-*3906-restricted autoreactive CD8+ T cells in T1D. Collectively, our results provide evidence that β-cell-reactive CD8+ T cells restricted by disease-associated HLA class I molecules display an antigen-experienced phenotype and acquire enhanced effector function during the period leading to clinical diagnosis, implicating these cells in driving disease.© 2019 British Society for Immunology.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31639408>Long non-coding RNAs and nuclear factor- crosstalk in cancer and other human diseases.</a></h2><p>The regulation of the pleiotropic transcription factor, nuclear factor-κ (NF-κ) by miRNAs and proteins is extensively studied. More recently, the NF-κ signaling was also reported to be regulated by several long non-coding RNAs (lncRNAs) that constitute the major portion of the noncoding component of the human genome. The common NF-κ associated lncRNAs include NKILA, HOTAIR, MALAT1, ANRIL, Lethe, MIR31HG, and PACER. The lncRNA and NF-κ signaling crosstalk during cancer and other diseases such as cardiomyopathy, celiac disease, cerebral infarction, chronic kidney disease, , Kawasaki disease, pregnancy loss, and rheumatoid arthritis. Some NF-κ related lncRNAs can affect gene expression without modulating NF-κ signaling. Most of the lncRNAs with a potential to modulate NF-κ signaling are regulated by NF-κ itself suggesting a feedback regulation. The discovery of lncRNAs have provided a new type of regulation for the NF-κ signaling and thus could be explored for therapeutic interventions. The manner in which lncRNA and NF-κ crosstalk affects human pathophysiology is discussed in this review. The challenges associated with the therapeutic interventions of this crosstalk are also discussed.Copyright © 2019. Published by Elsevier .V.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31637182>Elevated Lactic Acid During Ketoacidosis: Pathophysiology and Management.</a></h2><p>Lactic acidosis results from an acid-base balance disorder of the body due to an excess of lactic acid. It is frequently found in critically ill patients admitted to the intensive care. The most common cause is type A, found in pathologies such as cardiogenic, septic and hypovolemic shock, trauma and severe hypoxemia. The type  is less common and arises without evidence of tissue hypoperfusion or shock. Divers etiologies have been described for this type of hyperlactatemia: Grand Mal seizures, liver failure, hematologic malignancies, congenital enzyme deficiencies, thiamine deficiencies and  and also alcohol abuse, which may induce a lactic acid under-use or an increased production. The authors describe a rare complication of type 1  (T1DM), leading to a major and persistent expression of a type  lactic acidosis during ketoacidosis.© 2019 Hamda Houssein Ahmed, David De Bels, Rachid Attou, Patrick M. Honore, Sebastien Redant, published by Sciendo.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31663504>Effect of Non-Surgical Periodontal Therapy on the Serum Sialic Acid Levels in Diabetic Patients with Periodontitis.</a></h2><p>Sialic acid (SA), a family of acetylated derivatives of neuraminic acid, an acute phase reactant by itself. It usually occurs as a terminal component at the non-reducing end of carbohydrate chains of glycoproteins and glycolipids. SA participates in multiple physiological functions, such as cell-to-cell interactions, cell migration and proliferation.  (DM) is a chronic metabolic disorder characterized by rise in blood glucose level. Periodontitis is a chronic inflammatory disease of the periodontal tissue, leading to destruction of bone surrounding the tooth and ultimately tooth loss. There is a two way relationship between  and periodontitis. Periodontitis is the sixth complication of  along with retinopathy, nephropathy, neuropathy, macrovascular disease, and altered wound healing. Inflammatory mediators like interleukin-6 and tumor necrosis factor-alpha produced during periodontal inflammation can interfere with the actions of insulin receptors and worsen the glycemic control of diabetic patients. Periodontitis is a major cause of tooth loss, affecting over 300 million people and bacteria associated with periodontitis are also linked with systemic problems like endocarditis, atherosclerosis. Recent work has highlighted a major role for the host sugar sialic acid in the biofilm physiology and host-pathogen interactions of T. forsithya, a key periodontal pathogen. There exists a need for a biomarker, for early detection of disease evolution and more robust therapy efficacy measurements. Serum sialic acids were estimated in Indian population by diphenylamine method and Thiobarbituric acid method. The average values were 68 ± 2.6 mg percent by DPA method and 56 ± 5 mg percent by TBA (thiobarbituric acid assay) method. Age and sex showed no influence on serum sialic acid level. Objectives of the present study was to compare (TSSA) level in healthy subjects, subjects with (CMP) with and without (NIDDM) and its effect on non-surgical periodontal therapy. In the present study, the participants were divided into three groups: Group A,  and C. Group A consists of systemically healthy subjects, Group  consists of subjects with (CMP) while Group C consists of subjects with (CMP) with (NIDDM) and results of this study indicated that, at baseline, there were significant differences between Group A,  and Group C with respect to all the clinical parameters, including (GI), (OHI-S), (PPD), (CAL), (TSSA) and (HbA1c) levels. Thus (TSSA) level could be considered as novel biomarker in the progression of periodontal disease and diabetic status. Periodontitis could be considered as a potential, modifiable, and independent risk factor for the development of . Early detection of elevated (TSSA) level may help in interpreting the progression of periodontitis, risk of development of  in future and also to prevent complications.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31657272>Screening Glucose Challenge Test in Pregnancy Can Identify Women With an Adverse Postpartum Cardiovascular Risk Factor Profile: Implications for Cardiovascular Risk Reduction.</a></h2><p>Background The 1-hour glucose challenge test (GCT) is routinely performed in pregnancy to screen for gestational . Remarkably, it has recently emerged that the GCT can also predict a woman's future risk of cardiovascular disease, although the mechanistic basis of this relationship is unclear. In this context we hypothesized that a higher GCT may identify women with an otherwise unrecognized adverse cardiovascular phenotype. Thus, we sought to evaluate the relationship between the antepartum GCT and subsequent postpartum cardiovascular risk factor profile. Methods and Results In this study 503 women completed a screening GCT in late second trimester and then underwent cardiometabolic characterization at 3 months postpartum, whereupon traditional (blood pressure, glucose, lipids) and nontraditional (apolipoprotein , C-reactive protein, adiponectin) cardiovascular risk factors were compared across GCT tertiles. At 3 months postpartum, each of the following risk factors progressively worsened from the lowest to middle to highest GCT tertile: fasting glucose (=0.0002), 2-hour glucose (<0.0001), total cholesterol:high-density lipoprotein cholesterol (=0.0004), high-density lipoprotein cholesterol (=0.004), triglycerides (=0.001), apolipoprotein  (=0.001), and adiponectin (=0.02). On multiple linear regression analyses, the GCT emerged as a significant independent predictor of higher fasting glucose (=0.0006), 2-hour glucose (<0.0001), total cholesterol: high-density lipoprotein cholesterol (=0.0004), triglycerides (=0.001), low-density lipoprotein cholesterol (=0.01), and apolipoprotein  (=0.004) and of lower high-density lipoprotein cholesterol (=0.02) and adiponectin (=0.0099). Moreover, these independent associations persisted after excluding women who had gestational . Conclusions The antepartum GCT can identify women with an adverse underlying cardiovascular risk factor phenotype.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31620788>Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction.</a></h2><p>Glucagon-like peptide 1 (GLP-1) is a gut incretin hormone inducing post-prandial insulin secretion. Glucagon-like peptide 1 levels were recently found to be increased in patients with acute myocardial infarction. Glucagon-like peptide 1 receptor agonists improve cardiovascular outcomes in patients with . The aim of this study was to assess the predictive capacity of GLP-1 serum levels for cardiovascular outcome in patients with myocardial infarction.In 918 patients presenting with myocardial infarction [321 ST-segment elevation myocardial infarction and 597 non-ST-segment elevation myocardial infarction (NSTEMI)] total GLP-1, N-terminal pro--type natriuretic peptide (NT-proBNP) levels and the Global Registry of Acute Coronary Events (GRACE) score were assessed at time of hospital admission. The primary composite outcome of the study was the first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. Kaplan-Meier survival plots and univariable Cox regression analyses found GLP-1 to be associated with adverse outcome [hazard ratio (HR) of logarithmized GLP-1 values: 6.29, 95% confidence interval (CI): 2.67-14.81; P < 0.0001]. After further adjustment for age, sex, family history of cardiovascular disease, smoking, , hypertension, hypercholesterinaemia, glomerular filtration rate (GFR) CKD-EPI, hs-CRP, hs-Troponin T, and NT-proBNP levels the HR remained significant at 10.98 (95% CI: 2.63-45.90; P = 0.0010). Time-dependent receiver operating characteristic curve analyses illustrated that GLP-1 levels are a strong indicator for early events. For events up to 30 days after admission, GLP-1 proved to be superior to other biomarkers including hs-Troponin T, GFR CKD-EPI, hs-CRP, and NT-proBNP. Adjustment of the GRACE risk estimate by addition of GLP-1 increased the area under the receiver operating characteristic curve over time in NSTEMI patients.In patients hospitalized for myocardial infarction, GLP-1 levels are associated with cardiovascular events.Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31669407>The effect of smoking on the risk of gestational  and the OGTT profile during pregnancy.</a></h2><p>To analyze the relationship between smoking and the risk of GDM, as well as with the OGTT profile during pregnancy.A total of 7,437 pregnant women were studied. OGTT was performed at the 3rd trimester. Women were categorized as non-smokers (A), as those who ceased smoking at pregnancy (), and as smokers (C).5,434 (73.1%) women were group A, 1,191 (16%) group  and 812 (10.9%) group C. The rates of GDM among the groups were: A 33.7%,  34.2%, C 34.2% (ns). However, the number of individuals requiring insulin treatment was significantly different: A 39.2%,  47.5%, C 50.6% (p<0.001). Regarding OGTT, fasting glucose levels were significantly higher in group C (89+13 vs 86+12mg/dl) compared to A, whereas 3-h glucose values were significantly lower (104+33 vs 112+32mg/dl) (p<0.001). Group  demonstrated intermediate glucose concentrations. Similar findings were observed in women without GDM. In women with GDM, higher 1-h glucose levels were measured in group C (210+31 vs 205+28mg/dl) compared with A (p=0.024). Further, group C sub-analysis found that those who smoked more than 10 cigarettes showed significantly lower 3-h glucose levels (111+31 vs 128+40mg/dl) compared to those who smoked less than 10 (p=0.006). HbA1c in women with GDM was higher in group C (4.6+0.6 vs 4.5+0.6%) compared with A (p=0.027).The present study did not show any correlation between smoking and GDM risk. However, OGTT profile and HbA1c differed according to smoking status in women with and without GDM.Copyright © 2019. Published by Elsevier .V.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643211>Daclatasvir.</a></h2><p>Daclatasvir is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) and is used in combination with other oral antiviral agents to treat chronic hepatitis C. Elevations in serum enzyme levels during daclatasvir therapy are uncommon, and it has yet to be convincingly implicated in cases of clinically apparent liver injury with jaundice. Nevertheless, and for unknown reasons, successful all-oral regimens of antiviral therapy in patients with chronic hepatitis C and cirrhosis is occasionally complicated by hepatic decompensation and may cause reactivation of hepatitis  in susceptible patients coinfected with the hepatitis  virus (HBV).</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643985>Indinavir.</a></h2><p>Indinavir is an antiretroviral protease inhibitor used in the therapy and prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). Indinavir can cause transient and usually asymptomatic elevations in serum aminotransferase levels and mild elevations in indirect bilirubin concentration. Indinavir is a rare cause of clinically apparent, acute liver injury. In HBV or HCV coinfected patients, antiretroviral therapy with indinavir may result in an exacerbation of the underlying chronic hepatitis  or C.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31644032>Endothelin Receptor Antagonists.</a></h2><p>The endothelin receptor antagonists inhibit the binding of endothelin, a vasoconstrictive peptide, to its receptors on smooth muscle cells which results in vasodilation. Endothelin receptors are relatively enriched in pulmonary vasculature and their inibition results in a decrease in pulmonary vascular pressure. In patients with pulmonary arterial hypertension, (PAH) the endothelin receptor antagonists have been shown to improve exercise tolerance and slow progression of disease. Three endothelin receptor antagonists are currently approved and in use in the United States: bosentan (2001: Tracleer), ambrisentan (2007: Letairis) and macitentan (2013: Opsumit). Sitaxsentan, a forth endothelin receptor blocker, was approved in Europe, but not in the United States, and has subsequently been withdrawn because of cases of severe liver injury linked to its use. While all endothelin receptor antagonists have been associated with occasional transient serum enzyme elevations during therapy, only bosentan and sitaxentan have been clearly linked to instances of clinically apparent, acute liver injury. Endothelin-1 (ET-1) is a 21 amino acid peptide that acts in a paracrine and autocrine fashion as a potent vasoconstrictor. ET-1 appears to play a key role in regulation of vascular tone and can also induce hypertrophy of myocytes, proliferation of fibroblasts and fibrosis. ET-1 acts by engagement of cell surface receptors that result in activation of intracellular pathways leading to vasoconstriction and proliferation of smooth muscle cells. Two forms of endothelin receptors have been identified – type A (ETA) and type  (ETB). The ETA receptor is found predominantly on smooth muscle cells, whereas the ETB receptor is present on both smooth muscle and vascular endothelial cells. The intracellular signaling pathways and overall effects are somewhat different for the two receptors, and there may be an advantage to specific inhibition of the type A receptor as opposed to bimodal inhibition of both. The use of endothelin receptor antagonists in pulmonary arterial hypertension (PAH) is based upon the proposed pathogenesis of this disease, which is marked by enhanced synthesis of ET-1 and progressive proliferation and hypertrophy of smooth muscle cells in the pulmonary vasculature. In several randomized controlled trials, endothelin receptor antagonists were shown to decrease pulmonary vascular pressure and improve exercise tolerance and symptoms in patients with PAH. Their efficacy has been best demonstrated in patients with idiopathic PAH (World Health Organization [WHO] group 1 PAH) and less well in the secondary forms due to left heart failure [WHO group 2], lung disease or hypoxemia [WHO group 3], chronic pulmonary thromboembolic disease [WHO group 4] or unclear, multifactorial conditions [WHO group 5].</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31643761>Abatacept.</a></h2><p>Abatacept is a recombinant fusion protein of the cell surface marker CTLA-4 and immunoglobulin that acts by interfering with T cell activation and is used to treat rheumatoid arthritis. Abatacept has been linked to a low rate of serum enzyme elevations during therapy, but has not been linked to cases of idiosyncratic, clinically apparent liver injury with jaundice. Because abatacept is a potent inhibitor of lymphocyte function, it may cause reactivation of chronic hepatitis  in susceptible patients.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31644152>Fludarabine.</a></h2><p>Fludarabine is a purine analogue and antineoplastic agent used in the therapy of chronic lymphocytic leukemia (CLL) and in immunosuppressive regimens in preparation of hematopoietic cell transplantation (HCT). Fludarabine is associated with a low rate of transient serum enzyme elevations during therapy and has only rarely been implicated in cases of clinically apparent acute liver injury with jaundice. Fludarabine has potent immunosuppressive activity and has been associated with many cases of reactivation of hepatitis .</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31672147>Luseogliflozin attenuates neointimal hyperplasia after wire injury in high-fat diet-fed mice via inhibition of perivascular adipose tissue remodeling.</a></h2><p>Excess fat deposition could induce phenotypic changes of perivascular adipose tissue (PVAT remodeling), which may promote the progression of atherosclerosis via modulation of adipocytokine secretion. However, it remains unclear whether and how suppression of PVAT remodeling could attenuate vascular injury. In this study, we examined the effect of sodium-glucose cotransporter 2 (SGLT2) inhibitor, luseogliflozin on PVAT remodeling and neointima formation after wire injury in mice.Wilt-type mice fed with low-fat diet (LFD) or high-fat diet (HFD) received oral administration of luseogliflozin (18 mg/kg/day) or vehicle. Mice underwent bilateral femoral artery wire injury followed by unilateral removal of surrounding PVAT. After 25 days, injured femoral arteries and surrounding PVAT were analyzed.In LFD-fed lean mice, neither luseogliflozin treatment or PVAT removal attenuated the intima-to-media (I/M) ratio of injured arteries. However, in HFD-fed mice, luseogliflozin or PVAT removal reduced the I/M ratio, whereas their combination showed no additive reduction. In PVAT surrounding injured femoral arteries of HFD-fed mice, luseogliflozin treatment decreased the adipocyte sizes. Furthermore, luseogliflozin reduced accumulation of macrophages expressing platelet-derived growth factor- (PDGF-) and increased adiponectin gene expression. Gene expression levels of Pdgf- in PVAT were correlated with the I/M ratio.Our present study suggests that luseogliflozin could attenuate neointimal hyperplasia after wire injury in HFD-fed mice partly via suppression of macrophage PDGF- expression in PVAT. Inhibition of PVAT remodeling by luseogliflozin may be a novel therapeutic target for vascular remodeling after angioplasty.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31670977>ATP synthase inhibitory factor 1 (IF1), a novel myokine, regulates glucose metabolism by AMPK and Akt dual pathways.</a></h2><p>ATPase inhibitory factor 1 (IF1) is an ATP synthase-interacting protein that suppresses the hydrolysis activity of ATP synthase. In this study, we observed that the expression of IF1 was up-regulated in response to electrical pulse stimulation of skeletal muscle cells and in exercized mice and healthy men. IF1 stimulates glucose uptake  AMPK in skeletal muscle cells and primary cultured myoblasts. Reactive oxygen species and Rac family small GTPase 1 (Rac1) function in the upstream and downstream of AMPK, respectively, in IF1-mediated glucose uptake. In diabetic animal models, the administration of recombinant IF1 improved glucose tolerance and down-regulated blood glucose level. In addition, IF1 inhibits ATP hydrolysis by β-F1-ATPase in plasma membrane, thereby increasing extracellular ATP and activating the protein kinase  (Akt) pathway, ultimately leading to glucose uptake. Thus, we suggest that IF1 is a novel myokine and propose a mechanism by which AMPK and Akt contribute independently to IF1-mediated improvement of glucose tolerance impairment. These results demonstrate the importance of IF1 as a potential antidiabetic agent.-Lee, H. J., Moon, J., Chung, I., Chung, J. H., Park, C., Lee, J. O., Han, J. A., Kang, M. J., Yoo, E. H., Kwak, S.-Y., Jo, G., Park, W., Park, J., Kim, K. M., Lim, S., Ngoei, K. R. W., Ling, N. X. Y., Oakhill, J. S., Galic, S., Murray-Segal, L., Kemp, . E., Mantzoros, C. S., Krauss, R. M., Shin, M.-J., Kim, H. S. ATP synthase inhibitory factor 1 (IF1), a novel myokine, regulates glucose metabolism by AMPK and Akt dual pathways.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31646744>All things considered, my risk for  is medium: A risk personalization process of familial risk for type 2 .</a></h2><p>A positive family history of type 2  (T2D) has been associated with risk awareness and risk-reducing behaviours among the unaffected relatives. Yet, little is known about how people with a positive family history for  develop and manage their personal sense of risk.To characterize two key concepts, salience and vulnerability, within the familial risk perception (FRP) model among unaffected individuals, at increased familial risk for T2D.We conducted a mixed method study. Descriptions of salience and vulnerability were collected through semi-structured interviews. Participant's perception of self-reported risk factors (family history, age, race/ethnicity, medical history, weight and exercise) was measured using the Perceived Risk Factors for T2D Tool and was compared to a clinical evaluation of the same risk factors.We identified two components of salience: (a) concern for developing T2D and () risk awareness triggers, and two features of vulnerability: (a) statement of risk and () risk assessment devices. Although few participants (26%) were concordant between their perceived and clinical overall T2D risk, concordance for individual risk factors was higher, ranging from 42% (medical history) to 90% (family history).Both familial and non-familial events lead people to contemplate their T2D risk, even among people who have a positive family history. Participants often downplayed their overall risk and underestimated their overall risk compared to a clinical risk assessment of the same self-reported risk factors. Clinicians could leverage key components of the FRP process as way to engage patients in risk reduction strategies earlier.© 2019 The Authors Health Expectations published by John Wiley & Sons Ltd.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31644147>Idelalisib.</a></h2><p>Idelalisib is an oral kinase inhibitor that is approved for use in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia (CLL) and as monotherapy for relapsed follicular  cell and small lymphocytic lymphoma. Idelalisib is associated with a high rate of minor serum enzyme elevations during therapy and has been reported to cause clinically apparent acute liver injury that can be severe and even fatal.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31654220>Candida urinary tract infections in adults.</a></h2><p>Candiduria is commonly seen in hospitalized patients and most of the patients are asymptomatic, but it may be due to cystitis, pyelonephritis, prostatitis, epididymo-orchitis or disseminated candidiasis. Major risk factors are , indwelling urinary catheters, use of broad-spectrum antibiotics, urinary obstruction, and admission to intensive care units. Candida urinary tract infections can be caused by hematogenous spread following candidemia, or retrograde route via the urethra. The presence of Candida species in urine in asymptomatic patients does not warrant antifungal therapy except neutropenic patients, very low-birth-weight infants and patients undergoing urologic procedures. Fluconazole is the treatment of choice for symptomatic infections, it achieves high urinary levels. The other azole antifungals and echinocandins do not reach sufficient urine levels. Amphotericin  deoxycholate is the alternative antifungal agent if fluconazole can not be used because of resistance, allergy or failure.</p><h2><a href=https://www.ncbi.nlm.nih.gov/pubmed/31634265>Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis .</a></h2><p>It is unclear whether entecavir (ETV) and tenofovir disoproxil fumarate (TDF) differ in their effectiveness for preventing hepatocellular carcinoma (HCC) in patients with chronic hepatitis  (CHB).This retrospective cohort study analyzed an international consortium that encompassed 19 centers from 6 countries or regions composed of previously untreated CHB patients then treated with either ETV or TDF monotherapy. Those who developed HCC before antiviral treatment or within 1 year of therapy were excluded. The association between antiviral regimen and HCC risk was evaluated using competing-risk survival regression. We also applied propensity score matching (PSM) to 1:1 balance the 2 treatment cohorts. A total of 5,537 patients were eligible (n = 4,837 received ETV and n = 700 received TDF) and observed for HCC occurrence until December 23, 2018. Before PSM, the TDF cohort was significantly younger and had generally less advanced diseases.In the unadjusted analysis, TDF was associated with a lower risk of HCC (subdistribution hazard ratio [SHR], 0.45; 95% confidence interval [CI], 0.26-0.79; P = 0.005). The multivariable analysis, however, found that the association between TDF and HCC no longer existed (SHR, 0.81; 95% CI, 0.42-1.56; P = 0.52) after adjustment for age, sex, country, albumin, platelet, α-fetoprotein, cirrhosis, and . Furthermore, the PSM analysis (n = 1,040) found no between-cohort differences in HCC incidences (P = 0.51) and no association between regimens (TDF or ETV) and HCC risk in the multivariable-adjusted analysis (adjusted SHR, 0.89; 95% CI, 0.41-1.92; P = 0.77).TDF and ETV did not significantly differ in the prevention of HCC in patients with CHB.</p></html>